News

Firms to take equal stakes in new entity Domixtar Pharmaceuticals

Trilantic Europe, a leading mid-market, pan-European private equity investor, is pleased to announce the successful merger of portfolio company Doppel Farmaceutici, and Alto Partners-owned Mipharm. Completion of the transaction is expected to occur in September 2024.

Headquartered in Italy and founded in 1994 and 1998 respectively, Doppel Farmaceutici and Mipharm are two leading contract development and manufacturing organisations (CDMOs), bringing fully integrated drug development and manufacturing solutions to the pharmaceuticals market.

Trilantic Europe and Alto Partners will each be taking a 50% stake in the new merged entity, named Domixtar Pharmaceuticals (“DMX Pharma”). The entity generated an aggregate turnover of approximately 180 million euros in 2023 and will be led by current Mipharm Executive President, Maurizio Silvestri.

Together, Doppel Farmaceutici and Mipharm service a 100-strong, global portfolio of blue-chip clients, offering a comprehensive suite of technologies and products including liquid, solid and semisolid dosage forms with myriad applications, including anti-tumour, anti-inflammatory, cardiovascular and metabolic.

With 900 employees spread across four production plants located between Milan, Piacenza and Ferrara, DMX Pharma is set to become the largest independent Italian CDMO; equipped with state-of-the-art laboratories capable of supporting its customers in complex research and development (R&D) projects, starting from the investigational phase and product pre-formulation studies, up to the scale up of commercial production.

Vittorio Pignatti-Morano, Chairman and Co-Founder at Trilantic Europe, said: “This merger exemplifies our commitment to growing our portfolio companies into global players, and underscores our ability to identify strategic consolidation opportunities in ever-developing markets. By integrating both Doppel Farmaceutici’s and Mipharm’s unique strengths, scale-up capabilities, and advanced technologies, we're establishing a comprehensive platform to serve the intricate needs of global pharmaceutical clients, supporting with a broader range of activities and sophisticated drug development and manufacturing. We look forward to working with Alto Partners in this next chapter of the companies’ growth journeys.

Maurizio Silvestri, current Executive President of Mipharm and newly appointed Executive President of Domixtar Pharmaceuticals, said: "This strategic merger delivers powerful synergies both commercially and technologically, creating a real powerhouse in the pharmaceuticals market by combining decades of expertise with cutting-edge innovation.”
The terms of the transaction are not disclosed. Trilantic Europe was advised by LMCR / Studio Legale, EY, goetzpartners, ERM and Foglia & Partners.

Press Contact :

Trilantic Europe:

Agnes Riousse/Camilla Wyatt

Citigate Dewe Rogerson

E: agnes.riousse@citigatedewerogerson.com / camilla.wyatt@citigatedewerogerson.com 

T: +44 7770 762828

About Trilantic Europe

Trilantic Europe is a mid-market private equity firm focused on management buyouts, buy-ins and partnerships with founders, families and management teams across its themes and sectors of focus including energy transition, consumer and leisure, business services and healthcare. Trilantic Europe is managed by an experienced group of over 30 investment professionals and 15 operating partners and senior advisors, having invested over €2.7bn in 30 platform portfolio companies since 2004 and currently managing c. €2.6bn in assets from a wide base of investors.

More information: www.trilanticeurope.com 

About Alto Partners

Alto Partners SGR S.p.A. is an independent management company founded by Stefano Scarpis and Raffaele de Courten, focusing on private equity investments in the Italian mid-market. With close to 25 years market experience and 50 transactions completed, it is a choice partner to accompany medium to long-term growth programmes of portfolio companies. The team works alongside entrepreneurial families and managers to address the generation transition and bridge expansion capital gaps. 

Alto Capital V, vintage 2022 (Euro 273 million raised) has completed 5 investment transactions to date: Larioplast (cosmetic and food packaging), Dierre Group (industrial security solutions) e EF Group (general contractor for fairs and tri-dimensional spaces), Fragesa (pizza restaurant chain under the brand “Fra Diavolo”) and Eurosirel (manufacturer and distributor of woundcare and cosmetic products).

More information: www.altopartners.it 

Firms to take equal stakes in new entity Domixtar Pharmaceuticals

Trilantic Europe, a leading mid-market, pan-European private equity investor, is pleased to announce the successful merger of portfolio company Doppel Farmaceutici, and Alto Partners-owned Mipharm. Completion of the transaction is expected to occur in September 2024.

Headquartered in Italy and founded in 1994 and 1998 respectively, Doppel Farmaceutici and Mipharm are two leading contract development and manufacturing organisations (CDMOs), bringing fully integrated drug development and manufacturing solutions to the pharmaceuticals market.

Trilantic Europe and Alto Partners will each be taking a 50% stake in the new merged entity, named Domixtar Pharmaceuticals (“DMX Pharma”). The entity generated an aggregate turnover of approximately 180 million euros in 2023 and will be led by current Mipharm Executive President, Maurizio Silvestri.

Together, Doppel Farmaceutici and Mipharm service a 100-strong, global portfolio of blue-chip clients, offering a comprehensive suite of technologies and products including liquid, solid and semisolid dosage forms with myriad applications, including anti-tumour, anti-inflammatory, cardiovascular and metabolic.

With 900 employees spread across four production plants located between Milan, Piacenza and Ferrara, DMX Pharma is set to become the largest independent Italian CDMO; equipped with state-of-the-art laboratories capable of supporting its customers in complex research and development (R&D) projects, starting from the investigational phase and product pre-formulation studies, up to the scale up of commercial production.

Vittorio Pignatti-Morano, Chairman and Co-Founder at Trilantic Europe, said: “This merger exemplifies our commitment to growing our portfolio companies into global players, and underscores our ability to identify strategic consolidation opportunities in ever-developing markets. By integrating both Doppel Farmaceutici’s and Mipharm’s unique strengths, scale-up capabilities, and advanced technologies, we're establishing a comprehensive platform to serve the intricate needs of global pharmaceutical clients, supporting with a broader range of activities and sophisticated drug development and manufacturing. We look forward to working with Alto Partners in this next chapter of the companies’ growth journeys.

Maurizio Silvestri, current Executive President of Mipharm and newly appointed Executive President of Domixtar Pharmaceuticals, said: "This strategic merger delivers powerful synergies both commercially and technologically, creating a real powerhouse in the pharmaceuticals market by combining decades of expertise with cutting-edge innovation.”
The terms of the transaction are not disclosed. Trilantic Europe was advised by LMCR / Studio Legale, EY, goetzpartners, ERM and Foglia & Partners.

Press Contact :

Trilantic Europe:

Agnes Riousse/Camilla Wyatt

Citigate Dewe Rogerson

E: agnes.riousse@citigatedewerogerson.com / camilla.wyatt@citigatedewerogerson.com 

T: +44 7770 762828

About Trilantic Europe

Trilantic Europe is a mid-market private equity firm focused on management buyouts, buy-ins and partnerships with founders, families and management teams across its themes and sectors of focus including energy transition, consumer and leisure, business services and healthcare. Trilantic Europe is managed by an experienced group of over 30 investment professionals and 15 operating partners and senior advisors, having invested over €2.7bn in 30 platform portfolio companies since 2004 and currently managing c. €2.6bn in assets from a wide base of investors.

More information: www.trilanticeurope.com 

About Alto Partners

Alto Partners SGR S.p.A. is an independent management company founded by Stefano Scarpis and Raffaele de Courten, focusing on private equity investments in the Italian mid-market. With close to 25 years market experience and 50 transactions completed, it is a choice partner to accompany medium to long-term growth programmes of portfolio companies. The team works alongside entrepreneurial families and managers to address the generation transition and bridge expansion capital gaps. 

Alto Capital V, vintage 2022 (Euro 273 million raised) has completed 5 investment transactions to date: Larioplast (cosmetic and food packaging), Dierre Group (industrial security solutions) e EF Group (general contractor for fairs and tri-dimensional spaces), Fragesa (pizza restaurant chain under the brand “Fra Diavolo”) and Eurosirel (manufacturer and distributor of woundcare and cosmetic products).

More information: www.altopartners.it 

Firms to take equal stakes in new entity Domixtar Pharmaceuticals

Trilantic Europe, a leading mid-market, pan-European private equity investor, is pleased to announce the successful merger of portfolio company Doppel Farmaceutici, and Alto Partners-owned Mipharm. Completion of the transaction is expected to occur in September 2024.

Headquartered in Italy and founded in 1994 and 1998 respectively, Doppel Farmaceutici and Mipharm are two leading contract development and manufacturing organisations (CDMOs), bringing fully integrated drug development and manufacturing solutions to the pharmaceuticals market.

Trilantic Europe and Alto Partners will each be taking a 50% stake in the new merged entity, named Domixtar Pharmaceuticals (“DMX Pharma”). The entity generated an aggregate turnover of approximately 180 million euros in 2023 and will be led by current Mipharm Executive President, Maurizio Silvestri.

Together, Doppel Farmaceutici and Mipharm service a 100-strong, global portfolio of blue-chip clients, offering a comprehensive suite of technologies and products including liquid, solid and semisolid dosage forms with myriad applications, including anti-tumour, anti-inflammatory, cardiovascular and metabolic.

With 900 employees spread across four production plants located between Milan, Piacenza and Ferrara, DMX Pharma is set to become the largest independent Italian CDMO; equipped with state-of-the-art laboratories capable of supporting its customers in complex research and development (R&D) projects, starting from the investigational phase and product pre-formulation studies, up to the scale up of commercial production.

Vittorio Pignatti-Morano, Chairman and Co-Founder at Trilantic Europe, said: “This merger exemplifies our commitment to growing our portfolio companies into global players, and underscores our ability to identify strategic consolidation opportunities in ever-developing markets. By integrating both Doppel Farmaceutici’s and Mipharm’s unique strengths, scale-up capabilities, and advanced technologies, we're establishing a comprehensive platform to serve the intricate needs of global pharmaceutical clients, supporting with a broader range of activities and sophisticated drug development and manufacturing. We look forward to working with Alto Partners in this next chapter of the companies’ growth journeys.

Maurizio Silvestri, current Executive President of Mipharm and newly appointed Executive President of Domixtar Pharmaceuticals, said: "This strategic merger delivers powerful synergies both commercially and technologically, creating a real powerhouse in the pharmaceuticals market by combining decades of expertise with cutting-edge innovation.”
The terms of the transaction are not disclosed. Trilantic Europe was advised by LMCR / Studio Legale, EY, goetzpartners, ERM and Foglia & Partners.

Press Contact :

Trilantic Europe:

Agnes Riousse/Camilla Wyatt

Citigate Dewe Rogerson

E: agnes.riousse@citigatedewerogerson.com / camilla.wyatt@citigatedewerogerson.com 

T: +44 7770 762828

About Trilantic Europe

Trilantic Europe is a mid-market private equity firm focused on management buyouts, buy-ins and partnerships with founders, families and management teams across its themes and sectors of focus including energy transition, consumer and leisure, business services and healthcare. Trilantic Europe is managed by an experienced group of over 30 investment professionals and 15 operating partners and senior advisors, having invested over €2.7bn in 30 platform portfolio companies since 2004 and currently managing c. €2.6bn in assets from a wide base of investors.

More information: www.trilanticeurope.com 

About Alto Partners

Alto Partners SGR S.p.A. is an independent management company founded by Stefano Scarpis and Raffaele de Courten, focusing on private equity investments in the Italian mid-market. With close to 25 years market experience and 50 transactions completed, it is a choice partner to accompany medium to long-term growth programmes of portfolio companies. The team works alongside entrepreneurial families and managers to address the generation transition and bridge expansion capital gaps. 

Alto Capital V, vintage 2022 (Euro 273 million raised) has completed 5 investment transactions to date: Larioplast (cosmetic and food packaging), Dierre Group (industrial security solutions) e EF Group (general contractor for fairs and tri-dimensional spaces), Fragesa (pizza restaurant chain under the brand “Fra Diavolo”) and Eurosirel (manufacturer and distributor of woundcare and cosmetic products).

More information: www.altopartners.it 

Firms to take equal stakes in new entity Domixtar Pharmaceuticals

Trilantic Europe, a leading mid-market, pan-European private equity investor, is pleased to announce the successful merger of portfolio company Doppel Farmaceutici, and Alto Partners-owned Mipharm. Completion of the transaction is expected to occur in September 2024.

Headquartered in Italy and founded in 1994 and 1998 respectively, Doppel Farmaceutici and Mipharm are two leading contract development and manufacturing organisations (CDMOs), bringing fully integrated drug development and manufacturing solutions to the pharmaceuticals market.

Trilantic Europe and Alto Partners will each be taking a 50% stake in the new merged entity, named Domixtar Pharmaceuticals (“DMX Pharma”). The entity generated an aggregate turnover of approximately 180 million euros in 2023 and will be led by current Mipharm Executive President, Maurizio Silvestri.

Together, Doppel Farmaceutici and Mipharm service a 100-strong, global portfolio of blue-chip clients, offering a comprehensive suite of technologies and products including liquid, solid and semisolid dosage forms with myriad applications, including anti-tumour, anti-inflammatory, cardiovascular and metabolic.

With 900 employees spread across four production plants located between Milan, Piacenza and Ferrara, DMX Pharma is set to become the largest independent Italian CDMO; equipped with state-of-the-art laboratories capable of supporting its customers in complex research and development (R&D) projects, starting from the investigational phase and product pre-formulation studies, up to the scale up of commercial production.

Vittorio Pignatti-Morano, Chairman and Co-Founder at Trilantic Europe, said: “This merger exemplifies our commitment to growing our portfolio companies into global players, and underscores our ability to identify strategic consolidation opportunities in ever-developing markets. By integrating both Doppel Farmaceutici’s and Mipharm’s unique strengths, scale-up capabilities, and advanced technologies, we're establishing a comprehensive platform to serve the intricate needs of global pharmaceutical clients, supporting with a broader range of activities and sophisticated drug development and manufacturing. We look forward to working with Alto Partners in this next chapter of the companies’ growth journeys.

Maurizio Silvestri, current Executive President of Mipharm and newly appointed Executive President of Domixtar Pharmaceuticals, said: "This strategic merger delivers powerful synergies both commercially and technologically, creating a real powerhouse in the pharmaceuticals market by combining decades of expertise with cutting-edge innovation.”
The terms of the transaction are not disclosed. Trilantic Europe was advised by LMCR / Studio Legale, EY, goetzpartners, ERM and Foglia & Partners.

Press Contact :

Trilantic Europe:

Agnes Riousse/Camilla Wyatt

Citigate Dewe Rogerson

E: agnes.riousse@citigatedewerogerson.com / camilla.wyatt@citigatedewerogerson.com 

T: +44 7770 762828

About Trilantic Europe

Trilantic Europe is a mid-market private equity firm focused on management buyouts, buy-ins and partnerships with founders, families and management teams across its themes and sectors of focus including energy transition, consumer and leisure, business services and healthcare. Trilantic Europe is managed by an experienced group of over 30 investment professionals and 15 operating partners and senior advisors, having invested over €2.7bn in 30 platform portfolio companies since 2004 and currently managing c. €2.6bn in assets from a wide base of investors.

More information: www.trilanticeurope.com 

About Alto Partners

Alto Partners SGR S.p.A. is an independent management company founded by Stefano Scarpis and Raffaele de Courten, focusing on private equity investments in the Italian mid-market. With close to 25 years market experience and 50 transactions completed, it is a choice partner to accompany medium to long-term growth programmes of portfolio companies. The team works alongside entrepreneurial families and managers to address the generation transition and bridge expansion capital gaps. 

Alto Capital V, vintage 2022 (Euro 273 million raised) has completed 5 investment transactions to date: Larioplast (cosmetic and food packaging), Dierre Group (industrial security solutions) e EF Group (general contractor for fairs and tri-dimensional spaces), Fragesa (pizza restaurant chain under the brand “Fra Diavolo”) and Eurosirel (manufacturer and distributor of woundcare and cosmetic products).

More information: www.altopartners.it 

Firms to take equal stakes in new entity Domixtar Pharmaceuticals

Trilantic Europe, a leading mid-market, pan-European private equity investor, is pleased to announce the successful merger of portfolio company Doppel Farmaceutici, and Alto Partners-owned Mipharm. Completion of the transaction is expected to occur in September 2024.

Headquartered in Italy and founded in 1994 and 1998 respectively, Doppel Farmaceutici and Mipharm are two leading contract development and manufacturing organisations (CDMOs), bringing fully integrated drug development and manufacturing solutions to the pharmaceuticals market.

Trilantic Europe and Alto Partners will each be taking a 50% stake in the new merged entity, named Domixtar Pharmaceuticals (“DMX Pharma”). The entity generated an aggregate turnover of approximately 180 million euros in 2023 and will be led by current Mipharm Executive President, Maurizio Silvestri.

Together, Doppel Farmaceutici and Mipharm service a 100-strong, global portfolio of blue-chip clients, offering a comprehensive suite of technologies and products including liquid, solid and semisolid dosage forms with myriad applications, including anti-tumour, anti-inflammatory, cardiovascular and metabolic.

With 900 employees spread across four production plants located between Milan, Piacenza and Ferrara, DMX Pharma is set to become the largest independent Italian CDMO; equipped with state-of-the-art laboratories capable of supporting its customers in complex research and development (R&D) projects, starting from the investigational phase and product pre-formulation studies, up to the scale up of commercial production.

Vittorio Pignatti-Morano, Chairman and Co-Founder at Trilantic Europe, said: “This merger exemplifies our commitment to growing our portfolio companies into global players, and underscores our ability to identify strategic consolidation opportunities in ever-developing markets. By integrating both Doppel Farmaceutici’s and Mipharm’s unique strengths, scale-up capabilities, and advanced technologies, we're establishing a comprehensive platform to serve the intricate needs of global pharmaceutical clients, supporting with a broader range of activities and sophisticated drug development and manufacturing. We look forward to working with Alto Partners in this next chapter of the companies’ growth journeys.

Maurizio Silvestri, current Executive President of Mipharm and newly appointed Executive President of Domixtar Pharmaceuticals, said: "This strategic merger delivers powerful synergies both commercially and technologically, creating a real powerhouse in the pharmaceuticals market by combining decades of expertise with cutting-edge innovation.”
The terms of the transaction are not disclosed. Trilantic Europe was advised by LMCR / Studio Legale, EY, goetzpartners, ERM and Foglia & Partners.

Press Contact :

Trilantic Europe:

Agnes Riousse/Camilla Wyatt

Citigate Dewe Rogerson

E: agnes.riousse@citigatedewerogerson.com / camilla.wyatt@citigatedewerogerson.com 

T: +44 7770 762828

About Trilantic Europe

Trilantic Europe is a mid-market private equity firm focused on management buyouts, buy-ins and partnerships with founders, families and management teams across its themes and sectors of focus including energy transition, consumer and leisure, business services and healthcare. Trilantic Europe is managed by an experienced group of over 30 investment professionals and 15 operating partners and senior advisors, having invested over €2.7bn in 30 platform portfolio companies since 2004 and currently managing c. €2.6bn in assets from a wide base of investors.

More information: www.trilanticeurope.com 

About Alto Partners

Alto Partners SGR S.p.A. is an independent management company founded by Stefano Scarpis and Raffaele de Courten, focusing on private equity investments in the Italian mid-market. With close to 25 years market experience and 50 transactions completed, it is a choice partner to accompany medium to long-term growth programmes of portfolio companies. The team works alongside entrepreneurial families and managers to address the generation transition and bridge expansion capital gaps. 

Alto Capital V, vintage 2022 (Euro 273 million raised) has completed 5 investment transactions to date: Larioplast (cosmetic and food packaging), Dierre Group (industrial security solutions) e EF Group (general contractor for fairs and tri-dimensional spaces), Fragesa (pizza restaurant chain under the brand “Fra Diavolo”) and Eurosirel (manufacturer and distributor of woundcare and cosmetic products).

More information: www.altopartners.it 

Firms to take equal stakes in new entity Domixtar Pharmaceuticals

Trilantic Europe, a leading mid-market, pan-European private equity investor, is pleased to announce the successful merger of portfolio company Doppel Farmaceutici, and Alto Partners-owned Mipharm. Completion of the transaction is expected to occur in September 2024.

Headquartered in Italy and founded in 1994 and 1998 respectively, Doppel Farmaceutici and Mipharm are two leading contract development and manufacturing organisations (CDMOs), bringing fully integrated drug development and manufacturing solutions to the pharmaceuticals market.

Trilantic Europe and Alto Partners will each be taking a 50% stake in the new merged entity, named Domixtar Pharmaceuticals (“DMX Pharma”). The entity generated an aggregate turnover of approximately 180 million euros in 2023 and will be led by current Mipharm Executive President, Maurizio Silvestri.

Together, Doppel Farmaceutici and Mipharm service a 100-strong, global portfolio of blue-chip clients, offering a comprehensive suite of technologies and products including liquid, solid and semisolid dosage forms with myriad applications, including anti-tumour, anti-inflammatory, cardiovascular and metabolic.

With 900 employees spread across four production plants located between Milan, Piacenza and Ferrara, DMX Pharma is set to become the largest independent Italian CDMO; equipped with state-of-the-art laboratories capable of supporting its customers in complex research and development (R&D) projects, starting from the investigational phase and product pre-formulation studies, up to the scale up of commercial production.

Vittorio Pignatti-Morano, Chairman and Co-Founder at Trilantic Europe, said: “This merger exemplifies our commitment to growing our portfolio companies into global players, and underscores our ability to identify strategic consolidation opportunities in ever-developing markets. By integrating both Doppel Farmaceutici’s and Mipharm’s unique strengths, scale-up capabilities, and advanced technologies, we're establishing a comprehensive platform to serve the intricate needs of global pharmaceutical clients, supporting with a broader range of activities and sophisticated drug development and manufacturing. We look forward to working with Alto Partners in this next chapter of the companies’ growth journeys.

Maurizio Silvestri, current Executive President of Mipharm and newly appointed Executive President of Domixtar Pharmaceuticals, said: "This strategic merger delivers powerful synergies both commercially and technologically, creating a real powerhouse in the pharmaceuticals market by combining decades of expertise with cutting-edge innovation.”
The terms of the transaction are not disclosed. Trilantic Europe was advised by LMCR / Studio Legale, EY, goetzpartners, ERM and Foglia & Partners.

Press Contact :

Trilantic Europe:

Agnes Riousse/Camilla Wyatt

Citigate Dewe Rogerson

E: agnes.riousse@citigatedewerogerson.com / camilla.wyatt@citigatedewerogerson.com 

T: +44 7770 762828

About Trilantic Europe

Trilantic Europe is a mid-market private equity firm focused on management buyouts, buy-ins and partnerships with founders, families and management teams across its themes and sectors of focus including energy transition, consumer and leisure, business services and healthcare. Trilantic Europe is managed by an experienced group of over 30 investment professionals and 15 operating partners and senior advisors, having invested over €2.7bn in 30 platform portfolio companies since 2004 and currently managing c. €2.6bn in assets from a wide base of investors.

More information: www.trilanticeurope.com 

About Alto Partners

Alto Partners SGR S.p.A. is an independent management company founded by Stefano Scarpis and Raffaele de Courten, focusing on private equity investments in the Italian mid-market. With close to 25 years market experience and 50 transactions completed, it is a choice partner to accompany medium to long-term growth programmes of portfolio companies. The team works alongside entrepreneurial families and managers to address the generation transition and bridge expansion capital gaps. 

Alto Capital V, vintage 2022 (Euro 273 million raised) has completed 5 investment transactions to date: Larioplast (cosmetic and food packaging), Dierre Group (industrial security solutions) e EF Group (general contractor for fairs and tri-dimensional spaces), Fragesa (pizza restaurant chain under the brand “Fra Diavolo”) and Eurosirel (manufacturer and distributor of woundcare and cosmetic products).

More information: www.altopartners.it 

Firms to take equal stakes in new entity Domixtar Pharmaceuticals

Trilantic Europe, a leading mid-market, pan-European private equity investor, is pleased to announce the successful merger of portfolio company Doppel Farmaceutici, and Alto Partners-owned Mipharm. Completion of the transaction is expected to occur in September 2024.

Headquartered in Italy and founded in 1994 and 1998 respectively, Doppel Farmaceutici and Mipharm are two leading contract development and manufacturing organisations (CDMOs), bringing fully integrated drug development and manufacturing solutions to the pharmaceuticals market.

Trilantic Europe and Alto Partners will each be taking a 50% stake in the new merged entity, named Domixtar Pharmaceuticals (“DMX Pharma”). The entity generated an aggregate turnover of approximately 180 million euros in 2023 and will be led by current Mipharm Executive President, Maurizio Silvestri.

Together, Doppel Farmaceutici and Mipharm service a 100-strong, global portfolio of blue-chip clients, offering a comprehensive suite of technologies and products including liquid, solid and semisolid dosage forms with myriad applications, including anti-tumour, anti-inflammatory, cardiovascular and metabolic.

With 900 employees spread across four production plants located between Milan, Piacenza and Ferrara, DMX Pharma is set to become the largest independent Italian CDMO; equipped with state-of-the-art laboratories capable of supporting its customers in complex research and development (R&D) projects, starting from the investigational phase and product pre-formulation studies, up to the scale up of commercial production.

Vittorio Pignatti-Morano, Chairman and Co-Founder at Trilantic Europe, said: “This merger exemplifies our commitment to growing our portfolio companies into global players, and underscores our ability to identify strategic consolidation opportunities in ever-developing markets. By integrating both Doppel Farmaceutici’s and Mipharm’s unique strengths, scale-up capabilities, and advanced technologies, we're establishing a comprehensive platform to serve the intricate needs of global pharmaceutical clients, supporting with a broader range of activities and sophisticated drug development and manufacturing. We look forward to working with Alto Partners in this next chapter of the companies’ growth journeys.

Maurizio Silvestri, current Executive President of Mipharm and newly appointed Executive President of Domixtar Pharmaceuticals, said: "This strategic merger delivers powerful synergies both commercially and technologically, creating a real powerhouse in the pharmaceuticals market by combining decades of expertise with cutting-edge innovation.”
The terms of the transaction are not disclosed. Trilantic Europe was advised by LMCR / Studio Legale, EY, goetzpartners, ERM and Foglia & Partners.

Press Contact :

Trilantic Europe:

Agnes Riousse/Camilla Wyatt

Citigate Dewe Rogerson

E: agnes.riousse@citigatedewerogerson.com / camilla.wyatt@citigatedewerogerson.com 

T: +44 7770 762828

About Trilantic Europe

Trilantic Europe is a mid-market private equity firm focused on management buyouts, buy-ins and partnerships with founders, families and management teams across its themes and sectors of focus including energy transition, consumer and leisure, business services and healthcare. Trilantic Europe is managed by an experienced group of over 30 investment professionals and 15 operating partners and senior advisors, having invested over €2.7bn in 30 platform portfolio companies since 2004 and currently managing c. €2.6bn in assets from a wide base of investors.

More information: www.trilanticeurope.com 

About Alto Partners

Alto Partners SGR S.p.A. is an independent management company founded by Stefano Scarpis and Raffaele de Courten, focusing on private equity investments in the Italian mid-market. With close to 25 years market experience and 50 transactions completed, it is a choice partner to accompany medium to long-term growth programmes of portfolio companies. The team works alongside entrepreneurial families and managers to address the generation transition and bridge expansion capital gaps. 

Alto Capital V, vintage 2022 (Euro 273 million raised) has completed 5 investment transactions to date: Larioplast (cosmetic and food packaging), Dierre Group (industrial security solutions) e EF Group (general contractor for fairs and tri-dimensional spaces), Fragesa (pizza restaurant chain under the brand “Fra Diavolo”) and Eurosirel (manufacturer and distributor of woundcare and cosmetic products).

More information: www.altopartners.it 

Firms to take equal stakes in new entity Domixtar Pharmaceuticals

Trilantic Europe, a leading mid-market, pan-European private equity investor, is pleased to announce the successful merger of portfolio company Doppel Farmaceutici, and Alto Partners-owned Mipharm. Completion of the transaction is expected to occur in September 2024.

Headquartered in Italy and founded in 1994 and 1998 respectively, Doppel Farmaceutici and Mipharm are two leading contract development and manufacturing organisations (CDMOs), bringing fully integrated drug development and manufacturing solutions to the pharmaceuticals market.

Trilantic Europe and Alto Partners will each be taking a 50% stake in the new merged entity, named Domixtar Pharmaceuticals (“DMX Pharma”). The entity generated an aggregate turnover of approximately 180 million euros in 2023 and will be led by current Mipharm Executive President, Maurizio Silvestri.

Together, Doppel Farmaceutici and Mipharm service a 100-strong, global portfolio of blue-chip clients, offering a comprehensive suite of technologies and products including liquid, solid and semisolid dosage forms with myriad applications, including anti-tumour, anti-inflammatory, cardiovascular and metabolic.

With 900 employees spread across four production plants located between Milan, Piacenza and Ferrara, DMX Pharma is set to become the largest independent Italian CDMO; equipped with state-of-the-art laboratories capable of supporting its customers in complex research and development (R&D) projects, starting from the investigational phase and product pre-formulation studies, up to the scale up of commercial production.

Vittorio Pignatti-Morano, Chairman and Co-Founder at Trilantic Europe, said: “This merger exemplifies our commitment to growing our portfolio companies into global players, and underscores our ability to identify strategic consolidation opportunities in ever-developing markets. By integrating both Doppel Farmaceutici’s and Mipharm’s unique strengths, scale-up capabilities, and advanced technologies, we're establishing a comprehensive platform to serve the intricate needs of global pharmaceutical clients, supporting with a broader range of activities and sophisticated drug development and manufacturing. We look forward to working with Alto Partners in this next chapter of the companies’ growth journeys.

Maurizio Silvestri, current Executive President of Mipharm and newly appointed Executive President of Domixtar Pharmaceuticals, said: "This strategic merger delivers powerful synergies both commercially and technologically, creating a real powerhouse in the pharmaceuticals market by combining decades of expertise with cutting-edge innovation.”
The terms of the transaction are not disclosed. Trilantic Europe was advised by LMCR / Studio Legale, EY, goetzpartners, ERM and Foglia & Partners.

Press Contact :

Trilantic Europe:

Agnes Riousse/Camilla Wyatt

Citigate Dewe Rogerson

E: agnes.riousse@citigatedewerogerson.com / camilla.wyatt@citigatedewerogerson.com 

T: +44 7770 762828

About Trilantic Europe

Trilantic Europe is a mid-market private equity firm focused on management buyouts, buy-ins and partnerships with founders, families and management teams across its themes and sectors of focus including energy transition, consumer and leisure, business services and healthcare. Trilantic Europe is managed by an experienced group of over 30 investment professionals and 15 operating partners and senior advisors, having invested over €2.7bn in 30 platform portfolio companies since 2004 and currently managing c. €2.6bn in assets from a wide base of investors.

More information: www.trilanticeurope.com 

About Alto Partners

Alto Partners SGR S.p.A. is an independent management company founded by Stefano Scarpis and Raffaele de Courten, focusing on private equity investments in the Italian mid-market. With close to 25 years market experience and 50 transactions completed, it is a choice partner to accompany medium to long-term growth programmes of portfolio companies. The team works alongside entrepreneurial families and managers to address the generation transition and bridge expansion capital gaps. 

Alto Capital V, vintage 2022 (Euro 273 million raised) has completed 5 investment transactions to date: Larioplast (cosmetic and food packaging), Dierre Group (industrial security solutions) e EF Group (general contractor for fairs and tri-dimensional spaces), Fragesa (pizza restaurant chain under the brand “Fra Diavolo”) and Eurosirel (manufacturer and distributor of woundcare and cosmetic products).

More information: www.altopartners.it 

Firms to take equal stakes in new entity Domixtar Pharmaceuticals

Trilantic Europe, a leading mid-market, pan-European private equity investor, is pleased to announce the successful merger of portfolio company Doppel Farmaceutici, and Alto Partners-owned Mipharm. Completion of the transaction is expected to occur in September 2024.

Headquartered in Italy and founded in 1994 and 1998 respectively, Doppel Farmaceutici and Mipharm are two leading contract development and manufacturing organisations (CDMOs), bringing fully integrated drug development and manufacturing solutions to the pharmaceuticals market.

Trilantic Europe and Alto Partners will each be taking a 50% stake in the new merged entity, named Domixtar Pharmaceuticals (“DMX Pharma”). The entity generated an aggregate turnover of approximately 180 million euros in 2023 and will be led by current Mipharm Executive President, Maurizio Silvestri.

Together, Doppel Farmaceutici and Mipharm service a 100-strong, global portfolio of blue-chip clients, offering a comprehensive suite of technologies and products including liquid, solid and semisolid dosage forms with myriad applications, including anti-tumour, anti-inflammatory, cardiovascular and metabolic.

With 900 employees spread across four production plants located between Milan, Piacenza and Ferrara, DMX Pharma is set to become the largest independent Italian CDMO; equipped with state-of-the-art laboratories capable of supporting its customers in complex research and development (R&D) projects, starting from the investigational phase and product pre-formulation studies, up to the scale up of commercial production.

Vittorio Pignatti-Morano, Chairman and Co-Founder at Trilantic Europe, said: “This merger exemplifies our commitment to growing our portfolio companies into global players, and underscores our ability to identify strategic consolidation opportunities in ever-developing markets. By integrating both Doppel Farmaceutici’s and Mipharm’s unique strengths, scale-up capabilities, and advanced technologies, we're establishing a comprehensive platform to serve the intricate needs of global pharmaceutical clients, supporting with a broader range of activities and sophisticated drug development and manufacturing. We look forward to working with Alto Partners in this next chapter of the companies’ growth journeys.

Maurizio Silvestri, current Executive President of Mipharm and newly appointed Executive President of Domixtar Pharmaceuticals, said: "This strategic merger delivers powerful synergies both commercially and technologically, creating a real powerhouse in the pharmaceuticals market by combining decades of expertise with cutting-edge innovation.”
The terms of the transaction are not disclosed. Trilantic Europe was advised by LMCR / Studio Legale, EY, goetzpartners, ERM and Foglia & Partners.

Press Contact :

Trilantic Europe:

Agnes Riousse/Camilla Wyatt

Citigate Dewe Rogerson

E: agnes.riousse@citigatedewerogerson.com / camilla.wyatt@citigatedewerogerson.com 

T: +44 7770 762828

About Trilantic Europe

Trilantic Europe is a mid-market private equity firm focused on management buyouts, buy-ins and partnerships with founders, families and management teams across its themes and sectors of focus including energy transition, consumer and leisure, business services and healthcare. Trilantic Europe is managed by an experienced group of over 30 investment professionals and 15 operating partners and senior advisors, having invested over €2.7bn in 30 platform portfolio companies since 2004 and currently managing c. €2.6bn in assets from a wide base of investors.

More information: www.trilanticeurope.com 

About Alto Partners

Alto Partners SGR S.p.A. is an independent management company founded by Stefano Scarpis and Raffaele de Courten, focusing on private equity investments in the Italian mid-market. With close to 25 years market experience and 50 transactions completed, it is a choice partner to accompany medium to long-term growth programmes of portfolio companies. The team works alongside entrepreneurial families and managers to address the generation transition and bridge expansion capital gaps. 

Alto Capital V, vintage 2022 (Euro 273 million raised) has completed 5 investment transactions to date: Larioplast (cosmetic and food packaging), Dierre Group (industrial security solutions) e EF Group (general contractor for fairs and tri-dimensional spaces), Fragesa (pizza restaurant chain under the brand “Fra Diavolo”) and Eurosirel (manufacturer and distributor of woundcare and cosmetic products).

More information: www.altopartners.it 

Firms to take equal stakes in new entity Domixtar Pharmaceuticals

Trilantic Europe, a leading mid-market, pan-European private equity investor, is pleased to announce the successful merger of portfolio company Doppel Farmaceutici, and Alto Partners-owned Mipharm. Completion of the transaction is expected to occur in September 2024.

Headquartered in Italy and founded in 1994 and 1998 respectively, Doppel Farmaceutici and Mipharm are two leading contract development and manufacturing organisations (CDMOs), bringing fully integrated drug development and manufacturing solutions to the pharmaceuticals market.

Trilantic Europe and Alto Partners will each be taking a 50% stake in the new merged entity, named Domixtar Pharmaceuticals (“DMX Pharma”). The entity generated an aggregate turnover of approximately 180 million euros in 2023 and will be led by current Mipharm Executive President, Maurizio Silvestri.

Together, Doppel Farmaceutici and Mipharm service a 100-strong, global portfolio of blue-chip clients, offering a comprehensive suite of technologies and products including liquid, solid and semisolid dosage forms with myriad applications, including anti-tumour, anti-inflammatory, cardiovascular and metabolic.

With 900 employees spread across four production plants located between Milan, Piacenza and Ferrara, DMX Pharma is set to become the largest independent Italian CDMO; equipped with state-of-the-art laboratories capable of supporting its customers in complex research and development (R&D) projects, starting from the investigational phase and product pre-formulation studies, up to the scale up of commercial production.

Vittorio Pignatti-Morano, Chairman and Co-Founder at Trilantic Europe, said: “This merger exemplifies our commitment to growing our portfolio companies into global players, and underscores our ability to identify strategic consolidation opportunities in ever-developing markets. By integrating both Doppel Farmaceutici’s and Mipharm’s unique strengths, scale-up capabilities, and advanced technologies, we're establishing a comprehensive platform to serve the intricate needs of global pharmaceutical clients, supporting with a broader range of activities and sophisticated drug development and manufacturing. We look forward to working with Alto Partners in this next chapter of the companies’ growth journeys.

Maurizio Silvestri, current Executive President of Mipharm and newly appointed Executive President of Domixtar Pharmaceuticals, said: "This strategic merger delivers powerful synergies both commercially and technologically, creating a real powerhouse in the pharmaceuticals market by combining decades of expertise with cutting-edge innovation.”
The terms of the transaction are not disclosed. Trilantic Europe was advised by LMCR / Studio Legale, EY, goetzpartners, ERM and Foglia & Partners.

Press Contact :

Trilantic Europe:

Agnes Riousse/Camilla Wyatt

Citigate Dewe Rogerson

E: agnes.riousse@citigatedewerogerson.com / camilla.wyatt@citigatedewerogerson.com 

T: +44 7770 762828

About Trilantic Europe

Trilantic Europe is a mid-market private equity firm focused on management buyouts, buy-ins and partnerships with founders, families and management teams across its themes and sectors of focus including energy transition, consumer and leisure, business services and healthcare. Trilantic Europe is managed by an experienced group of over 30 investment professionals and 15 operating partners and senior advisors, having invested over €2.7bn in 30 platform portfolio companies since 2004 and currently managing c. €2.6bn in assets from a wide base of investors.

More information: www.trilanticeurope.com 

About Alto Partners

Alto Partners SGR S.p.A. is an independent management company founded by Stefano Scarpis and Raffaele de Courten, focusing on private equity investments in the Italian mid-market. With close to 25 years market experience and 50 transactions completed, it is a choice partner to accompany medium to long-term growth programmes of portfolio companies. The team works alongside entrepreneurial families and managers to address the generation transition and bridge expansion capital gaps. 

Alto Capital V, vintage 2022 (Euro 273 million raised) has completed 5 investment transactions to date: Larioplast (cosmetic and food packaging), Dierre Group (industrial security solutions) e EF Group (general contractor for fairs and tri-dimensional spaces), Fragesa (pizza restaurant chain under the brand “Fra Diavolo”) and Eurosirel (manufacturer and distributor of woundcare and cosmetic products).

More information: www.altopartners.it 

Firms to take equal stakes in new entity Domixtar Pharmaceuticals

Trilantic Europe, a leading mid-market, pan-European private equity investor, is pleased to announce the successful merger of portfolio company Doppel Farmaceutici, and Alto Partners-owned Mipharm. Completion of the transaction is expected to occur in September 2024.

Headquartered in Italy and founded in 1994 and 1998 respectively, Doppel Farmaceutici and Mipharm are two leading contract development and manufacturing organisations (CDMOs), bringing fully integrated drug development and manufacturing solutions to the pharmaceuticals market.

Trilantic Europe and Alto Partners will each be taking a 50% stake in the new merged entity, named Domixtar Pharmaceuticals (“DMX Pharma”). The entity generated an aggregate turnover of approximately 180 million euros in 2023 and will be led by current Mipharm Executive President, Maurizio Silvestri.

Together, Doppel Farmaceutici and Mipharm service a 100-strong, global portfolio of blue-chip clients, offering a comprehensive suite of technologies and products including liquid, solid and semisolid dosage forms with myriad applications, including anti-tumour, anti-inflammatory, cardiovascular and metabolic.

With 900 employees spread across four production plants located between Milan, Piacenza and Ferrara, DMX Pharma is set to become the largest independent Italian CDMO; equipped with state-of-the-art laboratories capable of supporting its customers in complex research and development (R&D) projects, starting from the investigational phase and product pre-formulation studies, up to the scale up of commercial production.

Vittorio Pignatti-Morano, Chairman and Co-Founder at Trilantic Europe, said: “This merger exemplifies our commitment to growing our portfolio companies into global players, and underscores our ability to identify strategic consolidation opportunities in ever-developing markets. By integrating both Doppel Farmaceutici’s and Mipharm’s unique strengths, scale-up capabilities, and advanced technologies, we're establishing a comprehensive platform to serve the intricate needs of global pharmaceutical clients, supporting with a broader range of activities and sophisticated drug development and manufacturing. We look forward to working with Alto Partners in this next chapter of the companies’ growth journeys.

Maurizio Silvestri, current Executive President of Mipharm and newly appointed Executive President of Domixtar Pharmaceuticals, said: "This strategic merger delivers powerful synergies both commercially and technologically, creating a real powerhouse in the pharmaceuticals market by combining decades of expertise with cutting-edge innovation.”
The terms of the transaction are not disclosed. Trilantic Europe was advised by LMCR / Studio Legale, EY, goetzpartners, ERM and Foglia & Partners.

Press Contact :

Trilantic Europe:

Agnes Riousse/Camilla Wyatt

Citigate Dewe Rogerson

E: agnes.riousse@citigatedewerogerson.com / camilla.wyatt@citigatedewerogerson.com 

T: +44 7770 762828

About Trilantic Europe

Trilantic Europe is a mid-market private equity firm focused on management buyouts, buy-ins and partnerships with founders, families and management teams across its themes and sectors of focus including energy transition, consumer and leisure, business services and healthcare. Trilantic Europe is managed by an experienced group of over 30 investment professionals and 15 operating partners and senior advisors, having invested over €2.7bn in 30 platform portfolio companies since 2004 and currently managing c. €2.6bn in assets from a wide base of investors.

More information: www.trilanticeurope.com 

About Alto Partners

Alto Partners SGR S.p.A. is an independent management company founded by Stefano Scarpis and Raffaele de Courten, focusing on private equity investments in the Italian mid-market. With close to 25 years market experience and 50 transactions completed, it is a choice partner to accompany medium to long-term growth programmes of portfolio companies. The team works alongside entrepreneurial families and managers to address the generation transition and bridge expansion capital gaps. 

Alto Capital V, vintage 2022 (Euro 273 million raised) has completed 5 investment transactions to date: Larioplast (cosmetic and food packaging), Dierre Group (industrial security solutions) e EF Group (general contractor for fairs and tri-dimensional spaces), Fragesa (pizza restaurant chain under the brand “Fra Diavolo”) and Eurosirel (manufacturer and distributor of woundcare and cosmetic products).

More information: www.altopartners.it 

Firms to take equal stakes in new entity Domixtar Pharmaceuticals

Trilantic Europe, a leading mid-market, pan-European private equity investor, is pleased to announce the successful merger of portfolio company Doppel Farmaceutici, and Alto Partners-owned Mipharm. Completion of the transaction is expected to occur in September 2024.

Headquartered in Italy and founded in 1994 and 1998 respectively, Doppel Farmaceutici and Mipharm are two leading contract development and manufacturing organisations (CDMOs), bringing fully integrated drug development and manufacturing solutions to the pharmaceuticals market.

Trilantic Europe and Alto Partners will each be taking a 50% stake in the new merged entity, named Domixtar Pharmaceuticals (“DMX Pharma”). The entity generated an aggregate turnover of approximately 180 million euros in 2023 and will be led by current Mipharm Executive President, Maurizio Silvestri.

Together, Doppel Farmaceutici and Mipharm service a 100-strong, global portfolio of blue-chip clients, offering a comprehensive suite of technologies and products including liquid, solid and semisolid dosage forms with myriad applications, including anti-tumour, anti-inflammatory, cardiovascular and metabolic.

With 900 employees spread across four production plants located between Milan, Piacenza and Ferrara, DMX Pharma is set to become the largest independent Italian CDMO; equipped with state-of-the-art laboratories capable of supporting its customers in complex research and development (R&D) projects, starting from the investigational phase and product pre-formulation studies, up to the scale up of commercial production.

Vittorio Pignatti-Morano, Chairman and Co-Founder at Trilantic Europe, said: “This merger exemplifies our commitment to growing our portfolio companies into global players, and underscores our ability to identify strategic consolidation opportunities in ever-developing markets. By integrating both Doppel Farmaceutici’s and Mipharm’s unique strengths, scale-up capabilities, and advanced technologies, we're establishing a comprehensive platform to serve the intricate needs of global pharmaceutical clients, supporting with a broader range of activities and sophisticated drug development and manufacturing. We look forward to working with Alto Partners in this next chapter of the companies’ growth journeys.

Maurizio Silvestri, current Executive President of Mipharm and newly appointed Executive President of Domixtar Pharmaceuticals, said: "This strategic merger delivers powerful synergies both commercially and technologically, creating a real powerhouse in the pharmaceuticals market by combining decades of expertise with cutting-edge innovation.”
The terms of the transaction are not disclosed. Trilantic Europe was advised by LMCR / Studio Legale, EY, goetzpartners, ERM and Foglia & Partners.

Press Contact :

Trilantic Europe:

Agnes Riousse/Camilla Wyatt

Citigate Dewe Rogerson

E: agnes.riousse@citigatedewerogerson.com / camilla.wyatt@citigatedewerogerson.com 

T: +44 7770 762828

About Trilantic Europe

Trilantic Europe is a mid-market private equity firm focused on management buyouts, buy-ins and partnerships with founders, families and management teams across its themes and sectors of focus including energy transition, consumer and leisure, business services and healthcare. Trilantic Europe is managed by an experienced group of over 30 investment professionals and 15 operating partners and senior advisors, having invested over €2.7bn in 30 platform portfolio companies since 2004 and currently managing c. €2.6bn in assets from a wide base of investors.

More information: www.trilanticeurope.com 

About Alto Partners

Alto Partners SGR S.p.A. is an independent management company founded by Stefano Scarpis and Raffaele de Courten, focusing on private equity investments in the Italian mid-market. With close to 25 years market experience and 50 transactions completed, it is a choice partner to accompany medium to long-term growth programmes of portfolio companies. The team works alongside entrepreneurial families and managers to address the generation transition and bridge expansion capital gaps. 

Alto Capital V, vintage 2022 (Euro 273 million raised) has completed 5 investment transactions to date: Larioplast (cosmetic and food packaging), Dierre Group (industrial security solutions) e EF Group (general contractor for fairs and tri-dimensional spaces), Fragesa (pizza restaurant chain under the brand “Fra Diavolo”) and Eurosirel (manufacturer and distributor of woundcare and cosmetic products).

More information: www.altopartners.it 

Firms to take equal stakes in new entity Domixtar Pharmaceuticals

Trilantic Europe, a leading mid-market, pan-European private equity investor, is pleased to announce the successful merger of portfolio company Doppel Farmaceutici, and Alto Partners-owned Mipharm. Completion of the transaction is expected to occur in September 2024.

Headquartered in Italy and founded in 1994 and 1998 respectively, Doppel Farmaceutici and Mipharm are two leading contract development and manufacturing organisations (CDMOs), bringing fully integrated drug development and manufacturing solutions to the pharmaceuticals market.

Trilantic Europe and Alto Partners will each be taking a 50% stake in the new merged entity, named Domixtar Pharmaceuticals (“DMX Pharma”). The entity generated an aggregate turnover of approximately 180 million euros in 2023 and will be led by current Mipharm Executive President, Maurizio Silvestri.

Together, Doppel Farmaceutici and Mipharm service a 100-strong, global portfolio of blue-chip clients, offering a comprehensive suite of technologies and products including liquid, solid and semisolid dosage forms with myriad applications, including anti-tumour, anti-inflammatory, cardiovascular and metabolic.

With 900 employees spread across four production plants located between Milan, Piacenza and Ferrara, DMX Pharma is set to become the largest independent Italian CDMO; equipped with state-of-the-art laboratories capable of supporting its customers in complex research and development (R&D) projects, starting from the investigational phase and product pre-formulation studies, up to the scale up of commercial production.

Vittorio Pignatti-Morano, Chairman and Co-Founder at Trilantic Europe, said: “This merger exemplifies our commitment to growing our portfolio companies into global players, and underscores our ability to identify strategic consolidation opportunities in ever-developing markets. By integrating both Doppel Farmaceutici’s and Mipharm’s unique strengths, scale-up capabilities, and advanced technologies, we're establishing a comprehensive platform to serve the intricate needs of global pharmaceutical clients, supporting with a broader range of activities and sophisticated drug development and manufacturing. We look forward to working with Alto Partners in this next chapter of the companies’ growth journeys.

Maurizio Silvestri, current Executive President of Mipharm and newly appointed Executive President of Domixtar Pharmaceuticals, said: "This strategic merger delivers powerful synergies both commercially and technologically, creating a real powerhouse in the pharmaceuticals market by combining decades of expertise with cutting-edge innovation.”
The terms of the transaction are not disclosed. Trilantic Europe was advised by LMCR / Studio Legale, EY, goetzpartners, ERM and Foglia & Partners.

Press Contact :

Trilantic Europe:

Agnes Riousse/Camilla Wyatt

Citigate Dewe Rogerson

E: agnes.riousse@citigatedewerogerson.com / camilla.wyatt@citigatedewerogerson.com 

T: +44 7770 762828

About Trilantic Europe

Trilantic Europe is a mid-market private equity firm focused on management buyouts, buy-ins and partnerships with founders, families and management teams across its themes and sectors of focus including energy transition, consumer and leisure, business services and healthcare. Trilantic Europe is managed by an experienced group of over 30 investment professionals and 15 operating partners and senior advisors, having invested over €2.7bn in 30 platform portfolio companies since 2004 and currently managing c. €2.6bn in assets from a wide base of investors.

More information: www.trilanticeurope.com 

About Alto Partners

Alto Partners SGR S.p.A. is an independent management company founded by Stefano Scarpis and Raffaele de Courten, focusing on private equity investments in the Italian mid-market. With close to 25 years market experience and 50 transactions completed, it is a choice partner to accompany medium to long-term growth programmes of portfolio companies. The team works alongside entrepreneurial families and managers to address the generation transition and bridge expansion capital gaps. 

Alto Capital V, vintage 2022 (Euro 273 million raised) has completed 5 investment transactions to date: Larioplast (cosmetic and food packaging), Dierre Group (industrial security solutions) e EF Group (general contractor for fairs and tri-dimensional spaces), Fragesa (pizza restaurant chain under the brand “Fra Diavolo”) and Eurosirel (manufacturer and distributor of woundcare and cosmetic products).

More information: www.altopartners.it 

Firms to take equal stakes in new entity Domixtar Pharmaceuticals

Trilantic Europe, a leading mid-market, pan-European private equity investor, is pleased to announce the successful merger of portfolio company Doppel Farmaceutici, and Alto Partners-owned Mipharm. Completion of the transaction is expected to occur in September 2024.

Headquartered in Italy and founded in 1994 and 1998 respectively, Doppel Farmaceutici and Mipharm are two leading contract development and manufacturing organisations (CDMOs), bringing fully integrated drug development and manufacturing solutions to the pharmaceuticals market.

Trilantic Europe and Alto Partners will each be taking a 50% stake in the new merged entity, named Domixtar Pharmaceuticals (“DMX Pharma”). The entity generated an aggregate turnover of approximately 180 million euros in 2023 and will be led by current Mipharm Executive President, Maurizio Silvestri.

Together, Doppel Farmaceutici and Mipharm service a 100-strong, global portfolio of blue-chip clients, offering a comprehensive suite of technologies and products including liquid, solid and semisolid dosage forms with myriad applications, including anti-tumour, anti-inflammatory, cardiovascular and metabolic.

With 900 employees spread across four production plants located between Milan, Piacenza and Ferrara, DMX Pharma is set to become the largest independent Italian CDMO; equipped with state-of-the-art laboratories capable of supporting its customers in complex research and development (R&D) projects, starting from the investigational phase and product pre-formulation studies, up to the scale up of commercial production.

Vittorio Pignatti-Morano, Chairman and Co-Founder at Trilantic Europe, said: “This merger exemplifies our commitment to growing our portfolio companies into global players, and underscores our ability to identify strategic consolidation opportunities in ever-developing markets. By integrating both Doppel Farmaceutici’s and Mipharm’s unique strengths, scale-up capabilities, and advanced technologies, we're establishing a comprehensive platform to serve the intricate needs of global pharmaceutical clients, supporting with a broader range of activities and sophisticated drug development and manufacturing. We look forward to working with Alto Partners in this next chapter of the companies’ growth journeys.

Maurizio Silvestri, current Executive President of Mipharm and newly appointed Executive President of Domixtar Pharmaceuticals, said: "This strategic merger delivers powerful synergies both commercially and technologically, creating a real powerhouse in the pharmaceuticals market by combining decades of expertise with cutting-edge innovation.”
The terms of the transaction are not disclosed. Trilantic Europe was advised by LMCR / Studio Legale, EY, goetzpartners, ERM and Foglia & Partners.

Press Contact :

Trilantic Europe:

Agnes Riousse/Camilla Wyatt

Citigate Dewe Rogerson

E: agnes.riousse@citigatedewerogerson.com / camilla.wyatt@citigatedewerogerson.com 

T: +44 7770 762828

About Trilantic Europe

Trilantic Europe is a mid-market private equity firm focused on management buyouts, buy-ins and partnerships with founders, families and management teams across its themes and sectors of focus including energy transition, consumer and leisure, business services and healthcare. Trilantic Europe is managed by an experienced group of over 30 investment professionals and 15 operating partners and senior advisors, having invested over €2.7bn in 30 platform portfolio companies since 2004 and currently managing c. €2.6bn in assets from a wide base of investors.

More information: www.trilanticeurope.com 

About Alto Partners

Alto Partners SGR S.p.A. is an independent management company founded by Stefano Scarpis and Raffaele de Courten, focusing on private equity investments in the Italian mid-market. With close to 25 years market experience and 50 transactions completed, it is a choice partner to accompany medium to long-term growth programmes of portfolio companies. The team works alongside entrepreneurial families and managers to address the generation transition and bridge expansion capital gaps. 

Alto Capital V, vintage 2022 (Euro 273 million raised) has completed 5 investment transactions to date: Larioplast (cosmetic and food packaging), Dierre Group (industrial security solutions) e EF Group (general contractor for fairs and tri-dimensional spaces), Fragesa (pizza restaurant chain under the brand “Fra Diavolo”) and Eurosirel (manufacturer and distributor of woundcare and cosmetic products).

More information: www.altopartners.it 

Firms to take equal stakes in new entity Domixtar Pharmaceuticals

Trilantic Europe, a leading mid-market, pan-European private equity investor, is pleased to announce the successful merger of portfolio company Doppel Farmaceutici, and Alto Partners-owned Mipharm. Completion of the transaction is expected to occur in September 2024.

Headquartered in Italy and founded in 1994 and 1998 respectively, Doppel Farmaceutici and Mipharm are two leading contract development and manufacturing organisations (CDMOs), bringing fully integrated drug development and manufacturing solutions to the pharmaceuticals market.

Trilantic Europe and Alto Partners will each be taking a 50% stake in the new merged entity, named Domixtar Pharmaceuticals (“DMX Pharma”). The entity generated an aggregate turnover of approximately 180 million euros in 2023 and will be led by current Mipharm Executive President, Maurizio Silvestri.

Together, Doppel Farmaceutici and Mipharm service a 100-strong, global portfolio of blue-chip clients, offering a comprehensive suite of technologies and products including liquid, solid and semisolid dosage forms with myriad applications, including anti-tumour, anti-inflammatory, cardiovascular and metabolic.

With 900 employees spread across four production plants located between Milan, Piacenza and Ferrara, DMX Pharma is set to become the largest independent Italian CDMO; equipped with state-of-the-art laboratories capable of supporting its customers in complex research and development (R&D) projects, starting from the investigational phase and product pre-formulation studies, up to the scale up of commercial production.

Vittorio Pignatti-Morano, Chairman and Co-Founder at Trilantic Europe, said: “This merger exemplifies our commitment to growing our portfolio companies into global players, and underscores our ability to identify strategic consolidation opportunities in ever-developing markets. By integrating both Doppel Farmaceutici’s and Mipharm’s unique strengths, scale-up capabilities, and advanced technologies, we're establishing a comprehensive platform to serve the intricate needs of global pharmaceutical clients, supporting with a broader range of activities and sophisticated drug development and manufacturing. We look forward to working with Alto Partners in this next chapter of the companies’ growth journeys.

Maurizio Silvestri, current Executive President of Mipharm and newly appointed Executive President of Domixtar Pharmaceuticals, said: "This strategic merger delivers powerful synergies both commercially and technologically, creating a real powerhouse in the pharmaceuticals market by combining decades of expertise with cutting-edge innovation.”
The terms of the transaction are not disclosed. Trilantic Europe was advised by LMCR / Studio Legale, EY, goetzpartners, ERM and Foglia & Partners.

Press Contact :

Trilantic Europe:

Agnes Riousse/Camilla Wyatt

Citigate Dewe Rogerson

E: agnes.riousse@citigatedewerogerson.com / camilla.wyatt@citigatedewerogerson.com 

T: +44 7770 762828

About Trilantic Europe

Trilantic Europe is a mid-market private equity firm focused on management buyouts, buy-ins and partnerships with founders, families and management teams across its themes and sectors of focus including energy transition, consumer and leisure, business services and healthcare. Trilantic Europe is managed by an experienced group of over 30 investment professionals and 15 operating partners and senior advisors, having invested over €2.7bn in 30 platform portfolio companies since 2004 and currently managing c. €2.6bn in assets from a wide base of investors.

More information: www.trilanticeurope.com 

About Alto Partners

Alto Partners SGR S.p.A. is an independent management company founded by Stefano Scarpis and Raffaele de Courten, focusing on private equity investments in the Italian mid-market. With close to 25 years market experience and 50 transactions completed, it is a choice partner to accompany medium to long-term growth programmes of portfolio companies. The team works alongside entrepreneurial families and managers to address the generation transition and bridge expansion capital gaps. 

Alto Capital V, vintage 2022 (Euro 273 million raised) has completed 5 investment transactions to date: Larioplast (cosmetic and food packaging), Dierre Group (industrial security solutions) e EF Group (general contractor for fairs and tri-dimensional spaces), Fragesa (pizza restaurant chain under the brand “Fra Diavolo”) and Eurosirel (manufacturer and distributor of woundcare and cosmetic products).

More information: www.altopartners.it 

Firms to take equal stakes in new entity Domixtar Pharmaceuticals

Trilantic Europe, a leading mid-market, pan-European private equity investor, is pleased to announce the successful merger of portfolio company Doppel Farmaceutici, and Alto Partners-owned Mipharm. Completion of the transaction is expected to occur in September 2024.

Headquartered in Italy and founded in 1994 and 1998 respectively, Doppel Farmaceutici and Mipharm are two leading contract development and manufacturing organisations (CDMOs), bringing fully integrated drug development and manufacturing solutions to the pharmaceuticals market.

Trilantic Europe and Alto Partners will each be taking a 50% stake in the new merged entity, named Domixtar Pharmaceuticals (“DMX Pharma”). The entity generated an aggregate turnover of approximately 180 million euros in 2023 and will be led by current Mipharm Executive President, Maurizio Silvestri.

Together, Doppel Farmaceutici and Mipharm service a 100-strong, global portfolio of blue-chip clients, offering a comprehensive suite of technologies and products including liquid, solid and semisolid dosage forms with myriad applications, including anti-tumour, anti-inflammatory, cardiovascular and metabolic.

With 900 employees spread across four production plants located between Milan, Piacenza and Ferrara, DMX Pharma is set to become the largest independent Italian CDMO; equipped with state-of-the-art laboratories capable of supporting its customers in complex research and development (R&D) projects, starting from the investigational phase and product pre-formulation studies, up to the scale up of commercial production.

Vittorio Pignatti-Morano, Chairman and Co-Founder at Trilantic Europe, said: “This merger exemplifies our commitment to growing our portfolio companies into global players, and underscores our ability to identify strategic consolidation opportunities in ever-developing markets. By integrating both Doppel Farmaceutici’s and Mipharm’s unique strengths, scale-up capabilities, and advanced technologies, we're establishing a comprehensive platform to serve the intricate needs of global pharmaceutical clients, supporting with a broader range of activities and sophisticated drug development and manufacturing. We look forward to working with Alto Partners in this next chapter of the companies’ growth journeys.

Maurizio Silvestri, current Executive President of Mipharm and newly appointed Executive President of Domixtar Pharmaceuticals, said: "This strategic merger delivers powerful synergies both commercially and technologically, creating a real powerhouse in the pharmaceuticals market by combining decades of expertise with cutting-edge innovation.”
The terms of the transaction are not disclosed. Trilantic Europe was advised by LMCR / Studio Legale, EY, goetzpartners, ERM and Foglia & Partners.

Press Contact :

Trilantic Europe:

Agnes Riousse/Camilla Wyatt

Citigate Dewe Rogerson

E: agnes.riousse@citigatedewerogerson.com / camilla.wyatt@citigatedewerogerson.com 

T: +44 7770 762828

About Trilantic Europe

Trilantic Europe is a mid-market private equity firm focused on management buyouts, buy-ins and partnerships with founders, families and management teams across its themes and sectors of focus including energy transition, consumer and leisure, business services and healthcare. Trilantic Europe is managed by an experienced group of over 30 investment professionals and 15 operating partners and senior advisors, having invested over €2.7bn in 30 platform portfolio companies since 2004 and currently managing c. €2.6bn in assets from a wide base of investors.

More information: www.trilanticeurope.com 

About Alto Partners

Alto Partners SGR S.p.A. is an independent management company founded by Stefano Scarpis and Raffaele de Courten, focusing on private equity investments in the Italian mid-market. With close to 25 years market experience and 50 transactions completed, it is a choice partner to accompany medium to long-term growth programmes of portfolio companies. The team works alongside entrepreneurial families and managers to address the generation transition and bridge expansion capital gaps. 

Alto Capital V, vintage 2022 (Euro 273 million raised) has completed 5 investment transactions to date: Larioplast (cosmetic and food packaging), Dierre Group (industrial security solutions) e EF Group (general contractor for fairs and tri-dimensional spaces), Fragesa (pizza restaurant chain under the brand “Fra Diavolo”) and Eurosirel (manufacturer and distributor of woundcare and cosmetic products).

More information: www.altopartners.it 

Firms to take equal stakes in new entity Domixtar Pharmaceuticals

Trilantic Europe, a leading mid-market, pan-European private equity investor, is pleased to announce the successful merger of portfolio company Doppel Farmaceutici, and Alto Partners-owned Mipharm. Completion of the transaction is expected to occur in September 2024.

Headquartered in Italy and founded in 1994 and 1998 respectively, Doppel Farmaceutici and Mipharm are two leading contract development and manufacturing organisations (CDMOs), bringing fully integrated drug development and manufacturing solutions to the pharmaceuticals market.

Trilantic Europe and Alto Partners will each be taking a 50% stake in the new merged entity, named Domixtar Pharmaceuticals (“DMX Pharma”). The entity generated an aggregate turnover of approximately 180 million euros in 2023 and will be led by current Mipharm Executive President, Maurizio Silvestri.

Together, Doppel Farmaceutici and Mipharm service a 100-strong, global portfolio of blue-chip clients, offering a comprehensive suite of technologies and products including liquid, solid and semisolid dosage forms with myriad applications, including anti-tumour, anti-inflammatory, cardiovascular and metabolic.

With 900 employees spread across four production plants located between Milan, Piacenza and Ferrara, DMX Pharma is set to become the largest independent Italian CDMO; equipped with state-of-the-art laboratories capable of supporting its customers in complex research and development (R&D) projects, starting from the investigational phase and product pre-formulation studies, up to the scale up of commercial production.

Vittorio Pignatti-Morano, Chairman and Co-Founder at Trilantic Europe, said: “This merger exemplifies our commitment to growing our portfolio companies into global players, and underscores our ability to identify strategic consolidation opportunities in ever-developing markets. By integrating both Doppel Farmaceutici’s and Mipharm’s unique strengths, scale-up capabilities, and advanced technologies, we're establishing a comprehensive platform to serve the intricate needs of global pharmaceutical clients, supporting with a broader range of activities and sophisticated drug development and manufacturing. We look forward to working with Alto Partners in this next chapter of the companies’ growth journeys.

Maurizio Silvestri, current Executive President of Mipharm and newly appointed Executive President of Domixtar Pharmaceuticals, said: "This strategic merger delivers powerful synergies both commercially and technologically, creating a real powerhouse in the pharmaceuticals market by combining decades of expertise with cutting-edge innovation.”
The terms of the transaction are not disclosed. Trilantic Europe was advised by LMCR / Studio Legale, EY, goetzpartners, ERM and Foglia & Partners.

Press Contact :

Trilantic Europe:

Agnes Riousse/Camilla Wyatt

Citigate Dewe Rogerson

E: agnes.riousse@citigatedewerogerson.com / camilla.wyatt@citigatedewerogerson.com 

T: +44 7770 762828

About Trilantic Europe

Trilantic Europe is a mid-market private equity firm focused on management buyouts, buy-ins and partnerships with founders, families and management teams across its themes and sectors of focus including energy transition, consumer and leisure, business services and healthcare. Trilantic Europe is managed by an experienced group of over 30 investment professionals and 15 operating partners and senior advisors, having invested over €2.7bn in 30 platform portfolio companies since 2004 and currently managing c. €2.6bn in assets from a wide base of investors.

More information: www.trilanticeurope.com 

About Alto Partners

Alto Partners SGR S.p.A. is an independent management company founded by Stefano Scarpis and Raffaele de Courten, focusing on private equity investments in the Italian mid-market. With close to 25 years market experience and 50 transactions completed, it is a choice partner to accompany medium to long-term growth programmes of portfolio companies. The team works alongside entrepreneurial families and managers to address the generation transition and bridge expansion capital gaps. 

Alto Capital V, vintage 2022 (Euro 273 million raised) has completed 5 investment transactions to date: Larioplast (cosmetic and food packaging), Dierre Group (industrial security solutions) e EF Group (general contractor for fairs and tri-dimensional spaces), Fragesa (pizza restaurant chain under the brand “Fra Diavolo”) and Eurosirel (manufacturer and distributor of woundcare and cosmetic products).

More information: www.altopartners.it 

Firms to take equal stakes in new entity Domixtar Pharmaceuticals

Trilantic Europe, a leading mid-market, pan-European private equity investor, is pleased to announce the successful merger of portfolio company Doppel Farmaceutici, and Alto Partners-owned Mipharm. Completion of the transaction is expected to occur in September 2024.

Headquartered in Italy and founded in 1994 and 1998 respectively, Doppel Farmaceutici and Mipharm are two leading contract development and manufacturing organisations (CDMOs), bringing fully integrated drug development and manufacturing solutions to the pharmaceuticals market.

Trilantic Europe and Alto Partners will each be taking a 50% stake in the new merged entity, named Domixtar Pharmaceuticals (“DMX Pharma”). The entity generated an aggregate turnover of approximately 180 million euros in 2023 and will be led by current Mipharm Executive President, Maurizio Silvestri.

Together, Doppel Farmaceutici and Mipharm service a 100-strong, global portfolio of blue-chip clients, offering a comprehensive suite of technologies and products including liquid, solid and semisolid dosage forms with myriad applications, including anti-tumour, anti-inflammatory, cardiovascular and metabolic.

With 900 employees spread across four production plants located between Milan, Piacenza and Ferrara, DMX Pharma is set to become the largest independent Italian CDMO; equipped with state-of-the-art laboratories capable of supporting its customers in complex research and development (R&D) projects, starting from the investigational phase and product pre-formulation studies, up to the scale up of commercial production.

Vittorio Pignatti-Morano, Chairman and Co-Founder at Trilantic Europe, said: “This merger exemplifies our commitment to growing our portfolio companies into global players, and underscores our ability to identify strategic consolidation opportunities in ever-developing markets. By integrating both Doppel Farmaceutici’s and Mipharm’s unique strengths, scale-up capabilities, and advanced technologies, we're establishing a comprehensive platform to serve the intricate needs of global pharmaceutical clients, supporting with a broader range of activities and sophisticated drug development and manufacturing. We look forward to working with Alto Partners in this next chapter of the companies’ growth journeys.

Maurizio Silvestri, current Executive President of Mipharm and newly appointed Executive President of Domixtar Pharmaceuticals, said: "This strategic merger delivers powerful synergies both commercially and technologically, creating a real powerhouse in the pharmaceuticals market by combining decades of expertise with cutting-edge innovation.”
The terms of the transaction are not disclosed. Trilantic Europe was advised by LMCR / Studio Legale, EY, goetzpartners, ERM and Foglia & Partners.

Press Contact :

Trilantic Europe:

Agnes Riousse/Camilla Wyatt

Citigate Dewe Rogerson

E: agnes.riousse@citigatedewerogerson.com / camilla.wyatt@citigatedewerogerson.com 

T: +44 7770 762828

About Trilantic Europe

Trilantic Europe is a mid-market private equity firm focused on management buyouts, buy-ins and partnerships with founders, families and management teams across its themes and sectors of focus including energy transition, consumer and leisure, business services and healthcare. Trilantic Europe is managed by an experienced group of over 30 investment professionals and 15 operating partners and senior advisors, having invested over €2.7bn in 30 platform portfolio companies since 2004 and currently managing c. €2.6bn in assets from a wide base of investors.

More information: www.trilanticeurope.com 

About Alto Partners

Alto Partners SGR S.p.A. is an independent management company founded by Stefano Scarpis and Raffaele de Courten, focusing on private equity investments in the Italian mid-market. With close to 25 years market experience and 50 transactions completed, it is a choice partner to accompany medium to long-term growth programmes of portfolio companies. The team works alongside entrepreneurial families and managers to address the generation transition and bridge expansion capital gaps. 

Alto Capital V, vintage 2022 (Euro 273 million raised) has completed 5 investment transactions to date: Larioplast (cosmetic and food packaging), Dierre Group (industrial security solutions) e EF Group (general contractor for fairs and tri-dimensional spaces), Fragesa (pizza restaurant chain under the brand “Fra Diavolo”) and Eurosirel (manufacturer and distributor of woundcare and cosmetic products).

More information: www.altopartners.it 

Firms to take equal stakes in new entity Domixtar Pharmaceuticals

Trilantic Europe, a leading mid-market, pan-European private equity investor, is pleased to announce the successful merger of portfolio company Doppel Farmaceutici, and Alto Partners-owned Mipharm. Completion of the transaction is expected to occur in September 2024.

Headquartered in Italy and founded in 1994 and 1998 respectively, Doppel Farmaceutici and Mipharm are two leading contract development and manufacturing organisations (CDMOs), bringing fully integrated drug development and manufacturing solutions to the pharmaceuticals market.

Trilantic Europe and Alto Partners will each be taking a 50% stake in the new merged entity, named Domixtar Pharmaceuticals (“DMX Pharma”). The entity generated an aggregate turnover of approximately 180 million euros in 2023 and will be led by current Mipharm Executive President, Maurizio Silvestri.

Together, Doppel Farmaceutici and Mipharm service a 100-strong, global portfolio of blue-chip clients, offering a comprehensive suite of technologies and products including liquid, solid and semisolid dosage forms with myriad applications, including anti-tumour, anti-inflammatory, cardiovascular and metabolic.

With 900 employees spread across four production plants located between Milan, Piacenza and Ferrara, DMX Pharma is set to become the largest independent Italian CDMO; equipped with state-of-the-art laboratories capable of supporting its customers in complex research and development (R&D) projects, starting from the investigational phase and product pre-formulation studies, up to the scale up of commercial production.

Vittorio Pignatti-Morano, Chairman and Co-Founder at Trilantic Europe, said: “This merger exemplifies our commitment to growing our portfolio companies into global players, and underscores our ability to identify strategic consolidation opportunities in ever-developing markets. By integrating both Doppel Farmaceutici’s and Mipharm’s unique strengths, scale-up capabilities, and advanced technologies, we're establishing a comprehensive platform to serve the intricate needs of global pharmaceutical clients, supporting with a broader range of activities and sophisticated drug development and manufacturing. We look forward to working with Alto Partners in this next chapter of the companies’ growth journeys.

Maurizio Silvestri, current Executive President of Mipharm and newly appointed Executive President of Domixtar Pharmaceuticals, said: "This strategic merger delivers powerful synergies both commercially and technologically, creating a real powerhouse in the pharmaceuticals market by combining decades of expertise with cutting-edge innovation.”
The terms of the transaction are not disclosed. Trilantic Europe was advised by LMCR / Studio Legale, EY, goetzpartners, ERM and Foglia & Partners.

Press Contact :

Trilantic Europe:

Agnes Riousse/Camilla Wyatt

Citigate Dewe Rogerson

E: agnes.riousse@citigatedewerogerson.com / camilla.wyatt@citigatedewerogerson.com 

T: +44 7770 762828

About Trilantic Europe

Trilantic Europe is a mid-market private equity firm focused on management buyouts, buy-ins and partnerships with founders, families and management teams across its themes and sectors of focus including energy transition, consumer and leisure, business services and healthcare. Trilantic Europe is managed by an experienced group of over 30 investment professionals and 15 operating partners and senior advisors, having invested over €2.7bn in 30 platform portfolio companies since 2004 and currently managing c. €2.6bn in assets from a wide base of investors.

More information: www.trilanticeurope.com 

About Alto Partners

Alto Partners SGR S.p.A. is an independent management company founded by Stefano Scarpis and Raffaele de Courten, focusing on private equity investments in the Italian mid-market. With close to 25 years market experience and 50 transactions completed, it is a choice partner to accompany medium to long-term growth programmes of portfolio companies. The team works alongside entrepreneurial families and managers to address the generation transition and bridge expansion capital gaps. 

Alto Capital V, vintage 2022 (Euro 273 million raised) has completed 5 investment transactions to date: Larioplast (cosmetic and food packaging), Dierre Group (industrial security solutions) e EF Group (general contractor for fairs and tri-dimensional spaces), Fragesa (pizza restaurant chain under the brand “Fra Diavolo”) and Eurosirel (manufacturer and distributor of woundcare and cosmetic products).

More information: www.altopartners.it 

Firms to take equal stakes in new entity Domixtar Pharmaceuticals

Trilantic Europe, a leading mid-market, pan-European private equity investor, is pleased to announce the successful merger of portfolio company Doppel Farmaceutici, and Alto Partners-owned Mipharm. Completion of the transaction is expected to occur in September 2024.

Headquartered in Italy and founded in 1994 and 1998 respectively, Doppel Farmaceutici and Mipharm are two leading contract development and manufacturing organisations (CDMOs), bringing fully integrated drug development and manufacturing solutions to the pharmaceuticals market.

Trilantic Europe and Alto Partners will each be taking a 50% stake in the new merged entity, named Domixtar Pharmaceuticals (“DMX Pharma”). The entity generated an aggregate turnover of approximately 180 million euros in 2023 and will be led by current Mipharm Executive President, Maurizio Silvestri.

Together, Doppel Farmaceutici and Mipharm service a 100-strong, global portfolio of blue-chip clients, offering a comprehensive suite of technologies and products including liquid, solid and semisolid dosage forms with myriad applications, including anti-tumour, anti-inflammatory, cardiovascular and metabolic.

With 900 employees spread across four production plants located between Milan, Piacenza and Ferrara, DMX Pharma is set to become the largest independent Italian CDMO; equipped with state-of-the-art laboratories capable of supporting its customers in complex research and development (R&D) projects, starting from the investigational phase and product pre-formulation studies, up to the scale up of commercial production.

Vittorio Pignatti-Morano, Chairman and Co-Founder at Trilantic Europe, said: “This merger exemplifies our commitment to growing our portfolio companies into global players, and underscores our ability to identify strategic consolidation opportunities in ever-developing markets. By integrating both Doppel Farmaceutici’s and Mipharm’s unique strengths, scale-up capabilities, and advanced technologies, we're establishing a comprehensive platform to serve the intricate needs of global pharmaceutical clients, supporting with a broader range of activities and sophisticated drug development and manufacturing. We look forward to working with Alto Partners in this next chapter of the companies’ growth journeys.

Maurizio Silvestri, current Executive President of Mipharm and newly appointed Executive President of Domixtar Pharmaceuticals, said: "This strategic merger delivers powerful synergies both commercially and technologically, creating a real powerhouse in the pharmaceuticals market by combining decades of expertise with cutting-edge innovation.”
The terms of the transaction are not disclosed. Trilantic Europe was advised by LMCR / Studio Legale, EY, goetzpartners, ERM and Foglia & Partners.

Press Contact :

Trilantic Europe:

Agnes Riousse/Camilla Wyatt

Citigate Dewe Rogerson

E: agnes.riousse@citigatedewerogerson.com / camilla.wyatt@citigatedewerogerson.com 

T: +44 7770 762828

About Trilantic Europe

Trilantic Europe is a mid-market private equity firm focused on management buyouts, buy-ins and partnerships with founders, families and management teams across its themes and sectors of focus including energy transition, consumer and leisure, business services and healthcare. Trilantic Europe is managed by an experienced group of over 30 investment professionals and 15 operating partners and senior advisors, having invested over €2.7bn in 30 platform portfolio companies since 2004 and currently managing c. €2.6bn in assets from a wide base of investors.

More information: www.trilanticeurope.com 

About Alto Partners

Alto Partners SGR S.p.A. is an independent management company founded by Stefano Scarpis and Raffaele de Courten, focusing on private equity investments in the Italian mid-market. With close to 25 years market experience and 50 transactions completed, it is a choice partner to accompany medium to long-term growth programmes of portfolio companies. The team works alongside entrepreneurial families and managers to address the generation transition and bridge expansion capital gaps. 

Alto Capital V, vintage 2022 (Euro 273 million raised) has completed 5 investment transactions to date: Larioplast (cosmetic and food packaging), Dierre Group (industrial security solutions) e EF Group (general contractor for fairs and tri-dimensional spaces), Fragesa (pizza restaurant chain under the brand “Fra Diavolo”) and Eurosirel (manufacturer and distributor of woundcare and cosmetic products).

More information: www.altopartners.it 

Firms to take equal stakes in new entity Domixtar Pharmaceuticals

Trilantic Europe, a leading mid-market, pan-European private equity investor, is pleased to announce the successful merger of portfolio company Doppel Farmaceutici, and Alto Partners-owned Mipharm. Completion of the transaction is expected to occur in September 2024.

Headquartered in Italy and founded in 1994 and 1998 respectively, Doppel Farmaceutici and Mipharm are two leading contract development and manufacturing organisations (CDMOs), bringing fully integrated drug development and manufacturing solutions to the pharmaceuticals market.

Trilantic Europe and Alto Partners will each be taking a 50% stake in the new merged entity, named Domixtar Pharmaceuticals (“DMX Pharma”). The entity generated an aggregate turnover of approximately 180 million euros in 2023 and will be led by current Mipharm Executive President, Maurizio Silvestri.

Together, Doppel Farmaceutici and Mipharm service a 100-strong, global portfolio of blue-chip clients, offering a comprehensive suite of technologies and products including liquid, solid and semisolid dosage forms with myriad applications, including anti-tumour, anti-inflammatory, cardiovascular and metabolic.

With 900 employees spread across four production plants located between Milan, Piacenza and Ferrara, DMX Pharma is set to become the largest independent Italian CDMO; equipped with state-of-the-art laboratories capable of supporting its customers in complex research and development (R&D) projects, starting from the investigational phase and product pre-formulation studies, up to the scale up of commercial production.

Vittorio Pignatti-Morano, Chairman and Co-Founder at Trilantic Europe, said: “This merger exemplifies our commitment to growing our portfolio companies into global players, and underscores our ability to identify strategic consolidation opportunities in ever-developing markets. By integrating both Doppel Farmaceutici’s and Mipharm’s unique strengths, scale-up capabilities, and advanced technologies, we're establishing a comprehensive platform to serve the intricate needs of global pharmaceutical clients, supporting with a broader range of activities and sophisticated drug development and manufacturing. We look forward to working with Alto Partners in this next chapter of the companies’ growth journeys.

Maurizio Silvestri, current Executive President of Mipharm and newly appointed Executive President of Domixtar Pharmaceuticals, said: "This strategic merger delivers powerful synergies both commercially and technologically, creating a real powerhouse in the pharmaceuticals market by combining decades of expertise with cutting-edge innovation.”
The terms of the transaction are not disclosed. Trilantic Europe was advised by LMCR / Studio Legale, EY, goetzpartners, ERM and Foglia & Partners.

Press Contact :

Trilantic Europe:

Agnes Riousse/Camilla Wyatt

Citigate Dewe Rogerson

E: agnes.riousse@citigatedewerogerson.com / camilla.wyatt@citigatedewerogerson.com 

T: +44 7770 762828

About Trilantic Europe

Trilantic Europe is a mid-market private equity firm focused on management buyouts, buy-ins and partnerships with founders, families and management teams across its themes and sectors of focus including energy transition, consumer and leisure, business services and healthcare. Trilantic Europe is managed by an experienced group of over 30 investment professionals and 15 operating partners and senior advisors, having invested over €2.7bn in 30 platform portfolio companies since 2004 and currently managing c. €2.6bn in assets from a wide base of investors.

More information: www.trilanticeurope.com 

About Alto Partners

Alto Partners SGR S.p.A. is an independent management company founded by Stefano Scarpis and Raffaele de Courten, focusing on private equity investments in the Italian mid-market. With close to 25 years market experience and 50 transactions completed, it is a choice partner to accompany medium to long-term growth programmes of portfolio companies. The team works alongside entrepreneurial families and managers to address the generation transition and bridge expansion capital gaps. 

Alto Capital V, vintage 2022 (Euro 273 million raised) has completed 5 investment transactions to date: Larioplast (cosmetic and food packaging), Dierre Group (industrial security solutions) e EF Group (general contractor for fairs and tri-dimensional spaces), Fragesa (pizza restaurant chain under the brand “Fra Diavolo”) and Eurosirel (manufacturer and distributor of woundcare and cosmetic products).

More information: www.altopartners.it 

Firms to take equal stakes in new entity Domixtar Pharmaceuticals

Trilantic Europe, a leading mid-market, pan-European private equity investor, is pleased to announce the successful merger of portfolio company Doppel Farmaceutici, and Alto Partners-owned Mipharm. Completion of the transaction is expected to occur in September 2024.

Headquartered in Italy and founded in 1994 and 1998 respectively, Doppel Farmaceutici and Mipharm are two leading contract development and manufacturing organisations (CDMOs), bringing fully integrated drug development and manufacturing solutions to the pharmaceuticals market.

Trilantic Europe and Alto Partners will each be taking a 50% stake in the new merged entity, named Domixtar Pharmaceuticals (“DMX Pharma”). The entity generated an aggregate turnover of approximately 180 million euros in 2023 and will be led by current Mipharm Executive President, Maurizio Silvestri.

Together, Doppel Farmaceutici and Mipharm service a 100-strong, global portfolio of blue-chip clients, offering a comprehensive suite of technologies and products including liquid, solid and semisolid dosage forms with myriad applications, including anti-tumour, anti-inflammatory, cardiovascular and metabolic.

With 900 employees spread across four production plants located between Milan, Piacenza and Ferrara, DMX Pharma is set to become the largest independent Italian CDMO; equipped with state-of-the-art laboratories capable of supporting its customers in complex research and development (R&D) projects, starting from the investigational phase and product pre-formulation studies, up to the scale up of commercial production.

Vittorio Pignatti-Morano, Chairman and Co-Founder at Trilantic Europe, said: “This merger exemplifies our commitment to growing our portfolio companies into global players, and underscores our ability to identify strategic consolidation opportunities in ever-developing markets. By integrating both Doppel Farmaceutici’s and Mipharm’s unique strengths, scale-up capabilities, and advanced technologies, we're establishing a comprehensive platform to serve the intricate needs of global pharmaceutical clients, supporting with a broader range of activities and sophisticated drug development and manufacturing. We look forward to working with Alto Partners in this next chapter of the companies’ growth journeys.

Maurizio Silvestri, current Executive President of Mipharm and newly appointed Executive President of Domixtar Pharmaceuticals, said: "This strategic merger delivers powerful synergies both commercially and technologically, creating a real powerhouse in the pharmaceuticals market by combining decades of expertise with cutting-edge innovation.”
The terms of the transaction are not disclosed. Trilantic Europe was advised by LMCR / Studio Legale, EY, goetzpartners, ERM and Foglia & Partners.

Press Contact :

Trilantic Europe:

Agnes Riousse/Camilla Wyatt

Citigate Dewe Rogerson

E: agnes.riousse@citigatedewerogerson.com / camilla.wyatt@citigatedewerogerson.com 

T: +44 7770 762828

About Trilantic Europe

Trilantic Europe is a mid-market private equity firm focused on management buyouts, buy-ins and partnerships with founders, families and management teams across its themes and sectors of focus including energy transition, consumer and leisure, business services and healthcare. Trilantic Europe is managed by an experienced group of over 30 investment professionals and 15 operating partners and senior advisors, having invested over €2.7bn in 30 platform portfolio companies since 2004 and currently managing c. €2.6bn in assets from a wide base of investors.

More information: www.trilanticeurope.com 

About Alto Partners

Alto Partners SGR S.p.A. is an independent management company founded by Stefano Scarpis and Raffaele de Courten, focusing on private equity investments in the Italian mid-market. With close to 25 years market experience and 50 transactions completed, it is a choice partner to accompany medium to long-term growth programmes of portfolio companies. The team works alongside entrepreneurial families and managers to address the generation transition and bridge expansion capital gaps. 

Alto Capital V, vintage 2022 (Euro 273 million raised) has completed 5 investment transactions to date: Larioplast (cosmetic and food packaging), Dierre Group (industrial security solutions) e EF Group (general contractor for fairs and tri-dimensional spaces), Fragesa (pizza restaurant chain under the brand “Fra Diavolo”) and Eurosirel (manufacturer and distributor of woundcare and cosmetic products).

More information: www.altopartners.it 

Firms to take equal stakes in new entity Domixtar Pharmaceuticals

Trilantic Europe, a leading mid-market, pan-European private equity investor, is pleased to announce the successful merger of portfolio company Doppel Farmaceutici, and Alto Partners-owned Mipharm. Completion of the transaction is expected to occur in September 2024.

Headquartered in Italy and founded in 1994 and 1998 respectively, Doppel Farmaceutici and Mipharm are two leading contract development and manufacturing organisations (CDMOs), bringing fully integrated drug development and manufacturing solutions to the pharmaceuticals market.

Trilantic Europe and Alto Partners will each be taking a 50% stake in the new merged entity, named Domixtar Pharmaceuticals (“DMX Pharma”). The entity generated an aggregate turnover of approximately 180 million euros in 2023 and will be led by current Mipharm Executive President, Maurizio Silvestri.

Together, Doppel Farmaceutici and Mipharm service a 100-strong, global portfolio of blue-chip clients, offering a comprehensive suite of technologies and products including liquid, solid and semisolid dosage forms with myriad applications, including anti-tumour, anti-inflammatory, cardiovascular and metabolic.

With 900 employees spread across four production plants located between Milan, Piacenza and Ferrara, DMX Pharma is set to become the largest independent Italian CDMO; equipped with state-of-the-art laboratories capable of supporting its customers in complex research and development (R&D) projects, starting from the investigational phase and product pre-formulation studies, up to the scale up of commercial production.

Vittorio Pignatti-Morano, Chairman and Co-Founder at Trilantic Europe, said: “This merger exemplifies our commitment to growing our portfolio companies into global players, and underscores our ability to identify strategic consolidation opportunities in ever-developing markets. By integrating both Doppel Farmaceutici’s and Mipharm’s unique strengths, scale-up capabilities, and advanced technologies, we're establishing a comprehensive platform to serve the intricate needs of global pharmaceutical clients, supporting with a broader range of activities and sophisticated drug development and manufacturing. We look forward to working with Alto Partners in this next chapter of the companies’ growth journeys.

Maurizio Silvestri, current Executive President of Mipharm and newly appointed Executive President of Domixtar Pharmaceuticals, said: "This strategic merger delivers powerful synergies both commercially and technologically, creating a real powerhouse in the pharmaceuticals market by combining decades of expertise with cutting-edge innovation.”
The terms of the transaction are not disclosed. Trilantic Europe was advised by LMCR / Studio Legale, EY, goetzpartners, ERM and Foglia & Partners.

Press Contact :

Trilantic Europe:

Agnes Riousse/Camilla Wyatt

Citigate Dewe Rogerson

E: agnes.riousse@citigatedewerogerson.com / camilla.wyatt@citigatedewerogerson.com 

T: +44 7770 762828

About Trilantic Europe

Trilantic Europe is a mid-market private equity firm focused on management buyouts, buy-ins and partnerships with founders, families and management teams across its themes and sectors of focus including energy transition, consumer and leisure, business services and healthcare. Trilantic Europe is managed by an experienced group of over 30 investment professionals and 15 operating partners and senior advisors, having invested over €2.7bn in 30 platform portfolio companies since 2004 and currently managing c. €2.6bn in assets from a wide base of investors.

More information: www.trilanticeurope.com 

About Alto Partners

Alto Partners SGR S.p.A. is an independent management company founded by Stefano Scarpis and Raffaele de Courten, focusing on private equity investments in the Italian mid-market. With close to 25 years market experience and 50 transactions completed, it is a choice partner to accompany medium to long-term growth programmes of portfolio companies. The team works alongside entrepreneurial families and managers to address the generation transition and bridge expansion capital gaps. 

Alto Capital V, vintage 2022 (Euro 273 million raised) has completed 5 investment transactions to date: Larioplast (cosmetic and food packaging), Dierre Group (industrial security solutions) e EF Group (general contractor for fairs and tri-dimensional spaces), Fragesa (pizza restaurant chain under the brand “Fra Diavolo”) and Eurosirel (manufacturer and distributor of woundcare and cosmetic products).

More information: www.altopartners.it 

Firms to take equal stakes in new entity Domixtar Pharmaceuticals

Trilantic Europe, a leading mid-market, pan-European private equity investor, is pleased to announce the successful merger of portfolio company Doppel Farmaceutici, and Alto Partners-owned Mipharm. Completion of the transaction is expected to occur in September 2024.

Headquartered in Italy and founded in 1994 and 1998 respectively, Doppel Farmaceutici and Mipharm are two leading contract development and manufacturing organisations (CDMOs), bringing fully integrated drug development and manufacturing solutions to the pharmaceuticals market.

Trilantic Europe and Alto Partners will each be taking a 50% stake in the new merged entity, named Domixtar Pharmaceuticals (“DMX Pharma”). The entity generated an aggregate turnover of approximately 180 million euros in 2023 and will be led by current Mipharm Executive President, Maurizio Silvestri.

Together, Doppel Farmaceutici and Mipharm service a 100-strong, global portfolio of blue-chip clients, offering a comprehensive suite of technologies and products including liquid, solid and semisolid dosage forms with myriad applications, including anti-tumour, anti-inflammatory, cardiovascular and metabolic.

With 900 employees spread across four production plants located between Milan, Piacenza and Ferrara, DMX Pharma is set to become the largest independent Italian CDMO; equipped with state-of-the-art laboratories capable of supporting its customers in complex research and development (R&D) projects, starting from the investigational phase and product pre-formulation studies, up to the scale up of commercial production.

Vittorio Pignatti-Morano, Chairman and Co-Founder at Trilantic Europe, said: “This merger exemplifies our commitment to growing our portfolio companies into global players, and underscores our ability to identify strategic consolidation opportunities in ever-developing markets. By integrating both Doppel Farmaceutici’s and Mipharm’s unique strengths, scale-up capabilities, and advanced technologies, we're establishing a comprehensive platform to serve the intricate needs of global pharmaceutical clients, supporting with a broader range of activities and sophisticated drug development and manufacturing. We look forward to working with Alto Partners in this next chapter of the companies’ growth journeys.

Maurizio Silvestri, current Executive President of Mipharm and newly appointed Executive President of Domixtar Pharmaceuticals, said: "This strategic merger delivers powerful synergies both commercially and technologically, creating a real powerhouse in the pharmaceuticals market by combining decades of expertise with cutting-edge innovation.”
The terms of the transaction are not disclosed. Trilantic Europe was advised by LMCR / Studio Legale, EY, goetzpartners, ERM and Foglia & Partners.

Press Contact :

Trilantic Europe:

Agnes Riousse/Camilla Wyatt

Citigate Dewe Rogerson

E: agnes.riousse@citigatedewerogerson.com / camilla.wyatt@citigatedewerogerson.com 

T: +44 7770 762828

About Trilantic Europe

Trilantic Europe is a mid-market private equity firm focused on management buyouts, buy-ins and partnerships with founders, families and management teams across its themes and sectors of focus including energy transition, consumer and leisure, business services and healthcare. Trilantic Europe is managed by an experienced group of over 30 investment professionals and 15 operating partners and senior advisors, having invested over €2.7bn in 30 platform portfolio companies since 2004 and currently managing c. €2.6bn in assets from a wide base of investors.

More information: www.trilanticeurope.com 

About Alto Partners

Alto Partners SGR S.p.A. is an independent management company founded by Stefano Scarpis and Raffaele de Courten, focusing on private equity investments in the Italian mid-market. With close to 25 years market experience and 50 transactions completed, it is a choice partner to accompany medium to long-term growth programmes of portfolio companies. The team works alongside entrepreneurial families and managers to address the generation transition and bridge expansion capital gaps. 

Alto Capital V, vintage 2022 (Euro 273 million raised) has completed 5 investment transactions to date: Larioplast (cosmetic and food packaging), Dierre Group (industrial security solutions) e EF Group (general contractor for fairs and tri-dimensional spaces), Fragesa (pizza restaurant chain under the brand “Fra Diavolo”) and Eurosirel (manufacturer and distributor of woundcare and cosmetic products).

More information: www.altopartners.it 

Firms to take equal stakes in new entity Domixtar Pharmaceuticals

Trilantic Europe, a leading mid-market, pan-European private equity investor, is pleased to announce the successful merger of portfolio company Doppel Farmaceutici, and Alto Partners-owned Mipharm. Completion of the transaction is expected to occur in September 2024.

Headquartered in Italy and founded in 1994 and 1998 respectively, Doppel Farmaceutici and Mipharm are two leading contract development and manufacturing organisations (CDMOs), bringing fully integrated drug development and manufacturing solutions to the pharmaceuticals market.

Trilantic Europe and Alto Partners will each be taking a 50% stake in the new merged entity, named Domixtar Pharmaceuticals (“DMX Pharma”). The entity generated an aggregate turnover of approximately 180 million euros in 2023 and will be led by current Mipharm Executive President, Maurizio Silvestri.

Together, Doppel Farmaceutici and Mipharm service a 100-strong, global portfolio of blue-chip clients, offering a comprehensive suite of technologies and products including liquid, solid and semisolid dosage forms with myriad applications, including anti-tumour, anti-inflammatory, cardiovascular and metabolic.

With 900 employees spread across four production plants located between Milan, Piacenza and Ferrara, DMX Pharma is set to become the largest independent Italian CDMO; equipped with state-of-the-art laboratories capable of supporting its customers in complex research and development (R&D) projects, starting from the investigational phase and product pre-formulation studies, up to the scale up of commercial production.

Vittorio Pignatti-Morano, Chairman and Co-Founder at Trilantic Europe, said: “This merger exemplifies our commitment to growing our portfolio companies into global players, and underscores our ability to identify strategic consolidation opportunities in ever-developing markets. By integrating both Doppel Farmaceutici’s and Mipharm’s unique strengths, scale-up capabilities, and advanced technologies, we're establishing a comprehensive platform to serve the intricate needs of global pharmaceutical clients, supporting with a broader range of activities and sophisticated drug development and manufacturing. We look forward to working with Alto Partners in this next chapter of the companies’ growth journeys.

Maurizio Silvestri, current Executive President of Mipharm and newly appointed Executive President of Domixtar Pharmaceuticals, said: "This strategic merger delivers powerful synergies both commercially and technologically, creating a real powerhouse in the pharmaceuticals market by combining decades of expertise with cutting-edge innovation.”
The terms of the transaction are not disclosed. Trilantic Europe was advised by LMCR / Studio Legale, EY, goetzpartners, ERM and Foglia & Partners.

Press Contact :

Trilantic Europe:

Agnes Riousse/Camilla Wyatt

Citigate Dewe Rogerson

E: agnes.riousse@citigatedewerogerson.com / camilla.wyatt@citigatedewerogerson.com 

T: +44 7770 762828

About Trilantic Europe

Trilantic Europe is a mid-market private equity firm focused on management buyouts, buy-ins and partnerships with founders, families and management teams across its themes and sectors of focus including energy transition, consumer and leisure, business services and healthcare. Trilantic Europe is managed by an experienced group of over 30 investment professionals and 15 operating partners and senior advisors, having invested over €2.7bn in 30 platform portfolio companies since 2004 and currently managing c. €2.6bn in assets from a wide base of investors.

More information: www.trilanticeurope.com 

About Alto Partners

Alto Partners SGR S.p.A. is an independent management company founded by Stefano Scarpis and Raffaele de Courten, focusing on private equity investments in the Italian mid-market. With close to 25 years market experience and 50 transactions completed, it is a choice partner to accompany medium to long-term growth programmes of portfolio companies. The team works alongside entrepreneurial families and managers to address the generation transition and bridge expansion capital gaps. 

Alto Capital V, vintage 2022 (Euro 273 million raised) has completed 5 investment transactions to date: Larioplast (cosmetic and food packaging), Dierre Group (industrial security solutions) e EF Group (general contractor for fairs and tri-dimensional spaces), Fragesa (pizza restaurant chain under the brand “Fra Diavolo”) and Eurosirel (manufacturer and distributor of woundcare and cosmetic products).

More information: www.altopartners.it 

Firms to take equal stakes in new entity Domixtar Pharmaceuticals

Trilantic Europe, a leading mid-market, pan-European private equity investor, is pleased to announce the successful merger of portfolio company Doppel Farmaceutici, and Alto Partners-owned Mipharm. Completion of the transaction is expected to occur in September 2024.

Headquartered in Italy and founded in 1994 and 1998 respectively, Doppel Farmaceutici and Mipharm are two leading contract development and manufacturing organisations (CDMOs), bringing fully integrated drug development and manufacturing solutions to the pharmaceuticals market.

Trilantic Europe and Alto Partners will each be taking a 50% stake in the new merged entity, named Domixtar Pharmaceuticals (“DMX Pharma”). The entity generated an aggregate turnover of approximately 180 million euros in 2023 and will be led by current Mipharm Executive President, Maurizio Silvestri.

Together, Doppel Farmaceutici and Mipharm service a 100-strong, global portfolio of blue-chip clients, offering a comprehensive suite of technologies and products including liquid, solid and semisolid dosage forms with myriad applications, including anti-tumour, anti-inflammatory, cardiovascular and metabolic.

With 900 employees spread across four production plants located between Milan, Piacenza and Ferrara, DMX Pharma is set to become the largest independent Italian CDMO; equipped with state-of-the-art laboratories capable of supporting its customers in complex research and development (R&D) projects, starting from the investigational phase and product pre-formulation studies, up to the scale up of commercial production.

Vittorio Pignatti-Morano, Chairman and Co-Founder at Trilantic Europe, said: “This merger exemplifies our commitment to growing our portfolio companies into global players, and underscores our ability to identify strategic consolidation opportunities in ever-developing markets. By integrating both Doppel Farmaceutici’s and Mipharm’s unique strengths, scale-up capabilities, and advanced technologies, we're establishing a comprehensive platform to serve the intricate needs of global pharmaceutical clients, supporting with a broader range of activities and sophisticated drug development and manufacturing. We look forward to working with Alto Partners in this next chapter of the companies’ growth journeys.

Maurizio Silvestri, current Executive President of Mipharm and newly appointed Executive President of Domixtar Pharmaceuticals, said: "This strategic merger delivers powerful synergies both commercially and technologically, creating a real powerhouse in the pharmaceuticals market by combining decades of expertise with cutting-edge innovation.”
The terms of the transaction are not disclosed. Trilantic Europe was advised by LMCR / Studio Legale, EY, goetzpartners, ERM and Foglia & Partners.

Press Contact :

Trilantic Europe:

Agnes Riousse/Camilla Wyatt

Citigate Dewe Rogerson

E: agnes.riousse@citigatedewerogerson.com / camilla.wyatt@citigatedewerogerson.com 

T: +44 7770 762828

About Trilantic Europe

Trilantic Europe is a mid-market private equity firm focused on management buyouts, buy-ins and partnerships with founders, families and management teams across its themes and sectors of focus including energy transition, consumer and leisure, business services and healthcare. Trilantic Europe is managed by an experienced group of over 30 investment professionals and 15 operating partners and senior advisors, having invested over €2.7bn in 30 platform portfolio companies since 2004 and currently managing c. €2.6bn in assets from a wide base of investors.

More information: www.trilanticeurope.com 

About Alto Partners

Alto Partners SGR S.p.A. is an independent management company founded by Stefano Scarpis and Raffaele de Courten, focusing on private equity investments in the Italian mid-market. With close to 25 years market experience and 50 transactions completed, it is a choice partner to accompany medium to long-term growth programmes of portfolio companies. The team works alongside entrepreneurial families and managers to address the generation transition and bridge expansion capital gaps. 

Alto Capital V, vintage 2022 (Euro 273 million raised) has completed 5 investment transactions to date: Larioplast (cosmetic and food packaging), Dierre Group (industrial security solutions) e EF Group (general contractor for fairs and tri-dimensional spaces), Fragesa (pizza restaurant chain under the brand “Fra Diavolo”) and Eurosirel (manufacturer and distributor of woundcare and cosmetic products).

More information: www.altopartners.it 

Firms to take equal stakes in new entity Domixtar Pharmaceuticals

Trilantic Europe, a leading mid-market, pan-European private equity investor, is pleased to announce the successful merger of portfolio company Doppel Farmaceutici, and Alto Partners-owned Mipharm. Completion of the transaction is expected to occur in September 2024.

Headquartered in Italy and founded in 1994 and 1998 respectively, Doppel Farmaceutici and Mipharm are two leading contract development and manufacturing organisations (CDMOs), bringing fully integrated drug development and manufacturing solutions to the pharmaceuticals market.

Trilantic Europe and Alto Partners will each be taking a 50% stake in the new merged entity, named Domixtar Pharmaceuticals (“DMX Pharma”). The entity generated an aggregate turnover of approximately 180 million euros in 2023 and will be led by current Mipharm Executive President, Maurizio Silvestri.

Together, Doppel Farmaceutici and Mipharm service a 100-strong, global portfolio of blue-chip clients, offering a comprehensive suite of technologies and products including liquid, solid and semisolid dosage forms with myriad applications, including anti-tumour, anti-inflammatory, cardiovascular and metabolic.

With 900 employees spread across four production plants located between Milan, Piacenza and Ferrara, DMX Pharma is set to become the largest independent Italian CDMO; equipped with state-of-the-art laboratories capable of supporting its customers in complex research and development (R&D) projects, starting from the investigational phase and product pre-formulation studies, up to the scale up of commercial production.

Vittorio Pignatti-Morano, Chairman and Co-Founder at Trilantic Europe, said: “This merger exemplifies our commitment to growing our portfolio companies into global players, and underscores our ability to identify strategic consolidation opportunities in ever-developing markets. By integrating both Doppel Farmaceutici’s and Mipharm’s unique strengths, scale-up capabilities, and advanced technologies, we're establishing a comprehensive platform to serve the intricate needs of global pharmaceutical clients, supporting with a broader range of activities and sophisticated drug development and manufacturing. We look forward to working with Alto Partners in this next chapter of the companies’ growth journeys.

Maurizio Silvestri, current Executive President of Mipharm and newly appointed Executive President of Domixtar Pharmaceuticals, said: "This strategic merger delivers powerful synergies both commercially and technologically, creating a real powerhouse in the pharmaceuticals market by combining decades of expertise with cutting-edge innovation.”
The terms of the transaction are not disclosed. Trilantic Europe was advised by LMCR / Studio Legale, EY, goetzpartners, ERM and Foglia & Partners.

Press Contact :

Trilantic Europe:

Agnes Riousse/Camilla Wyatt

Citigate Dewe Rogerson

E: agnes.riousse@citigatedewerogerson.com / camilla.wyatt@citigatedewerogerson.com 

T: +44 7770 762828

About Trilantic Europe

Trilantic Europe is a mid-market private equity firm focused on management buyouts, buy-ins and partnerships with founders, families and management teams across its themes and sectors of focus including energy transition, consumer and leisure, business services and healthcare. Trilantic Europe is managed by an experienced group of over 30 investment professionals and 15 operating partners and senior advisors, having invested over €2.7bn in 30 platform portfolio companies since 2004 and currently managing c. €2.6bn in assets from a wide base of investors.

More information: www.trilanticeurope.com 

About Alto Partners

Alto Partners SGR S.p.A. is an independent management company founded by Stefano Scarpis and Raffaele de Courten, focusing on private equity investments in the Italian mid-market. With close to 25 years market experience and 50 transactions completed, it is a choice partner to accompany medium to long-term growth programmes of portfolio companies. The team works alongside entrepreneurial families and managers to address the generation transition and bridge expansion capital gaps. 

Alto Capital V, vintage 2022 (Euro 273 million raised) has completed 5 investment transactions to date: Larioplast (cosmetic and food packaging), Dierre Group (industrial security solutions) e EF Group (general contractor for fairs and tri-dimensional spaces), Fragesa (pizza restaurant chain under the brand “Fra Diavolo”) and Eurosirel (manufacturer and distributor of woundcare and cosmetic products).

More information: www.altopartners.it 

Firms to take equal stakes in new entity Domixtar Pharmaceuticals

Trilantic Europe, a leading mid-market, pan-European private equity investor, is pleased to announce the successful merger of portfolio company Doppel Farmaceutici, and Alto Partners-owned Mipharm. Completion of the transaction is expected to occur in September 2024.

Headquartered in Italy and founded in 1994 and 1998 respectively, Doppel Farmaceutici and Mipharm are two leading contract development and manufacturing organisations (CDMOs), bringing fully integrated drug development and manufacturing solutions to the pharmaceuticals market.

Trilantic Europe and Alto Partners will each be taking a 50% stake in the new merged entity, named Domixtar Pharmaceuticals (“DMX Pharma”). The entity generated an aggregate turnover of approximately 180 million euros in 2023 and will be led by current Mipharm Executive President, Maurizio Silvestri.

Together, Doppel Farmaceutici and Mipharm service a 100-strong, global portfolio of blue-chip clients, offering a comprehensive suite of technologies and products including liquid, solid and semisolid dosage forms with myriad applications, including anti-tumour, anti-inflammatory, cardiovascular and metabolic.

With 900 employees spread across four production plants located between Milan, Piacenza and Ferrara, DMX Pharma is set to become the largest independent Italian CDMO; equipped with state-of-the-art laboratories capable of supporting its customers in complex research and development (R&D) projects, starting from the investigational phase and product pre-formulation studies, up to the scale up of commercial production.

Vittorio Pignatti-Morano, Chairman and Co-Founder at Trilantic Europe, said: “This merger exemplifies our commitment to growing our portfolio companies into global players, and underscores our ability to identify strategic consolidation opportunities in ever-developing markets. By integrating both Doppel Farmaceutici’s and Mipharm’s unique strengths, scale-up capabilities, and advanced technologies, we're establishing a comprehensive platform to serve the intricate needs of global pharmaceutical clients, supporting with a broader range of activities and sophisticated drug development and manufacturing. We look forward to working with Alto Partners in this next chapter of the companies’ growth journeys.

Maurizio Silvestri, current Executive President of Mipharm and newly appointed Executive President of Domixtar Pharmaceuticals, said: "This strategic merger delivers powerful synergies both commercially and technologically, creating a real powerhouse in the pharmaceuticals market by combining decades of expertise with cutting-edge innovation.”
The terms of the transaction are not disclosed. Trilantic Europe was advised by LMCR / Studio Legale, EY, goetzpartners, ERM and Foglia & Partners.

Press Contact :

Trilantic Europe:

Agnes Riousse/Camilla Wyatt

Citigate Dewe Rogerson

E: agnes.riousse@citigatedewerogerson.com / camilla.wyatt@citigatedewerogerson.com 

T: +44 7770 762828

About Trilantic Europe

Trilantic Europe is a mid-market private equity firm focused on management buyouts, buy-ins and partnerships with founders, families and management teams across its themes and sectors of focus including energy transition, consumer and leisure, business services and healthcare. Trilantic Europe is managed by an experienced group of over 30 investment professionals and 15 operating partners and senior advisors, having invested over €2.7bn in 30 platform portfolio companies since 2004 and currently managing c. €2.6bn in assets from a wide base of investors.

More information: www.trilanticeurope.com 

About Alto Partners

Alto Partners SGR S.p.A. is an independent management company founded by Stefano Scarpis and Raffaele de Courten, focusing on private equity investments in the Italian mid-market. With close to 25 years market experience and 50 transactions completed, it is a choice partner to accompany medium to long-term growth programmes of portfolio companies. The team works alongside entrepreneurial families and managers to address the generation transition and bridge expansion capital gaps. 

Alto Capital V, vintage 2022 (Euro 273 million raised) has completed 5 investment transactions to date: Larioplast (cosmetic and food packaging), Dierre Group (industrial security solutions) e EF Group (general contractor for fairs and tri-dimensional spaces), Fragesa (pizza restaurant chain under the brand “Fra Diavolo”) and Eurosirel (manufacturer and distributor of woundcare and cosmetic products).

More information: www.altopartners.it 

Firms to take equal stakes in new entity Domixtar Pharmaceuticals

Trilantic Europe, a leading mid-market, pan-European private equity investor, is pleased to announce the successful merger of portfolio company Doppel Farmaceutici, and Alto Partners-owned Mipharm. Completion of the transaction is expected to occur in September 2024.

Headquartered in Italy and founded in 1994 and 1998 respectively, Doppel Farmaceutici and Mipharm are two leading contract development and manufacturing organisations (CDMOs), bringing fully integrated drug development and manufacturing solutions to the pharmaceuticals market.

Trilantic Europe and Alto Partners will each be taking a 50% stake in the new merged entity, named Domixtar Pharmaceuticals (“DMX Pharma”). The entity generated an aggregate turnover of approximately 180 million euros in 2023 and will be led by current Mipharm Executive President, Maurizio Silvestri.

Together, Doppel Farmaceutici and Mipharm service a 100-strong, global portfolio of blue-chip clients, offering a comprehensive suite of technologies and products including liquid, solid and semisolid dosage forms with myriad applications, including anti-tumour, anti-inflammatory, cardiovascular and metabolic.

With 900 employees spread across four production plants located between Milan, Piacenza and Ferrara, DMX Pharma is set to become the largest independent Italian CDMO; equipped with state-of-the-art laboratories capable of supporting its customers in complex research and development (R&D) projects, starting from the investigational phase and product pre-formulation studies, up to the scale up of commercial production.

Vittorio Pignatti-Morano, Chairman and Co-Founder at Trilantic Europe, said: “This merger exemplifies our commitment to growing our portfolio companies into global players, and underscores our ability to identify strategic consolidation opportunities in ever-developing markets. By integrating both Doppel Farmaceutici’s and Mipharm’s unique strengths, scale-up capabilities, and advanced technologies, we're establishing a comprehensive platform to serve the intricate needs of global pharmaceutical clients, supporting with a broader range of activities and sophisticated drug development and manufacturing. We look forward to working with Alto Partners in this next chapter of the companies’ growth journeys.

Maurizio Silvestri, current Executive President of Mipharm and newly appointed Executive President of Domixtar Pharmaceuticals, said: "This strategic merger delivers powerful synergies both commercially and technologically, creating a real powerhouse in the pharmaceuticals market by combining decades of expertise with cutting-edge innovation.”
The terms of the transaction are not disclosed. Trilantic Europe was advised by LMCR / Studio Legale, EY, goetzpartners, ERM and Foglia & Partners.

Press Contact :

Trilantic Europe:

Agnes Riousse/Camilla Wyatt

Citigate Dewe Rogerson

E: agnes.riousse@citigatedewerogerson.com / camilla.wyatt@citigatedewerogerson.com 

T: +44 7770 762828

About Trilantic Europe

Trilantic Europe is a mid-market private equity firm focused on management buyouts, buy-ins and partnerships with founders, families and management teams across its themes and sectors of focus including energy transition, consumer and leisure, business services and healthcare. Trilantic Europe is managed by an experienced group of over 30 investment professionals and 15 operating partners and senior advisors, having invested over €2.7bn in 30 platform portfolio companies since 2004 and currently managing c. €2.6bn in assets from a wide base of investors.

More information: www.trilanticeurope.com 

About Alto Partners

Alto Partners SGR S.p.A. is an independent management company founded by Stefano Scarpis and Raffaele de Courten, focusing on private equity investments in the Italian mid-market. With close to 25 years market experience and 50 transactions completed, it is a choice partner to accompany medium to long-term growth programmes of portfolio companies. The team works alongside entrepreneurial families and managers to address the generation transition and bridge expansion capital gaps. 

Alto Capital V, vintage 2022 (Euro 273 million raised) has completed 5 investment transactions to date: Larioplast (cosmetic and food packaging), Dierre Group (industrial security solutions) e EF Group (general contractor for fairs and tri-dimensional spaces), Fragesa (pizza restaurant chain under the brand “Fra Diavolo”) and Eurosirel (manufacturer and distributor of woundcare and cosmetic products).

More information: www.altopartners.it 

Firms to take equal stakes in new entity Domixtar Pharmaceuticals

Trilantic Europe, a leading mid-market, pan-European private equity investor, is pleased to announce the successful merger of portfolio company Doppel Farmaceutici, and Alto Partners-owned Mipharm. Completion of the transaction is expected to occur in September 2024.

Headquartered in Italy and founded in 1994 and 1998 respectively, Doppel Farmaceutici and Mipharm are two leading contract development and manufacturing organisations (CDMOs), bringing fully integrated drug development and manufacturing solutions to the pharmaceuticals market.

Trilantic Europe and Alto Partners will each be taking a 50% stake in the new merged entity, named Domixtar Pharmaceuticals (“DMX Pharma”). The entity generated an aggregate turnover of approximately 180 million euros in 2023 and will be led by current Mipharm Executive President, Maurizio Silvestri.

Together, Doppel Farmaceutici and Mipharm service a 100-strong, global portfolio of blue-chip clients, offering a comprehensive suite of technologies and products including liquid, solid and semisolid dosage forms with myriad applications, including anti-tumour, anti-inflammatory, cardiovascular and metabolic.

With 900 employees spread across four production plants located between Milan, Piacenza and Ferrara, DMX Pharma is set to become the largest independent Italian CDMO; equipped with state-of-the-art laboratories capable of supporting its customers in complex research and development (R&D) projects, starting from the investigational phase and product pre-formulation studies, up to the scale up of commercial production.

Vittorio Pignatti-Morano, Chairman and Co-Founder at Trilantic Europe, said: “This merger exemplifies our commitment to growing our portfolio companies into global players, and underscores our ability to identify strategic consolidation opportunities in ever-developing markets. By integrating both Doppel Farmaceutici’s and Mipharm’s unique strengths, scale-up capabilities, and advanced technologies, we're establishing a comprehensive platform to serve the intricate needs of global pharmaceutical clients, supporting with a broader range of activities and sophisticated drug development and manufacturing. We look forward to working with Alto Partners in this next chapter of the companies’ growth journeys.

Maurizio Silvestri, current Executive President of Mipharm and newly appointed Executive President of Domixtar Pharmaceuticals, said: "This strategic merger delivers powerful synergies both commercially and technologically, creating a real powerhouse in the pharmaceuticals market by combining decades of expertise with cutting-edge innovation.”
The terms of the transaction are not disclosed. Trilantic Europe was advised by LMCR / Studio Legale, EY, goetzpartners, ERM and Foglia & Partners.

Press Contact :

Trilantic Europe:

Agnes Riousse/Camilla Wyatt

Citigate Dewe Rogerson

E: agnes.riousse@citigatedewerogerson.com / camilla.wyatt@citigatedewerogerson.com 

T: +44 7770 762828

About Trilantic Europe

Trilantic Europe is a mid-market private equity firm focused on management buyouts, buy-ins and partnerships with founders, families and management teams across its themes and sectors of focus including energy transition, consumer and leisure, business services and healthcare. Trilantic Europe is managed by an experienced group of over 30 investment professionals and 15 operating partners and senior advisors, having invested over €2.7bn in 30 platform portfolio companies since 2004 and currently managing c. €2.6bn in assets from a wide base of investors.

More information: www.trilanticeurope.com 

About Alto Partners

Alto Partners SGR S.p.A. is an independent management company founded by Stefano Scarpis and Raffaele de Courten, focusing on private equity investments in the Italian mid-market. With close to 25 years market experience and 50 transactions completed, it is a choice partner to accompany medium to long-term growth programmes of portfolio companies. The team works alongside entrepreneurial families and managers to address the generation transition and bridge expansion capital gaps. 

Alto Capital V, vintage 2022 (Euro 273 million raised) has completed 5 investment transactions to date: Larioplast (cosmetic and food packaging), Dierre Group (industrial security solutions) e EF Group (general contractor for fairs and tri-dimensional spaces), Fragesa (pizza restaurant chain under the brand “Fra Diavolo”) and Eurosirel (manufacturer and distributor of woundcare and cosmetic products).

More information: www.altopartners.it 

Firms to take equal stakes in new entity Domixtar Pharmaceuticals

Trilantic Europe, a leading mid-market, pan-European private equity investor, is pleased to announce the successful merger of portfolio company Doppel Farmaceutici, and Alto Partners-owned Mipharm. Completion of the transaction is expected to occur in September 2024.

Headquartered in Italy and founded in 1994 and 1998 respectively, Doppel Farmaceutici and Mipharm are two leading contract development and manufacturing organisations (CDMOs), bringing fully integrated drug development and manufacturing solutions to the pharmaceuticals market.

Trilantic Europe and Alto Partners will each be taking a 50% stake in the new merged entity, named Domixtar Pharmaceuticals (“DMX Pharma”). The entity generated an aggregate turnover of approximately 180 million euros in 2023 and will be led by current Mipharm Executive President, Maurizio Silvestri.

Together, Doppel Farmaceutici and Mipharm service a 100-strong, global portfolio of blue-chip clients, offering a comprehensive suite of technologies and products including liquid, solid and semisolid dosage forms with myriad applications, including anti-tumour, anti-inflammatory, cardiovascular and metabolic.

With 900 employees spread across four production plants located between Milan, Piacenza and Ferrara, DMX Pharma is set to become the largest independent Italian CDMO; equipped with state-of-the-art laboratories capable of supporting its customers in complex research and development (R&D) projects, starting from the investigational phase and product pre-formulation studies, up to the scale up of commercial production.

Vittorio Pignatti-Morano, Chairman and Co-Founder at Trilantic Europe, said: “This merger exemplifies our commitment to growing our portfolio companies into global players, and underscores our ability to identify strategic consolidation opportunities in ever-developing markets. By integrating both Doppel Farmaceutici’s and Mipharm’s unique strengths, scale-up capabilities, and advanced technologies, we're establishing a comprehensive platform to serve the intricate needs of global pharmaceutical clients, supporting with a broader range of activities and sophisticated drug development and manufacturing. We look forward to working with Alto Partners in this next chapter of the companies’ growth journeys.

Maurizio Silvestri, current Executive President of Mipharm and newly appointed Executive President of Domixtar Pharmaceuticals, said: "This strategic merger delivers powerful synergies both commercially and technologically, creating a real powerhouse in the pharmaceuticals market by combining decades of expertise with cutting-edge innovation.”
The terms of the transaction are not disclosed. Trilantic Europe was advised by LMCR / Studio Legale, EY, goetzpartners, ERM and Foglia & Partners.

Press Contact :

Trilantic Europe:

Agnes Riousse/Camilla Wyatt

Citigate Dewe Rogerson

E: agnes.riousse@citigatedewerogerson.com / camilla.wyatt@citigatedewerogerson.com 

T: +44 7770 762828

About Trilantic Europe

Trilantic Europe is a mid-market private equity firm focused on management buyouts, buy-ins and partnerships with founders, families and management teams across its themes and sectors of focus including energy transition, consumer and leisure, business services and healthcare. Trilantic Europe is managed by an experienced group of over 30 investment professionals and 15 operating partners and senior advisors, having invested over €2.7bn in 30 platform portfolio companies since 2004 and currently managing c. €2.6bn in assets from a wide base of investors.

More information: www.trilanticeurope.com 

About Alto Partners

Alto Partners SGR S.p.A. is an independent management company founded by Stefano Scarpis and Raffaele de Courten, focusing on private equity investments in the Italian mid-market. With close to 25 years market experience and 50 transactions completed, it is a choice partner to accompany medium to long-term growth programmes of portfolio companies. The team works alongside entrepreneurial families and managers to address the generation transition and bridge expansion capital gaps. 

Alto Capital V, vintage 2022 (Euro 273 million raised) has completed 5 investment transactions to date: Larioplast (cosmetic and food packaging), Dierre Group (industrial security solutions) e EF Group (general contractor for fairs and tri-dimensional spaces), Fragesa (pizza restaurant chain under the brand “Fra Diavolo”) and Eurosirel (manufacturer and distributor of woundcare and cosmetic products).

More information: www.altopartners.it 

Firms to take equal stakes in new entity Domixtar Pharmaceuticals

Trilantic Europe, a leading mid-market, pan-European private equity investor, is pleased to announce the successful merger of portfolio company Doppel Farmaceutici, and Alto Partners-owned Mipharm. Completion of the transaction is expected to occur in September 2024.

Headquartered in Italy and founded in 1994 and 1998 respectively, Doppel Farmaceutici and Mipharm are two leading contract development and manufacturing organisations (CDMOs), bringing fully integrated drug development and manufacturing solutions to the pharmaceuticals market.

Trilantic Europe and Alto Partners will each be taking a 50% stake in the new merged entity, named Domixtar Pharmaceuticals (“DMX Pharma”). The entity generated an aggregate turnover of approximately 180 million euros in 2023 and will be led by current Mipharm Executive President, Maurizio Silvestri.

Together, Doppel Farmaceutici and Mipharm service a 100-strong, global portfolio of blue-chip clients, offering a comprehensive suite of technologies and products including liquid, solid and semisolid dosage forms with myriad applications, including anti-tumour, anti-inflammatory, cardiovascular and metabolic.

With 900 employees spread across four production plants located between Milan, Piacenza and Ferrara, DMX Pharma is set to become the largest independent Italian CDMO; equipped with state-of-the-art laboratories capable of supporting its customers in complex research and development (R&D) projects, starting from the investigational phase and product pre-formulation studies, up to the scale up of commercial production.

Vittorio Pignatti-Morano, Chairman and Co-Founder at Trilantic Europe, said: “This merger exemplifies our commitment to growing our portfolio companies into global players, and underscores our ability to identify strategic consolidation opportunities in ever-developing markets. By integrating both Doppel Farmaceutici’s and Mipharm’s unique strengths, scale-up capabilities, and advanced technologies, we're establishing a comprehensive platform to serve the intricate needs of global pharmaceutical clients, supporting with a broader range of activities and sophisticated drug development and manufacturing. We look forward to working with Alto Partners in this next chapter of the companies’ growth journeys.

Maurizio Silvestri, current Executive President of Mipharm and newly appointed Executive President of Domixtar Pharmaceuticals, said: "This strategic merger delivers powerful synergies both commercially and technologically, creating a real powerhouse in the pharmaceuticals market by combining decades of expertise with cutting-edge innovation.”
The terms of the transaction are not disclosed. Trilantic Europe was advised by LMCR / Studio Legale, EY, goetzpartners, ERM and Foglia & Partners.

Press Contact :

Trilantic Europe:

Agnes Riousse/Camilla Wyatt

Citigate Dewe Rogerson

E: agnes.riousse@citigatedewerogerson.com / camilla.wyatt@citigatedewerogerson.com 

T: +44 7770 762828

About Trilantic Europe

Trilantic Europe is a mid-market private equity firm focused on management buyouts, buy-ins and partnerships with founders, families and management teams across its themes and sectors of focus including energy transition, consumer and leisure, business services and healthcare. Trilantic Europe is managed by an experienced group of over 30 investment professionals and 15 operating partners and senior advisors, having invested over €2.7bn in 30 platform portfolio companies since 2004 and currently managing c. €2.6bn in assets from a wide base of investors.

More information: www.trilanticeurope.com 

About Alto Partners

Alto Partners SGR S.p.A. is an independent management company founded by Stefano Scarpis and Raffaele de Courten, focusing on private equity investments in the Italian mid-market. With close to 25 years market experience and 50 transactions completed, it is a choice partner to accompany medium to long-term growth programmes of portfolio companies. The team works alongside entrepreneurial families and managers to address the generation transition and bridge expansion capital gaps. 

Alto Capital V, vintage 2022 (Euro 273 million raised) has completed 5 investment transactions to date: Larioplast (cosmetic and food packaging), Dierre Group (industrial security solutions) e EF Group (general contractor for fairs and tri-dimensional spaces), Fragesa (pizza restaurant chain under the brand “Fra Diavolo”) and Eurosirel (manufacturer and distributor of woundcare and cosmetic products).

More information: www.altopartners.it 

Firms to take equal stakes in new entity Domixtar Pharmaceuticals

Trilantic Europe, a leading mid-market, pan-European private equity investor, is pleased to announce the successful merger of portfolio company Doppel Farmaceutici, and Alto Partners-owned Mipharm. Completion of the transaction is expected to occur in September 2024.

Headquartered in Italy and founded in 1994 and 1998 respectively, Doppel Farmaceutici and Mipharm are two leading contract development and manufacturing organisations (CDMOs), bringing fully integrated drug development and manufacturing solutions to the pharmaceuticals market.

Trilantic Europe and Alto Partners will each be taking a 50% stake in the new merged entity, named Domixtar Pharmaceuticals (“DMX Pharma”). The entity generated an aggregate turnover of approximately 180 million euros in 2023 and will be led by current Mipharm Executive President, Maurizio Silvestri.

Together, Doppel Farmaceutici and Mipharm service a 100-strong, global portfolio of blue-chip clients, offering a comprehensive suite of technologies and products including liquid, solid and semisolid dosage forms with myriad applications, including anti-tumour, anti-inflammatory, cardiovascular and metabolic.

With 900 employees spread across four production plants located between Milan, Piacenza and Ferrara, DMX Pharma is set to become the largest independent Italian CDMO; equipped with state-of-the-art laboratories capable of supporting its customers in complex research and development (R&D) projects, starting from the investigational phase and product pre-formulation studies, up to the scale up of commercial production.

Vittorio Pignatti-Morano, Chairman and Co-Founder at Trilantic Europe, said: “This merger exemplifies our commitment to growing our portfolio companies into global players, and underscores our ability to identify strategic consolidation opportunities in ever-developing markets. By integrating both Doppel Farmaceutici’s and Mipharm’s unique strengths, scale-up capabilities, and advanced technologies, we're establishing a comprehensive platform to serve the intricate needs of global pharmaceutical clients, supporting with a broader range of activities and sophisticated drug development and manufacturing. We look forward to working with Alto Partners in this next chapter of the companies’ growth journeys.

Maurizio Silvestri, current Executive President of Mipharm and newly appointed Executive President of Domixtar Pharmaceuticals, said: "This strategic merger delivers powerful synergies both commercially and technologically, creating a real powerhouse in the pharmaceuticals market by combining decades of expertise with cutting-edge innovation.”
The terms of the transaction are not disclosed. Trilantic Europe was advised by LMCR / Studio Legale, EY, goetzpartners, ERM and Foglia & Partners.

Press Contact :

Trilantic Europe:

Agnes Riousse/Camilla Wyatt

Citigate Dewe Rogerson

E: agnes.riousse@citigatedewerogerson.com / camilla.wyatt@citigatedewerogerson.com 

T: +44 7770 762828

About Trilantic Europe

Trilantic Europe is a mid-market private equity firm focused on management buyouts, buy-ins and partnerships with founders, families and management teams across its themes and sectors of focus including energy transition, consumer and leisure, business services and healthcare. Trilantic Europe is managed by an experienced group of over 30 investment professionals and 15 operating partners and senior advisors, having invested over €2.7bn in 30 platform portfolio companies since 2004 and currently managing c. €2.6bn in assets from a wide base of investors.

More information: www.trilanticeurope.com 

About Alto Partners

Alto Partners SGR S.p.A. is an independent management company founded by Stefano Scarpis and Raffaele de Courten, focusing on private equity investments in the Italian mid-market. With close to 25 years market experience and 50 transactions completed, it is a choice partner to accompany medium to long-term growth programmes of portfolio companies. The team works alongside entrepreneurial families and managers to address the generation transition and bridge expansion capital gaps. 

Alto Capital V, vintage 2022 (Euro 273 million raised) has completed 5 investment transactions to date: Larioplast (cosmetic and food packaging), Dierre Group (industrial security solutions) e EF Group (general contractor for fairs and tri-dimensional spaces), Fragesa (pizza restaurant chain under the brand “Fra Diavolo”) and Eurosirel (manufacturer and distributor of woundcare and cosmetic products).

More information: www.altopartners.it 

Firms to take equal stakes in new entity Domixtar Pharmaceuticals

Trilantic Europe, a leading mid-market, pan-European private equity investor, is pleased to announce the successful merger of portfolio company Doppel Farmaceutici, and Alto Partners-owned Mipharm. Completion of the transaction is expected to occur in September 2024.

Headquartered in Italy and founded in 1994 and 1998 respectively, Doppel Farmaceutici and Mipharm are two leading contract development and manufacturing organisations (CDMOs), bringing fully integrated drug development and manufacturing solutions to the pharmaceuticals market.

Trilantic Europe and Alto Partners will each be taking a 50% stake in the new merged entity, named Domixtar Pharmaceuticals (“DMX Pharma”). The entity generated an aggregate turnover of approximately 180 million euros in 2023 and will be led by current Mipharm Executive President, Maurizio Silvestri.

Together, Doppel Farmaceutici and Mipharm service a 100-strong, global portfolio of blue-chip clients, offering a comprehensive suite of technologies and products including liquid, solid and semisolid dosage forms with myriad applications, including anti-tumour, anti-inflammatory, cardiovascular and metabolic.

With 900 employees spread across four production plants located between Milan, Piacenza and Ferrara, DMX Pharma is set to become the largest independent Italian CDMO; equipped with state-of-the-art laboratories capable of supporting its customers in complex research and development (R&D) projects, starting from the investigational phase and product pre-formulation studies, up to the scale up of commercial production.

Vittorio Pignatti-Morano, Chairman and Co-Founder at Trilantic Europe, said: “This merger exemplifies our commitment to growing our portfolio companies into global players, and underscores our ability to identify strategic consolidation opportunities in ever-developing markets. By integrating both Doppel Farmaceutici’s and Mipharm’s unique strengths, scale-up capabilities, and advanced technologies, we're establishing a comprehensive platform to serve the intricate needs of global pharmaceutical clients, supporting with a broader range of activities and sophisticated drug development and manufacturing. We look forward to working with Alto Partners in this next chapter of the companies’ growth journeys.

Maurizio Silvestri, current Executive President of Mipharm and newly appointed Executive President of Domixtar Pharmaceuticals, said: "This strategic merger delivers powerful synergies both commercially and technologically, creating a real powerhouse in the pharmaceuticals market by combining decades of expertise with cutting-edge innovation.”
The terms of the transaction are not disclosed. Trilantic Europe was advised by LMCR / Studio Legale, EY, goetzpartners, ERM and Foglia & Partners.

Press Contact :

Trilantic Europe:

Agnes Riousse/Camilla Wyatt

Citigate Dewe Rogerson

E: agnes.riousse@citigatedewerogerson.com / camilla.wyatt@citigatedewerogerson.com 

T: +44 7770 762828

About Trilantic Europe

Trilantic Europe is a mid-market private equity firm focused on management buyouts, buy-ins and partnerships with founders, families and management teams across its themes and sectors of focus including energy transition, consumer and leisure, business services and healthcare. Trilantic Europe is managed by an experienced group of over 30 investment professionals and 15 operating partners and senior advisors, having invested over €2.7bn in 30 platform portfolio companies since 2004 and currently managing c. €2.6bn in assets from a wide base of investors.

More information: www.trilanticeurope.com 

About Alto Partners

Alto Partners SGR S.p.A. is an independent management company founded by Stefano Scarpis and Raffaele de Courten, focusing on private equity investments in the Italian mid-market. With close to 25 years market experience and 50 transactions completed, it is a choice partner to accompany medium to long-term growth programmes of portfolio companies. The team works alongside entrepreneurial families and managers to address the generation transition and bridge expansion capital gaps. 

Alto Capital V, vintage 2022 (Euro 273 million raised) has completed 5 investment transactions to date: Larioplast (cosmetic and food packaging), Dierre Group (industrial security solutions) e EF Group (general contractor for fairs and tri-dimensional spaces), Fragesa (pizza restaurant chain under the brand “Fra Diavolo”) and Eurosirel (manufacturer and distributor of woundcare and cosmetic products).

More information: www.altopartners.it 

Firms to take equal stakes in new entity Domixtar Pharmaceuticals

Trilantic Europe, a leading mid-market, pan-European private equity investor, is pleased to announce the successful merger of portfolio company Doppel Farmaceutici, and Alto Partners-owned Mipharm. Completion of the transaction is expected to occur in September 2024.

Headquartered in Italy and founded in 1994 and 1998 respectively, Doppel Farmaceutici and Mipharm are two leading contract development and manufacturing organisations (CDMOs), bringing fully integrated drug development and manufacturing solutions to the pharmaceuticals market.

Trilantic Europe and Alto Partners will each be taking a 50% stake in the new merged entity, named Domixtar Pharmaceuticals (“DMX Pharma”). The entity generated an aggregate turnover of approximately 180 million euros in 2023 and will be led by current Mipharm Executive President, Maurizio Silvestri.

Together, Doppel Farmaceutici and Mipharm service a 100-strong, global portfolio of blue-chip clients, offering a comprehensive suite of technologies and products including liquid, solid and semisolid dosage forms with myriad applications, including anti-tumour, anti-inflammatory, cardiovascular and metabolic.

With 900 employees spread across four production plants located between Milan, Piacenza and Ferrara, DMX Pharma is set to become the largest independent Italian CDMO; equipped with state-of-the-art laboratories capable of supporting its customers in complex research and development (R&D) projects, starting from the investigational phase and product pre-formulation studies, up to the scale up of commercial production.

Vittorio Pignatti-Morano, Chairman and Co-Founder at Trilantic Europe, said: “This merger exemplifies our commitment to growing our portfolio companies into global players, and underscores our ability to identify strategic consolidation opportunities in ever-developing markets. By integrating both Doppel Farmaceutici’s and Mipharm’s unique strengths, scale-up capabilities, and advanced technologies, we're establishing a comprehensive platform to serve the intricate needs of global pharmaceutical clients, supporting with a broader range of activities and sophisticated drug development and manufacturing. We look forward to working with Alto Partners in this next chapter of the companies’ growth journeys.

Maurizio Silvestri, current Executive President of Mipharm and newly appointed Executive President of Domixtar Pharmaceuticals, said: "This strategic merger delivers powerful synergies both commercially and technologically, creating a real powerhouse in the pharmaceuticals market by combining decades of expertise with cutting-edge innovation.”
The terms of the transaction are not disclosed. Trilantic Europe was advised by LMCR / Studio Legale, EY, goetzpartners, ERM and Foglia & Partners.

Press Contact :

Trilantic Europe:

Agnes Riousse/Camilla Wyatt

Citigate Dewe Rogerson

E: agnes.riousse@citigatedewerogerson.com / camilla.wyatt@citigatedewerogerson.com 

T: +44 7770 762828

About Trilantic Europe

Trilantic Europe is a mid-market private equity firm focused on management buyouts, buy-ins and partnerships with founders, families and management teams across its themes and sectors of focus including energy transition, consumer and leisure, business services and healthcare. Trilantic Europe is managed by an experienced group of over 30 investment professionals and 15 operating partners and senior advisors, having invested over €2.7bn in 30 platform portfolio companies since 2004 and currently managing c. €2.6bn in assets from a wide base of investors.

More information: www.trilanticeurope.com 

About Alto Partners

Alto Partners SGR S.p.A. is an independent management company founded by Stefano Scarpis and Raffaele de Courten, focusing on private equity investments in the Italian mid-market. With close to 25 years market experience and 50 transactions completed, it is a choice partner to accompany medium to long-term growth programmes of portfolio companies. The team works alongside entrepreneurial families and managers to address the generation transition and bridge expansion capital gaps. 

Alto Capital V, vintage 2022 (Euro 273 million raised) has completed 5 investment transactions to date: Larioplast (cosmetic and food packaging), Dierre Group (industrial security solutions) e EF Group (general contractor for fairs and tri-dimensional spaces), Fragesa (pizza restaurant chain under the brand “Fra Diavolo”) and Eurosirel (manufacturer and distributor of woundcare and cosmetic products).

More information: www.altopartners.it 

Firms to take equal stakes in new entity Domixtar Pharmaceuticals

Trilantic Europe, a leading mid-market, pan-European private equity investor, is pleased to announce the successful merger of portfolio company Doppel Farmaceutici, and Alto Partners-owned Mipharm. Completion of the transaction is expected to occur in September 2024.

Headquartered in Italy and founded in 1994 and 1998 respectively, Doppel Farmaceutici and Mipharm are two leading contract development and manufacturing organisations (CDMOs), bringing fully integrated drug development and manufacturing solutions to the pharmaceuticals market.

Trilantic Europe and Alto Partners will each be taking a 50% stake in the new merged entity, named Domixtar Pharmaceuticals (“DMX Pharma”). The entity generated an aggregate turnover of approximately 180 million euros in 2023 and will be led by current Mipharm Executive President, Maurizio Silvestri.

Together, Doppel Farmaceutici and Mipharm service a 100-strong, global portfolio of blue-chip clients, offering a comprehensive suite of technologies and products including liquid, solid and semisolid dosage forms with myriad applications, including anti-tumour, anti-inflammatory, cardiovascular and metabolic.

With 900 employees spread across four production plants located between Milan, Piacenza and Ferrara, DMX Pharma is set to become the largest independent Italian CDMO; equipped with state-of-the-art laboratories capable of supporting its customers in complex research and development (R&D) projects, starting from the investigational phase and product pre-formulation studies, up to the scale up of commercial production.

Vittorio Pignatti-Morano, Chairman and Co-Founder at Trilantic Europe, said: “This merger exemplifies our commitment to growing our portfolio companies into global players, and underscores our ability to identify strategic consolidation opportunities in ever-developing markets. By integrating both Doppel Farmaceutici’s and Mipharm’s unique strengths, scale-up capabilities, and advanced technologies, we're establishing a comprehensive platform to serve the intricate needs of global pharmaceutical clients, supporting with a broader range of activities and sophisticated drug development and manufacturing. We look forward to working with Alto Partners in this next chapter of the companies’ growth journeys.

Maurizio Silvestri, current Executive President of Mipharm and newly appointed Executive President of Domixtar Pharmaceuticals, said: "This strategic merger delivers powerful synergies both commercially and technologically, creating a real powerhouse in the pharmaceuticals market by combining decades of expertise with cutting-edge innovation.”
The terms of the transaction are not disclosed. Trilantic Europe was advised by LMCR / Studio Legale, EY, goetzpartners, ERM and Foglia & Partners.

Press Contact :

Trilantic Europe:

Agnes Riousse/Camilla Wyatt

Citigate Dewe Rogerson

E: agnes.riousse@citigatedewerogerson.com / camilla.wyatt@citigatedewerogerson.com 

T: +44 7770 762828

About Trilantic Europe

Trilantic Europe is a mid-market private equity firm focused on management buyouts, buy-ins and partnerships with founders, families and management teams across its themes and sectors of focus including energy transition, consumer and leisure, business services and healthcare. Trilantic Europe is managed by an experienced group of over 30 investment professionals and 15 operating partners and senior advisors, having invested over €2.7bn in 30 platform portfolio companies since 2004 and currently managing c. €2.6bn in assets from a wide base of investors.

More information: www.trilanticeurope.com 

About Alto Partners

Alto Partners SGR S.p.A. is an independent management company founded by Stefano Scarpis and Raffaele de Courten, focusing on private equity investments in the Italian mid-market. With close to 25 years market experience and 50 transactions completed, it is a choice partner to accompany medium to long-term growth programmes of portfolio companies. The team works alongside entrepreneurial families and managers to address the generation transition and bridge expansion capital gaps. 

Alto Capital V, vintage 2022 (Euro 273 million raised) has completed 5 investment transactions to date: Larioplast (cosmetic and food packaging), Dierre Group (industrial security solutions) e EF Group (general contractor for fairs and tri-dimensional spaces), Fragesa (pizza restaurant chain under the brand “Fra Diavolo”) and Eurosirel (manufacturer and distributor of woundcare and cosmetic products).

More information: www.altopartners.it 

Firms to take equal stakes in new entity Domixtar Pharmaceuticals

Trilantic Europe, a leading mid-market, pan-European private equity investor, is pleased to announce the successful merger of portfolio company Doppel Farmaceutici, and Alto Partners-owned Mipharm. Completion of the transaction is expected to occur in September 2024.

Headquartered in Italy and founded in 1994 and 1998 respectively, Doppel Farmaceutici and Mipharm are two leading contract development and manufacturing organisations (CDMOs), bringing fully integrated drug development and manufacturing solutions to the pharmaceuticals market.

Trilantic Europe and Alto Partners will each be taking a 50% stake in the new merged entity, named Domixtar Pharmaceuticals (“DMX Pharma”). The entity generated an aggregate turnover of approximately 180 million euros in 2023 and will be led by current Mipharm Executive President, Maurizio Silvestri.

Together, Doppel Farmaceutici and Mipharm service a 100-strong, global portfolio of blue-chip clients, offering a comprehensive suite of technologies and products including liquid, solid and semisolid dosage forms with myriad applications, including anti-tumour, anti-inflammatory, cardiovascular and metabolic.

With 900 employees spread across four production plants located between Milan, Piacenza and Ferrara, DMX Pharma is set to become the largest independent Italian CDMO; equipped with state-of-the-art laboratories capable of supporting its customers in complex research and development (R&D) projects, starting from the investigational phase and product pre-formulation studies, up to the scale up of commercial production.

Vittorio Pignatti-Morano, Chairman and Co-Founder at Trilantic Europe, said: “This merger exemplifies our commitment to growing our portfolio companies into global players, and underscores our ability to identify strategic consolidation opportunities in ever-developing markets. By integrating both Doppel Farmaceutici’s and Mipharm’s unique strengths, scale-up capabilities, and advanced technologies, we're establishing a comprehensive platform to serve the intricate needs of global pharmaceutical clients, supporting with a broader range of activities and sophisticated drug development and manufacturing. We look forward to working with Alto Partners in this next chapter of the companies’ growth journeys.

Maurizio Silvestri, current Executive President of Mipharm and newly appointed Executive President of Domixtar Pharmaceuticals, said: "This strategic merger delivers powerful synergies both commercially and technologically, creating a real powerhouse in the pharmaceuticals market by combining decades of expertise with cutting-edge innovation.”
The terms of the transaction are not disclosed. Trilantic Europe was advised by LMCR / Studio Legale, EY, goetzpartners, ERM and Foglia & Partners.

Press Contact :

Trilantic Europe:

Agnes Riousse/Camilla Wyatt

Citigate Dewe Rogerson

E: agnes.riousse@citigatedewerogerson.com / camilla.wyatt@citigatedewerogerson.com 

T: +44 7770 762828

About Trilantic Europe

Trilantic Europe is a mid-market private equity firm focused on management buyouts, buy-ins and partnerships with founders, families and management teams across its themes and sectors of focus including energy transition, consumer and leisure, business services and healthcare. Trilantic Europe is managed by an experienced group of over 30 investment professionals and 15 operating partners and senior advisors, having invested over €2.7bn in 30 platform portfolio companies since 2004 and currently managing c. €2.6bn in assets from a wide base of investors.

More information: www.trilanticeurope.com 

About Alto Partners

Alto Partners SGR S.p.A. is an independent management company founded by Stefano Scarpis and Raffaele de Courten, focusing on private equity investments in the Italian mid-market. With close to 25 years market experience and 50 transactions completed, it is a choice partner to accompany medium to long-term growth programmes of portfolio companies. The team works alongside entrepreneurial families and managers to address the generation transition and bridge expansion capital gaps. 

Alto Capital V, vintage 2022 (Euro 273 million raised) has completed 5 investment transactions to date: Larioplast (cosmetic and food packaging), Dierre Group (industrial security solutions) e EF Group (general contractor for fairs and tri-dimensional spaces), Fragesa (pizza restaurant chain under the brand “Fra Diavolo”) and Eurosirel (manufacturer and distributor of woundcare and cosmetic products).

More information: www.altopartners.it 

Firms to take equal stakes in new entity Domixtar Pharmaceuticals

Trilantic Europe, a leading mid-market, pan-European private equity investor, is pleased to announce the successful merger of portfolio company Doppel Farmaceutici, and Alto Partners-owned Mipharm. Completion of the transaction is expected to occur in September 2024.

Headquartered in Italy and founded in 1994 and 1998 respectively, Doppel Farmaceutici and Mipharm are two leading contract development and manufacturing organisations (CDMOs), bringing fully integrated drug development and manufacturing solutions to the pharmaceuticals market.

Trilantic Europe and Alto Partners will each be taking a 50% stake in the new merged entity, named Domixtar Pharmaceuticals (“DMX Pharma”). The entity generated an aggregate turnover of approximately 180 million euros in 2023 and will be led by current Mipharm Executive President, Maurizio Silvestri.

Together, Doppel Farmaceutici and Mipharm service a 100-strong, global portfolio of blue-chip clients, offering a comprehensive suite of technologies and products including liquid, solid and semisolid dosage forms with myriad applications, including anti-tumour, anti-inflammatory, cardiovascular and metabolic.

With 900 employees spread across four production plants located between Milan, Piacenza and Ferrara, DMX Pharma is set to become the largest independent Italian CDMO; equipped with state-of-the-art laboratories capable of supporting its customers in complex research and development (R&D) projects, starting from the investigational phase and product pre-formulation studies, up to the scale up of commercial production.

Vittorio Pignatti-Morano, Chairman and Co-Founder at Trilantic Europe, said: “This merger exemplifies our commitment to growing our portfolio companies into global players, and underscores our ability to identify strategic consolidation opportunities in ever-developing markets. By integrating both Doppel Farmaceutici’s and Mipharm’s unique strengths, scale-up capabilities, and advanced technologies, we're establishing a comprehensive platform to serve the intricate needs of global pharmaceutical clients, supporting with a broader range of activities and sophisticated drug development and manufacturing. We look forward to working with Alto Partners in this next chapter of the companies’ growth journeys.

Maurizio Silvestri, current Executive President of Mipharm and newly appointed Executive President of Domixtar Pharmaceuticals, said: "This strategic merger delivers powerful synergies both commercially and technologically, creating a real powerhouse in the pharmaceuticals market by combining decades of expertise with cutting-edge innovation.”
The terms of the transaction are not disclosed. Trilantic Europe was advised by LMCR / Studio Legale, EY, goetzpartners, ERM and Foglia & Partners.

Press Contact :

Trilantic Europe:

Agnes Riousse/Camilla Wyatt

Citigate Dewe Rogerson

E: agnes.riousse@citigatedewerogerson.com / camilla.wyatt@citigatedewerogerson.com 

T: +44 7770 762828

About Trilantic Europe

Trilantic Europe is a mid-market private equity firm focused on management buyouts, buy-ins and partnerships with founders, families and management teams across its themes and sectors of focus including energy transition, consumer and leisure, business services and healthcare. Trilantic Europe is managed by an experienced group of over 30 investment professionals and 15 operating partners and senior advisors, having invested over €2.7bn in 30 platform portfolio companies since 2004 and currently managing c. €2.6bn in assets from a wide base of investors.

More information: www.trilanticeurope.com 

About Alto Partners

Alto Partners SGR S.p.A. is an independent management company founded by Stefano Scarpis and Raffaele de Courten, focusing on private equity investments in the Italian mid-market. With close to 25 years market experience and 50 transactions completed, it is a choice partner to accompany medium to long-term growth programmes of portfolio companies. The team works alongside entrepreneurial families and managers to address the generation transition and bridge expansion capital gaps. 

Alto Capital V, vintage 2022 (Euro 273 million raised) has completed 5 investment transactions to date: Larioplast (cosmetic and food packaging), Dierre Group (industrial security solutions) e EF Group (general contractor for fairs and tri-dimensional spaces), Fragesa (pizza restaurant chain under the brand “Fra Diavolo”) and Eurosirel (manufacturer and distributor of woundcare and cosmetic products).

More information: www.altopartners.it 

Firms to take equal stakes in new entity Domixtar Pharmaceuticals

Trilantic Europe, a leading mid-market, pan-European private equity investor, is pleased to announce the successful merger of portfolio company Doppel Farmaceutici, and Alto Partners-owned Mipharm. Completion of the transaction is expected to occur in September 2024.

Headquartered in Italy and founded in 1994 and 1998 respectively, Doppel Farmaceutici and Mipharm are two leading contract development and manufacturing organisations (CDMOs), bringing fully integrated drug development and manufacturing solutions to the pharmaceuticals market.

Trilantic Europe and Alto Partners will each be taking a 50% stake in the new merged entity, named Domixtar Pharmaceuticals (“DMX Pharma”). The entity generated an aggregate turnover of approximately 180 million euros in 2023 and will be led by current Mipharm Executive President, Maurizio Silvestri.

Together, Doppel Farmaceutici and Mipharm service a 100-strong, global portfolio of blue-chip clients, offering a comprehensive suite of technologies and products including liquid, solid and semisolid dosage forms with myriad applications, including anti-tumour, anti-inflammatory, cardiovascular and metabolic.

With 900 employees spread across four production plants located between Milan, Piacenza and Ferrara, DMX Pharma is set to become the largest independent Italian CDMO; equipped with state-of-the-art laboratories capable of supporting its customers in complex research and development (R&D) projects, starting from the investigational phase and product pre-formulation studies, up to the scale up of commercial production.

Vittorio Pignatti-Morano, Chairman and Co-Founder at Trilantic Europe, said: “This merger exemplifies our commitment to growing our portfolio companies into global players, and underscores our ability to identify strategic consolidation opportunities in ever-developing markets. By integrating both Doppel Farmaceutici’s and Mipharm’s unique strengths, scale-up capabilities, and advanced technologies, we're establishing a comprehensive platform to serve the intricate needs of global pharmaceutical clients, supporting with a broader range of activities and sophisticated drug development and manufacturing. We look forward to working with Alto Partners in this next chapter of the companies’ growth journeys.

Maurizio Silvestri, current Executive President of Mipharm and newly appointed Executive President of Domixtar Pharmaceuticals, said: "This strategic merger delivers powerful synergies both commercially and technologically, creating a real powerhouse in the pharmaceuticals market by combining decades of expertise with cutting-edge innovation.”
The terms of the transaction are not disclosed. Trilantic Europe was advised by LMCR / Studio Legale, EY, goetzpartners, ERM and Foglia & Partners.

Press Contact :

Trilantic Europe:

Agnes Riousse/Camilla Wyatt

Citigate Dewe Rogerson

E: agnes.riousse@citigatedewerogerson.com / camilla.wyatt@citigatedewerogerson.com 

T: +44 7770 762828

About Trilantic Europe

Trilantic Europe is a mid-market private equity firm focused on management buyouts, buy-ins and partnerships with founders, families and management teams across its themes and sectors of focus including energy transition, consumer and leisure, business services and healthcare. Trilantic Europe is managed by an experienced group of over 30 investment professionals and 15 operating partners and senior advisors, having invested over €2.7bn in 30 platform portfolio companies since 2004 and currently managing c. €2.6bn in assets from a wide base of investors.

More information: www.trilanticeurope.com 

About Alto Partners

Alto Partners SGR S.p.A. is an independent management company founded by Stefano Scarpis and Raffaele de Courten, focusing on private equity investments in the Italian mid-market. With close to 25 years market experience and 50 transactions completed, it is a choice partner to accompany medium to long-term growth programmes of portfolio companies. The team works alongside entrepreneurial families and managers to address the generation transition and bridge expansion capital gaps. 

Alto Capital V, vintage 2022 (Euro 273 million raised) has completed 5 investment transactions to date: Larioplast (cosmetic and food packaging), Dierre Group (industrial security solutions) e EF Group (general contractor for fairs and tri-dimensional spaces), Fragesa (pizza restaurant chain under the brand “Fra Diavolo”) and Eurosirel (manufacturer and distributor of woundcare and cosmetic products).

More information: www.altopartners.it 

Firms to take equal stakes in new entity Domixtar Pharmaceuticals

Trilantic Europe, a leading mid-market, pan-European private equity investor, is pleased to announce the successful merger of portfolio company Doppel Farmaceutici, and Alto Partners-owned Mipharm. Completion of the transaction is expected to occur in September 2024.

Headquartered in Italy and founded in 1994 and 1998 respectively, Doppel Farmaceutici and Mipharm are two leading contract development and manufacturing organisations (CDMOs), bringing fully integrated drug development and manufacturing solutions to the pharmaceuticals market.

Trilantic Europe and Alto Partners will each be taking a 50% stake in the new merged entity, named Domixtar Pharmaceuticals (“DMX Pharma”). The entity generated an aggregate turnover of approximately 180 million euros in 2023 and will be led by current Mipharm Executive President, Maurizio Silvestri.

Together, Doppel Farmaceutici and Mipharm service a 100-strong, global portfolio of blue-chip clients, offering a comprehensive suite of technologies and products including liquid, solid and semisolid dosage forms with myriad applications, including anti-tumour, anti-inflammatory, cardiovascular and metabolic.

With 900 employees spread across four production plants located between Milan, Piacenza and Ferrara, DMX Pharma is set to become the largest independent Italian CDMO; equipped with state-of-the-art laboratories capable of supporting its customers in complex research and development (R&D) projects, starting from the investigational phase and product pre-formulation studies, up to the scale up of commercial production.

Vittorio Pignatti-Morano, Chairman and Co-Founder at Trilantic Europe, said: “This merger exemplifies our commitment to growing our portfolio companies into global players, and underscores our ability to identify strategic consolidation opportunities in ever-developing markets. By integrating both Doppel Farmaceutici’s and Mipharm’s unique strengths, scale-up capabilities, and advanced technologies, we're establishing a comprehensive platform to serve the intricate needs of global pharmaceutical clients, supporting with a broader range of activities and sophisticated drug development and manufacturing. We look forward to working with Alto Partners in this next chapter of the companies’ growth journeys.

Maurizio Silvestri, current Executive President of Mipharm and newly appointed Executive President of Domixtar Pharmaceuticals, said: "This strategic merger delivers powerful synergies both commercially and technologically, creating a real powerhouse in the pharmaceuticals market by combining decades of expertise with cutting-edge innovation.”
The terms of the transaction are not disclosed. Trilantic Europe was advised by LMCR / Studio Legale, EY, goetzpartners, ERM and Foglia & Partners.

Press Contact :

Trilantic Europe:

Agnes Riousse/Camilla Wyatt

Citigate Dewe Rogerson

E: agnes.riousse@citigatedewerogerson.com / camilla.wyatt@citigatedewerogerson.com 

T: +44 7770 762828

About Trilantic Europe

Trilantic Europe is a mid-market private equity firm focused on management buyouts, buy-ins and partnerships with founders, families and management teams across its themes and sectors of focus including energy transition, consumer and leisure, business services and healthcare. Trilantic Europe is managed by an experienced group of over 30 investment professionals and 15 operating partners and senior advisors, having invested over €2.7bn in 30 platform portfolio companies since 2004 and currently managing c. €2.6bn in assets from a wide base of investors.

More information: www.trilanticeurope.com 

About Alto Partners

Alto Partners SGR S.p.A. is an independent management company founded by Stefano Scarpis and Raffaele de Courten, focusing on private equity investments in the Italian mid-market. With close to 25 years market experience and 50 transactions completed, it is a choice partner to accompany medium to long-term growth programmes of portfolio companies. The team works alongside entrepreneurial families and managers to address the generation transition and bridge expansion capital gaps. 

Alto Capital V, vintage 2022 (Euro 273 million raised) has completed 5 investment transactions to date: Larioplast (cosmetic and food packaging), Dierre Group (industrial security solutions) e EF Group (general contractor for fairs and tri-dimensional spaces), Fragesa (pizza restaurant chain under the brand “Fra Diavolo”) and Eurosirel (manufacturer and distributor of woundcare and cosmetic products).

More information: www.altopartners.it 

Firms to take equal stakes in new entity Domixtar Pharmaceuticals

Trilantic Europe, a leading mid-market, pan-European private equity investor, is pleased to announce the successful merger of portfolio company Doppel Farmaceutici, and Alto Partners-owned Mipharm. Completion of the transaction is expected to occur in September 2024.

Headquartered in Italy and founded in 1994 and 1998 respectively, Doppel Farmaceutici and Mipharm are two leading contract development and manufacturing organisations (CDMOs), bringing fully integrated drug development and manufacturing solutions to the pharmaceuticals market.

Trilantic Europe and Alto Partners will each be taking a 50% stake in the new merged entity, named Domixtar Pharmaceuticals (“DMX Pharma”). The entity generated an aggregate turnover of approximately 180 million euros in 2023 and will be led by current Mipharm Executive President, Maurizio Silvestri.

Together, Doppel Farmaceutici and Mipharm service a 100-strong, global portfolio of blue-chip clients, offering a comprehensive suite of technologies and products including liquid, solid and semisolid dosage forms with myriad applications, including anti-tumour, anti-inflammatory, cardiovascular and metabolic.

With 900 employees spread across four production plants located between Milan, Piacenza and Ferrara, DMX Pharma is set to become the largest independent Italian CDMO; equipped with state-of-the-art laboratories capable of supporting its customers in complex research and development (R&D) projects, starting from the investigational phase and product pre-formulation studies, up to the scale up of commercial production.

Vittorio Pignatti-Morano, Chairman and Co-Founder at Trilantic Europe, said: “This merger exemplifies our commitment to growing our portfolio companies into global players, and underscores our ability to identify strategic consolidation opportunities in ever-developing markets. By integrating both Doppel Farmaceutici’s and Mipharm’s unique strengths, scale-up capabilities, and advanced technologies, we're establishing a comprehensive platform to serve the intricate needs of global pharmaceutical clients, supporting with a broader range of activities and sophisticated drug development and manufacturing. We look forward to working with Alto Partners in this next chapter of the companies’ growth journeys.

Maurizio Silvestri, current Executive President of Mipharm and newly appointed Executive President of Domixtar Pharmaceuticals, said: "This strategic merger delivers powerful synergies both commercially and technologically, creating a real powerhouse in the pharmaceuticals market by combining decades of expertise with cutting-edge innovation.”
The terms of the transaction are not disclosed. Trilantic Europe was advised by LMCR / Studio Legale, EY, goetzpartners, ERM and Foglia & Partners.

Press Contact :

Trilantic Europe:

Agnes Riousse/Camilla Wyatt

Citigate Dewe Rogerson

E: agnes.riousse@citigatedewerogerson.com / camilla.wyatt@citigatedewerogerson.com 

T: +44 7770 762828

About Trilantic Europe

Trilantic Europe is a mid-market private equity firm focused on management buyouts, buy-ins and partnerships with founders, families and management teams across its themes and sectors of focus including energy transition, consumer and leisure, business services and healthcare. Trilantic Europe is managed by an experienced group of over 30 investment professionals and 15 operating partners and senior advisors, having invested over €2.7bn in 30 platform portfolio companies since 2004 and currently managing c. €2.6bn in assets from a wide base of investors.

More information: www.trilanticeurope.com 

About Alto Partners

Alto Partners SGR S.p.A. is an independent management company founded by Stefano Scarpis and Raffaele de Courten, focusing on private equity investments in the Italian mid-market. With close to 25 years market experience and 50 transactions completed, it is a choice partner to accompany medium to long-term growth programmes of portfolio companies. The team works alongside entrepreneurial families and managers to address the generation transition and bridge expansion capital gaps. 

Alto Capital V, vintage 2022 (Euro 273 million raised) has completed 5 investment transactions to date: Larioplast (cosmetic and food packaging), Dierre Group (industrial security solutions) e EF Group (general contractor for fairs and tri-dimensional spaces), Fragesa (pizza restaurant chain under the brand “Fra Diavolo”) and Eurosirel (manufacturer and distributor of woundcare and cosmetic products).

More information: www.altopartners.it 

Firms to take equal stakes in new entity Domixtar Pharmaceuticals

Trilantic Europe, a leading mid-market, pan-European private equity investor, is pleased to announce the successful merger of portfolio company Doppel Farmaceutici, and Alto Partners-owned Mipharm. Completion of the transaction is expected to occur in September 2024.

Headquartered in Italy and founded in 1994 and 1998 respectively, Doppel Farmaceutici and Mipharm are two leading contract development and manufacturing organisations (CDMOs), bringing fully integrated drug development and manufacturing solutions to the pharmaceuticals market.

Trilantic Europe and Alto Partners will each be taking a 50% stake in the new merged entity, named Domixtar Pharmaceuticals (“DMX Pharma”). The entity generated an aggregate turnover of approximately 180 million euros in 2023 and will be led by current Mipharm Executive President, Maurizio Silvestri.

Together, Doppel Farmaceutici and Mipharm service a 100-strong, global portfolio of blue-chip clients, offering a comprehensive suite of technologies and products including liquid, solid and semisolid dosage forms with myriad applications, including anti-tumour, anti-inflammatory, cardiovascular and metabolic.

With 900 employees spread across four production plants located between Milan, Piacenza and Ferrara, DMX Pharma is set to become the largest independent Italian CDMO; equipped with state-of-the-art laboratories capable of supporting its customers in complex research and development (R&D) projects, starting from the investigational phase and product pre-formulation studies, up to the scale up of commercial production.

Vittorio Pignatti-Morano, Chairman and Co-Founder at Trilantic Europe, said: “This merger exemplifies our commitment to growing our portfolio companies into global players, and underscores our ability to identify strategic consolidation opportunities in ever-developing markets. By integrating both Doppel Farmaceutici’s and Mipharm’s unique strengths, scale-up capabilities, and advanced technologies, we're establishing a comprehensive platform to serve the intricate needs of global pharmaceutical clients, supporting with a broader range of activities and sophisticated drug development and manufacturing. We look forward to working with Alto Partners in this next chapter of the companies’ growth journeys.

Maurizio Silvestri, current Executive President of Mipharm and newly appointed Executive President of Domixtar Pharmaceuticals, said: "This strategic merger delivers powerful synergies both commercially and technologically, creating a real powerhouse in the pharmaceuticals market by combining decades of expertise with cutting-edge innovation.”
The terms of the transaction are not disclosed. Trilantic Europe was advised by LMCR / Studio Legale, EY, goetzpartners, ERM and Foglia & Partners.

Press Contact :

Trilantic Europe:

Agnes Riousse/Camilla Wyatt

Citigate Dewe Rogerson

E: agnes.riousse@citigatedewerogerson.com / camilla.wyatt@citigatedewerogerson.com 

T: +44 7770 762828

About Trilantic Europe

Trilantic Europe is a mid-market private equity firm focused on management buyouts, buy-ins and partnerships with founders, families and management teams across its themes and sectors of focus including energy transition, consumer and leisure, business services and healthcare. Trilantic Europe is managed by an experienced group of over 30 investment professionals and 15 operating partners and senior advisors, having invested over €2.7bn in 30 platform portfolio companies since 2004 and currently managing c. €2.6bn in assets from a wide base of investors.

More information: www.trilanticeurope.com 

About Alto Partners

Alto Partners SGR S.p.A. is an independent management company founded by Stefano Scarpis and Raffaele de Courten, focusing on private equity investments in the Italian mid-market. With close to 25 years market experience and 50 transactions completed, it is a choice partner to accompany medium to long-term growth programmes of portfolio companies. The team works alongside entrepreneurial families and managers to address the generation transition and bridge expansion capital gaps. 

Alto Capital V, vintage 2022 (Euro 273 million raised) has completed 5 investment transactions to date: Larioplast (cosmetic and food packaging), Dierre Group (industrial security solutions) e EF Group (general contractor for fairs and tri-dimensional spaces), Fragesa (pizza restaurant chain under the brand “Fra Diavolo”) and Eurosirel (manufacturer and distributor of woundcare and cosmetic products).

More information: www.altopartners.it 

Firms to take equal stakes in new entity Domixtar Pharmaceuticals

Trilantic Europe, a leading mid-market, pan-European private equity investor, is pleased to announce the successful merger of portfolio company Doppel Farmaceutici, and Alto Partners-owned Mipharm. Completion of the transaction is expected to occur in September 2024.

Headquartered in Italy and founded in 1994 and 1998 respectively, Doppel Farmaceutici and Mipharm are two leading contract development and manufacturing organisations (CDMOs), bringing fully integrated drug development and manufacturing solutions to the pharmaceuticals market.

Trilantic Europe and Alto Partners will each be taking a 50% stake in the new merged entity, named Domixtar Pharmaceuticals (“DMX Pharma”). The entity generated an aggregate turnover of approximately 180 million euros in 2023 and will be led by current Mipharm Executive President, Maurizio Silvestri.

Together, Doppel Farmaceutici and Mipharm service a 100-strong, global portfolio of blue-chip clients, offering a comprehensive suite of technologies and products including liquid, solid and semisolid dosage forms with myriad applications, including anti-tumour, anti-inflammatory, cardiovascular and metabolic.

With 900 employees spread across four production plants located between Milan, Piacenza and Ferrara, DMX Pharma is set to become the largest independent Italian CDMO; equipped with state-of-the-art laboratories capable of supporting its customers in complex research and development (R&D) projects, starting from the investigational phase and product pre-formulation studies, up to the scale up of commercial production.

Vittorio Pignatti-Morano, Chairman and Co-Founder at Trilantic Europe, said: “This merger exemplifies our commitment to growing our portfolio companies into global players, and underscores our ability to identify strategic consolidation opportunities in ever-developing markets. By integrating both Doppel Farmaceutici’s and Mipharm’s unique strengths, scale-up capabilities, and advanced technologies, we're establishing a comprehensive platform to serve the intricate needs of global pharmaceutical clients, supporting with a broader range of activities and sophisticated drug development and manufacturing. We look forward to working with Alto Partners in this next chapter of the companies’ growth journeys.

Maurizio Silvestri, current Executive President of Mipharm and newly appointed Executive President of Domixtar Pharmaceuticals, said: "This strategic merger delivers powerful synergies both commercially and technologically, creating a real powerhouse in the pharmaceuticals market by combining decades of expertise with cutting-edge innovation.”
The terms of the transaction are not disclosed. Trilantic Europe was advised by LMCR / Studio Legale, EY, goetzpartners, ERM and Foglia & Partners.

Press Contact :

Trilantic Europe:

Agnes Riousse/Camilla Wyatt

Citigate Dewe Rogerson

E: agnes.riousse@citigatedewerogerson.com / camilla.wyatt@citigatedewerogerson.com 

T: +44 7770 762828

About Trilantic Europe

Trilantic Europe is a mid-market private equity firm focused on management buyouts, buy-ins and partnerships with founders, families and management teams across its themes and sectors of focus including energy transition, consumer and leisure, business services and healthcare. Trilantic Europe is managed by an experienced group of over 30 investment professionals and 15 operating partners and senior advisors, having invested over €2.7bn in 30 platform portfolio companies since 2004 and currently managing c. €2.6bn in assets from a wide base of investors.

More information: www.trilanticeurope.com 

About Alto Partners

Alto Partners SGR S.p.A. is an independent management company founded by Stefano Scarpis and Raffaele de Courten, focusing on private equity investments in the Italian mid-market. With close to 25 years market experience and 50 transactions completed, it is a choice partner to accompany medium to long-term growth programmes of portfolio companies. The team works alongside entrepreneurial families and managers to address the generation transition and bridge expansion capital gaps. 

Alto Capital V, vintage 2022 (Euro 273 million raised) has completed 5 investment transactions to date: Larioplast (cosmetic and food packaging), Dierre Group (industrial security solutions) e EF Group (general contractor for fairs and tri-dimensional spaces), Fragesa (pizza restaurant chain under the brand “Fra Diavolo”) and Eurosirel (manufacturer and distributor of woundcare and cosmetic products).

More information: www.altopartners.it 

Firms to take equal stakes in new entity Domixtar Pharmaceuticals

Trilantic Europe, a leading mid-market, pan-European private equity investor, is pleased to announce the successful merger of portfolio company Doppel Farmaceutici, and Alto Partners-owned Mipharm. Completion of the transaction is expected to occur in September 2024.

Headquartered in Italy and founded in 1994 and 1998 respectively, Doppel Farmaceutici and Mipharm are two leading contract development and manufacturing organisations (CDMOs), bringing fully integrated drug development and manufacturing solutions to the pharmaceuticals market.

Trilantic Europe and Alto Partners will each be taking a 50% stake in the new merged entity, named Domixtar Pharmaceuticals (“DMX Pharma”). The entity generated an aggregate turnover of approximately 180 million euros in 2023 and will be led by current Mipharm Executive President, Maurizio Silvestri.

Together, Doppel Farmaceutici and Mipharm service a 100-strong, global portfolio of blue-chip clients, offering a comprehensive suite of technologies and products including liquid, solid and semisolid dosage forms with myriad applications, including anti-tumour, anti-inflammatory, cardiovascular and metabolic.

With 900 employees spread across four production plants located between Milan, Piacenza and Ferrara, DMX Pharma is set to become the largest independent Italian CDMO; equipped with state-of-the-art laboratories capable of supporting its customers in complex research and development (R&D) projects, starting from the investigational phase and product pre-formulation studies, up to the scale up of commercial production.

Vittorio Pignatti-Morano, Chairman and Co-Founder at Trilantic Europe, said: “This merger exemplifies our commitment to growing our portfolio companies into global players, and underscores our ability to identify strategic consolidation opportunities in ever-developing markets. By integrating both Doppel Farmaceutici’s and Mipharm’s unique strengths, scale-up capabilities, and advanced technologies, we're establishing a comprehensive platform to serve the intricate needs of global pharmaceutical clients, supporting with a broader range of activities and sophisticated drug development and manufacturing. We look forward to working with Alto Partners in this next chapter of the companies’ growth journeys.

Maurizio Silvestri, current Executive President of Mipharm and newly appointed Executive President of Domixtar Pharmaceuticals, said: "This strategic merger delivers powerful synergies both commercially and technologically, creating a real powerhouse in the pharmaceuticals market by combining decades of expertise with cutting-edge innovation.”
The terms of the transaction are not disclosed. Trilantic Europe was advised by LMCR / Studio Legale, EY, goetzpartners, ERM and Foglia & Partners.

Press Contact :

Trilantic Europe:

Agnes Riousse/Camilla Wyatt

Citigate Dewe Rogerson

E: agnes.riousse@citigatedewerogerson.com / camilla.wyatt@citigatedewerogerson.com 

T: +44 7770 762828

About Trilantic Europe

Trilantic Europe is a mid-market private equity firm focused on management buyouts, buy-ins and partnerships with founders, families and management teams across its themes and sectors of focus including energy transition, consumer and leisure, business services and healthcare. Trilantic Europe is managed by an experienced group of over 30 investment professionals and 15 operating partners and senior advisors, having invested over €2.7bn in 30 platform portfolio companies since 2004 and currently managing c. €2.6bn in assets from a wide base of investors.

More information: www.trilanticeurope.com 

About Alto Partners

Alto Partners SGR S.p.A. is an independent management company founded by Stefano Scarpis and Raffaele de Courten, focusing on private equity investments in the Italian mid-market. With close to 25 years market experience and 50 transactions completed, it is a choice partner to accompany medium to long-term growth programmes of portfolio companies. The team works alongside entrepreneurial families and managers to address the generation transition and bridge expansion capital gaps. 

Alto Capital V, vintage 2022 (Euro 273 million raised) has completed 5 investment transactions to date: Larioplast (cosmetic and food packaging), Dierre Group (industrial security solutions) e EF Group (general contractor for fairs and tri-dimensional spaces), Fragesa (pizza restaurant chain under the brand “Fra Diavolo”) and Eurosirel (manufacturer and distributor of woundcare and cosmetic products).

More information: www.altopartners.it 

Firms to take equal stakes in new entity Domixtar Pharmaceuticals

Trilantic Europe, a leading mid-market, pan-European private equity investor, is pleased to announce the successful merger of portfolio company Doppel Farmaceutici, and Alto Partners-owned Mipharm. Completion of the transaction is expected to occur in September 2024.

Headquartered in Italy and founded in 1994 and 1998 respectively, Doppel Farmaceutici and Mipharm are two leading contract development and manufacturing organisations (CDMOs), bringing fully integrated drug development and manufacturing solutions to the pharmaceuticals market.

Trilantic Europe and Alto Partners will each be taking a 50% stake in the new merged entity, named Domixtar Pharmaceuticals (“DMX Pharma”). The entity generated an aggregate turnover of approximately 180 million euros in 2023 and will be led by current Mipharm Executive President, Maurizio Silvestri.

Together, Doppel Farmaceutici and Mipharm service a 100-strong, global portfolio of blue-chip clients, offering a comprehensive suite of technologies and products including liquid, solid and semisolid dosage forms with myriad applications, including anti-tumour, anti-inflammatory, cardiovascular and metabolic.

With 900 employees spread across four production plants located between Milan, Piacenza and Ferrara, DMX Pharma is set to become the largest independent Italian CDMO; equipped with state-of-the-art laboratories capable of supporting its customers in complex research and development (R&D) projects, starting from the investigational phase and product pre-formulation studies, up to the scale up of commercial production.

Vittorio Pignatti-Morano, Chairman and Co-Founder at Trilantic Europe, said: “This merger exemplifies our commitment to growing our portfolio companies into global players, and underscores our ability to identify strategic consolidation opportunities in ever-developing markets. By integrating both Doppel Farmaceutici’s and Mipharm’s unique strengths, scale-up capabilities, and advanced technologies, we're establishing a comprehensive platform to serve the intricate needs of global pharmaceutical clients, supporting with a broader range of activities and sophisticated drug development and manufacturing. We look forward to working with Alto Partners in this next chapter of the companies’ growth journeys.

Maurizio Silvestri, current Executive President of Mipharm and newly appointed Executive President of Domixtar Pharmaceuticals, said: "This strategic merger delivers powerful synergies both commercially and technologically, creating a real powerhouse in the pharmaceuticals market by combining decades of expertise with cutting-edge innovation.”
The terms of the transaction are not disclosed. Trilantic Europe was advised by LMCR / Studio Legale, EY, goetzpartners, ERM and Foglia & Partners.

Press Contact :

Trilantic Europe:

Agnes Riousse/Camilla Wyatt

Citigate Dewe Rogerson

E: agnes.riousse@citigatedewerogerson.com / camilla.wyatt@citigatedewerogerson.com 

T: +44 7770 762828

About Trilantic Europe

Trilantic Europe is a mid-market private equity firm focused on management buyouts, buy-ins and partnerships with founders, families and management teams across its themes and sectors of focus including energy transition, consumer and leisure, business services and healthcare. Trilantic Europe is managed by an experienced group of over 30 investment professionals and 15 operating partners and senior advisors, having invested over €2.7bn in 30 platform portfolio companies since 2004 and currently managing c. €2.6bn in assets from a wide base of investors.

More information: www.trilanticeurope.com 

About Alto Partners

Alto Partners SGR S.p.A. is an independent management company founded by Stefano Scarpis and Raffaele de Courten, focusing on private equity investments in the Italian mid-market. With close to 25 years market experience and 50 transactions completed, it is a choice partner to accompany medium to long-term growth programmes of portfolio companies. The team works alongside entrepreneurial families and managers to address the generation transition and bridge expansion capital gaps. 

Alto Capital V, vintage 2022 (Euro 273 million raised) has completed 5 investment transactions to date: Larioplast (cosmetic and food packaging), Dierre Group (industrial security solutions) e EF Group (general contractor for fairs and tri-dimensional spaces), Fragesa (pizza restaurant chain under the brand “Fra Diavolo”) and Eurosirel (manufacturer and distributor of woundcare and cosmetic products).

More information: www.altopartners.it 

Firms to take equal stakes in new entity Domixtar Pharmaceuticals

Trilantic Europe, a leading mid-market, pan-European private equity investor, is pleased to announce the successful merger of portfolio company Doppel Farmaceutici, and Alto Partners-owned Mipharm. Completion of the transaction is expected to occur in September 2024.

Headquartered in Italy and founded in 1994 and 1998 respectively, Doppel Farmaceutici and Mipharm are two leading contract development and manufacturing organisations (CDMOs), bringing fully integrated drug development and manufacturing solutions to the pharmaceuticals market.

Trilantic Europe and Alto Partners will each be taking a 50% stake in the new merged entity, named Domixtar Pharmaceuticals (“DMX Pharma”). The entity generated an aggregate turnover of approximately 180 million euros in 2023 and will be led by current Mipharm Executive President, Maurizio Silvestri.

Together, Doppel Farmaceutici and Mipharm service a 100-strong, global portfolio of blue-chip clients, offering a comprehensive suite of technologies and products including liquid, solid and semisolid dosage forms with myriad applications, including anti-tumour, anti-inflammatory, cardiovascular and metabolic.

With 900 employees spread across four production plants located between Milan, Piacenza and Ferrara, DMX Pharma is set to become the largest independent Italian CDMO; equipped with state-of-the-art laboratories capable of supporting its customers in complex research and development (R&D) projects, starting from the investigational phase and product pre-formulation studies, up to the scale up of commercial production.

Vittorio Pignatti-Morano, Chairman and Co-Founder at Trilantic Europe, said: “This merger exemplifies our commitment to growing our portfolio companies into global players, and underscores our ability to identify strategic consolidation opportunities in ever-developing markets. By integrating both Doppel Farmaceutici’s and Mipharm’s unique strengths, scale-up capabilities, and advanced technologies, we're establishing a comprehensive platform to serve the intricate needs of global pharmaceutical clients, supporting with a broader range of activities and sophisticated drug development and manufacturing. We look forward to working with Alto Partners in this next chapter of the companies’ growth journeys.

Maurizio Silvestri, current Executive President of Mipharm and newly appointed Executive President of Domixtar Pharmaceuticals, said: "This strategic merger delivers powerful synergies both commercially and technologically, creating a real powerhouse in the pharmaceuticals market by combining decades of expertise with cutting-edge innovation.”
The terms of the transaction are not disclosed. Trilantic Europe was advised by LMCR / Studio Legale, EY, goetzpartners, ERM and Foglia & Partners.

Press Contact :

Trilantic Europe:

Agnes Riousse/Camilla Wyatt

Citigate Dewe Rogerson

E: agnes.riousse@citigatedewerogerson.com / camilla.wyatt@citigatedewerogerson.com 

T: +44 7770 762828

About Trilantic Europe

Trilantic Europe is a mid-market private equity firm focused on management buyouts, buy-ins and partnerships with founders, families and management teams across its themes and sectors of focus including energy transition, consumer and leisure, business services and healthcare. Trilantic Europe is managed by an experienced group of over 30 investment professionals and 15 operating partners and senior advisors, having invested over €2.7bn in 30 platform portfolio companies since 2004 and currently managing c. €2.6bn in assets from a wide base of investors.

More information: www.trilanticeurope.com 

About Alto Partners

Alto Partners SGR S.p.A. is an independent management company founded by Stefano Scarpis and Raffaele de Courten, focusing on private equity investments in the Italian mid-market. With close to 25 years market experience and 50 transactions completed, it is a choice partner to accompany medium to long-term growth programmes of portfolio companies. The team works alongside entrepreneurial families and managers to address the generation transition and bridge expansion capital gaps. 

Alto Capital V, vintage 2022 (Euro 273 million raised) has completed 5 investment transactions to date: Larioplast (cosmetic and food packaging), Dierre Group (industrial security solutions) e EF Group (general contractor for fairs and tri-dimensional spaces), Fragesa (pizza restaurant chain under the brand “Fra Diavolo”) and Eurosirel (manufacturer and distributor of woundcare and cosmetic products).

More information: www.altopartners.it 

Firms to take equal stakes in new entity Domixtar Pharmaceuticals

Trilantic Europe, a leading mid-market, pan-European private equity investor, is pleased to announce the successful merger of portfolio company Doppel Farmaceutici, and Alto Partners-owned Mipharm. Completion of the transaction is expected to occur in September 2024.

Headquartered in Italy and founded in 1994 and 1998 respectively, Doppel Farmaceutici and Mipharm are two leading contract development and manufacturing organisations (CDMOs), bringing fully integrated drug development and manufacturing solutions to the pharmaceuticals market.

Trilantic Europe and Alto Partners will each be taking a 50% stake in the new merged entity, named Domixtar Pharmaceuticals (“DMX Pharma”). The entity generated an aggregate turnover of approximately 180 million euros in 2023 and will be led by current Mipharm Executive President, Maurizio Silvestri.

Together, Doppel Farmaceutici and Mipharm service a 100-strong, global portfolio of blue-chip clients, offering a comprehensive suite of technologies and products including liquid, solid and semisolid dosage forms with myriad applications, including anti-tumour, anti-inflammatory, cardiovascular and metabolic.

With 900 employees spread across four production plants located between Milan, Piacenza and Ferrara, DMX Pharma is set to become the largest independent Italian CDMO; equipped with state-of-the-art laboratories capable of supporting its customers in complex research and development (R&D) projects, starting from the investigational phase and product pre-formulation studies, up to the scale up of commercial production.

Vittorio Pignatti-Morano, Chairman and Co-Founder at Trilantic Europe, said: “This merger exemplifies our commitment to growing our portfolio companies into global players, and underscores our ability to identify strategic consolidation opportunities in ever-developing markets. By integrating both Doppel Farmaceutici’s and Mipharm’s unique strengths, scale-up capabilities, and advanced technologies, we're establishing a comprehensive platform to serve the intricate needs of global pharmaceutical clients, supporting with a broader range of activities and sophisticated drug development and manufacturing. We look forward to working with Alto Partners in this next chapter of the companies’ growth journeys.

Maurizio Silvestri, current Executive President of Mipharm and newly appointed Executive President of Domixtar Pharmaceuticals, said: "This strategic merger delivers powerful synergies both commercially and technologically, creating a real powerhouse in the pharmaceuticals market by combining decades of expertise with cutting-edge innovation.”
The terms of the transaction are not disclosed. Trilantic Europe was advised by LMCR / Studio Legale, EY, goetzpartners, ERM and Foglia & Partners.

Press Contact :

Trilantic Europe:

Agnes Riousse/Camilla Wyatt

Citigate Dewe Rogerson

E: agnes.riousse@citigatedewerogerson.com / camilla.wyatt@citigatedewerogerson.com 

T: +44 7770 762828

About Trilantic Europe

Trilantic Europe is a mid-market private equity firm focused on management buyouts, buy-ins and partnerships with founders, families and management teams across its themes and sectors of focus including energy transition, consumer and leisure, business services and healthcare. Trilantic Europe is managed by an experienced group of over 30 investment professionals and 15 operating partners and senior advisors, having invested over €2.7bn in 30 platform portfolio companies since 2004 and currently managing c. €2.6bn in assets from a wide base of investors.

More information: www.trilanticeurope.com 

About Alto Partners

Alto Partners SGR S.p.A. is an independent management company founded by Stefano Scarpis and Raffaele de Courten, focusing on private equity investments in the Italian mid-market. With close to 25 years market experience and 50 transactions completed, it is a choice partner to accompany medium to long-term growth programmes of portfolio companies. The team works alongside entrepreneurial families and managers to address the generation transition and bridge expansion capital gaps. 

Alto Capital V, vintage 2022 (Euro 273 million raised) has completed 5 investment transactions to date: Larioplast (cosmetic and food packaging), Dierre Group (industrial security solutions) e EF Group (general contractor for fairs and tri-dimensional spaces), Fragesa (pizza restaurant chain under the brand “Fra Diavolo”) and Eurosirel (manufacturer and distributor of woundcare and cosmetic products).

More information: www.altopartners.it 

Firms to take equal stakes in new entity Domixtar Pharmaceuticals

Trilantic Europe, a leading mid-market, pan-European private equity investor, is pleased to announce the successful merger of portfolio company Doppel Farmaceutici, and Alto Partners-owned Mipharm. Completion of the transaction is expected to occur in September 2024.

Headquartered in Italy and founded in 1994 and 1998 respectively, Doppel Farmaceutici and Mipharm are two leading contract development and manufacturing organisations (CDMOs), bringing fully integrated drug development and manufacturing solutions to the pharmaceuticals market.

Trilantic Europe and Alto Partners will each be taking a 50% stake in the new merged entity, named Domixtar Pharmaceuticals (“DMX Pharma”). The entity generated an aggregate turnover of approximately 180 million euros in 2023 and will be led by current Mipharm Executive President, Maurizio Silvestri.

Together, Doppel Farmaceutici and Mipharm service a 100-strong, global portfolio of blue-chip clients, offering a comprehensive suite of technologies and products including liquid, solid and semisolid dosage forms with myriad applications, including anti-tumour, anti-inflammatory, cardiovascular and metabolic.

With 900 employees spread across four production plants located between Milan, Piacenza and Ferrara, DMX Pharma is set to become the largest independent Italian CDMO; equipped with state-of-the-art laboratories capable of supporting its customers in complex research and development (R&D) projects, starting from the investigational phase and product pre-formulation studies, up to the scale up of commercial production.

Vittorio Pignatti-Morano, Chairman and Co-Founder at Trilantic Europe, said: “This merger exemplifies our commitment to growing our portfolio companies into global players, and underscores our ability to identify strategic consolidation opportunities in ever-developing markets. By integrating both Doppel Farmaceutici’s and Mipharm’s unique strengths, scale-up capabilities, and advanced technologies, we're establishing a comprehensive platform to serve the intricate needs of global pharmaceutical clients, supporting with a broader range of activities and sophisticated drug development and manufacturing. We look forward to working with Alto Partners in this next chapter of the companies’ growth journeys.

Maurizio Silvestri, current Executive President of Mipharm and newly appointed Executive President of Domixtar Pharmaceuticals, said: "This strategic merger delivers powerful synergies both commercially and technologically, creating a real powerhouse in the pharmaceuticals market by combining decades of expertise with cutting-edge innovation.”
The terms of the transaction are not disclosed. Trilantic Europe was advised by LMCR / Studio Legale, EY, goetzpartners, ERM and Foglia & Partners.

Press Contact :

Trilantic Europe:

Agnes Riousse/Camilla Wyatt

Citigate Dewe Rogerson

E: agnes.riousse@citigatedewerogerson.com / camilla.wyatt@citigatedewerogerson.com 

T: +44 7770 762828

About Trilantic Europe

Trilantic Europe is a mid-market private equity firm focused on management buyouts, buy-ins and partnerships with founders, families and management teams across its themes and sectors of focus including energy transition, consumer and leisure, business services and healthcare. Trilantic Europe is managed by an experienced group of over 30 investment professionals and 15 operating partners and senior advisors, having invested over €2.7bn in 30 platform portfolio companies since 2004 and currently managing c. €2.6bn in assets from a wide base of investors.

More information: www.trilanticeurope.com 

About Alto Partners

Alto Partners SGR S.p.A. is an independent management company founded by Stefano Scarpis and Raffaele de Courten, focusing on private equity investments in the Italian mid-market. With close to 25 years market experience and 50 transactions completed, it is a choice partner to accompany medium to long-term growth programmes of portfolio companies. The team works alongside entrepreneurial families and managers to address the generation transition and bridge expansion capital gaps. 

Alto Capital V, vintage 2022 (Euro 273 million raised) has completed 5 investment transactions to date: Larioplast (cosmetic and food packaging), Dierre Group (industrial security solutions) e EF Group (general contractor for fairs and tri-dimensional spaces), Fragesa (pizza restaurant chain under the brand “Fra Diavolo”) and Eurosirel (manufacturer and distributor of woundcare and cosmetic products).

More information: www.altopartners.it 

Firms to take equal stakes in new entity Domixtar Pharmaceuticals

Trilantic Europe, a leading mid-market, pan-European private equity investor, is pleased to announce the successful merger of portfolio company Doppel Farmaceutici, and Alto Partners-owned Mipharm. Completion of the transaction is expected to occur in September 2024.

Headquartered in Italy and founded in 1994 and 1998 respectively, Doppel Farmaceutici and Mipharm are two leading contract development and manufacturing organisations (CDMOs), bringing fully integrated drug development and manufacturing solutions to the pharmaceuticals market.

Trilantic Europe and Alto Partners will each be taking a 50% stake in the new merged entity, named Domixtar Pharmaceuticals (“DMX Pharma”). The entity generated an aggregate turnover of approximately 180 million euros in 2023 and will be led by current Mipharm Executive President, Maurizio Silvestri.

Together, Doppel Farmaceutici and Mipharm service a 100-strong, global portfolio of blue-chip clients, offering a comprehensive suite of technologies and products including liquid, solid and semisolid dosage forms with myriad applications, including anti-tumour, anti-inflammatory, cardiovascular and metabolic.

With 900 employees spread across four production plants located between Milan, Piacenza and Ferrara, DMX Pharma is set to become the largest independent Italian CDMO; equipped with state-of-the-art laboratories capable of supporting its customers in complex research and development (R&D) projects, starting from the investigational phase and product pre-formulation studies, up to the scale up of commercial production.

Vittorio Pignatti-Morano, Chairman and Co-Founder at Trilantic Europe, said: “This merger exemplifies our commitment to growing our portfolio companies into global players, and underscores our ability to identify strategic consolidation opportunities in ever-developing markets. By integrating both Doppel Farmaceutici’s and Mipharm’s unique strengths, scale-up capabilities, and advanced technologies, we're establishing a comprehensive platform to serve the intricate needs of global pharmaceutical clients, supporting with a broader range of activities and sophisticated drug development and manufacturing. We look forward to working with Alto Partners in this next chapter of the companies’ growth journeys.

Maurizio Silvestri, current Executive President of Mipharm and newly appointed Executive President of Domixtar Pharmaceuticals, said: "This strategic merger delivers powerful synergies both commercially and technologically, creating a real powerhouse in the pharmaceuticals market by combining decades of expertise with cutting-edge innovation.”
The terms of the transaction are not disclosed. Trilantic Europe was advised by LMCR / Studio Legale, EY, goetzpartners, ERM and Foglia & Partners.

Press Contact :

Trilantic Europe:

Agnes Riousse/Camilla Wyatt

Citigate Dewe Rogerson

E: agnes.riousse@citigatedewerogerson.com / camilla.wyatt@citigatedewerogerson.com 

T: +44 7770 762828

About Trilantic Europe

Trilantic Europe is a mid-market private equity firm focused on management buyouts, buy-ins and partnerships with founders, families and management teams across its themes and sectors of focus including energy transition, consumer and leisure, business services and healthcare. Trilantic Europe is managed by an experienced group of over 30 investment professionals and 15 operating partners and senior advisors, having invested over €2.7bn in 30 platform portfolio companies since 2004 and currently managing c. €2.6bn in assets from a wide base of investors.

More information: www.trilanticeurope.com 

About Alto Partners

Alto Partners SGR S.p.A. is an independent management company founded by Stefano Scarpis and Raffaele de Courten, focusing on private equity investments in the Italian mid-market. With close to 25 years market experience and 50 transactions completed, it is a choice partner to accompany medium to long-term growth programmes of portfolio companies. The team works alongside entrepreneurial families and managers to address the generation transition and bridge expansion capital gaps. 

Alto Capital V, vintage 2022 (Euro 273 million raised) has completed 5 investment transactions to date: Larioplast (cosmetic and food packaging), Dierre Group (industrial security solutions) e EF Group (general contractor for fairs and tri-dimensional spaces), Fragesa (pizza restaurant chain under the brand “Fra Diavolo”) and Eurosirel (manufacturer and distributor of woundcare and cosmetic products).

More information: www.altopartners.it 

Firms to take equal stakes in new entity Domixtar Pharmaceuticals

Trilantic Europe, a leading mid-market, pan-European private equity investor, is pleased to announce the successful merger of portfolio company Doppel Farmaceutici, and Alto Partners-owned Mipharm. Completion of the transaction is expected to occur in September 2024.

Headquartered in Italy and founded in 1994 and 1998 respectively, Doppel Farmaceutici and Mipharm are two leading contract development and manufacturing organisations (CDMOs), bringing fully integrated drug development and manufacturing solutions to the pharmaceuticals market.

Trilantic Europe and Alto Partners will each be taking a 50% stake in the new merged entity, named Domixtar Pharmaceuticals (“DMX Pharma”). The entity generated an aggregate turnover of approximately 180 million euros in 2023 and will be led by current Mipharm Executive President, Maurizio Silvestri.

Together, Doppel Farmaceutici and Mipharm service a 100-strong, global portfolio of blue-chip clients, offering a comprehensive suite of technologies and products including liquid, solid and semisolid dosage forms with myriad applications, including anti-tumour, anti-inflammatory, cardiovascular and metabolic.

With 900 employees spread across four production plants located between Milan, Piacenza and Ferrara, DMX Pharma is set to become the largest independent Italian CDMO; equipped with state-of-the-art laboratories capable of supporting its customers in complex research and development (R&D) projects, starting from the investigational phase and product pre-formulation studies, up to the scale up of commercial production.

Vittorio Pignatti-Morano, Chairman and Co-Founder at Trilantic Europe, said: “This merger exemplifies our commitment to growing our portfolio companies into global players, and underscores our ability to identify strategic consolidation opportunities in ever-developing markets. By integrating both Doppel Farmaceutici’s and Mipharm’s unique strengths, scale-up capabilities, and advanced technologies, we're establishing a comprehensive platform to serve the intricate needs of global pharmaceutical clients, supporting with a broader range of activities and sophisticated drug development and manufacturing. We look forward to working with Alto Partners in this next chapter of the companies’ growth journeys.

Maurizio Silvestri, current Executive President of Mipharm and newly appointed Executive President of Domixtar Pharmaceuticals, said: "This strategic merger delivers powerful synergies both commercially and technologically, creating a real powerhouse in the pharmaceuticals market by combining decades of expertise with cutting-edge innovation.”
The terms of the transaction are not disclosed. Trilantic Europe was advised by LMCR / Studio Legale, EY, goetzpartners, ERM and Foglia & Partners.

Press Contact :

Trilantic Europe:

Agnes Riousse/Camilla Wyatt

Citigate Dewe Rogerson

E: agnes.riousse@citigatedewerogerson.com / camilla.wyatt@citigatedewerogerson.com 

T: +44 7770 762828

About Trilantic Europe

Trilantic Europe is a mid-market private equity firm focused on management buyouts, buy-ins and partnerships with founders, families and management teams across its themes and sectors of focus including energy transition, consumer and leisure, business services and healthcare. Trilantic Europe is managed by an experienced group of over 30 investment professionals and 15 operating partners and senior advisors, having invested over €2.7bn in 30 platform portfolio companies since 2004 and currently managing c. €2.6bn in assets from a wide base of investors.

More information: www.trilanticeurope.com 

About Alto Partners

Alto Partners SGR S.p.A. is an independent management company founded by Stefano Scarpis and Raffaele de Courten, focusing on private equity investments in the Italian mid-market. With close to 25 years market experience and 50 transactions completed, it is a choice partner to accompany medium to long-term growth programmes of portfolio companies. The team works alongside entrepreneurial families and managers to address the generation transition and bridge expansion capital gaps. 

Alto Capital V, vintage 2022 (Euro 273 million raised) has completed 5 investment transactions to date: Larioplast (cosmetic and food packaging), Dierre Group (industrial security solutions) e EF Group (general contractor for fairs and tri-dimensional spaces), Fragesa (pizza restaurant chain under the brand “Fra Diavolo”) and Eurosirel (manufacturer and distributor of woundcare and cosmetic products).

More information: www.altopartners.it 

Firms to take equal stakes in new entity Domixtar Pharmaceuticals

Trilantic Europe, a leading mid-market, pan-European private equity investor, is pleased to announce the successful merger of portfolio company Doppel Farmaceutici, and Alto Partners-owned Mipharm. Completion of the transaction is expected to occur in September 2024.

Headquartered in Italy and founded in 1994 and 1998 respectively, Doppel Farmaceutici and Mipharm are two leading contract development and manufacturing organisations (CDMOs), bringing fully integrated drug development and manufacturing solutions to the pharmaceuticals market.

Trilantic Europe and Alto Partners will each be taking a 50% stake in the new merged entity, named Domixtar Pharmaceuticals (“DMX Pharma”). The entity generated an aggregate turnover of approximately 180 million euros in 2023 and will be led by current Mipharm Executive President, Maurizio Silvestri.

Together, Doppel Farmaceutici and Mipharm service a 100-strong, global portfolio of blue-chip clients, offering a comprehensive suite of technologies and products including liquid, solid and semisolid dosage forms with myriad applications, including anti-tumour, anti-inflammatory, cardiovascular and metabolic.

With 900 employees spread across four production plants located between Milan, Piacenza and Ferrara, DMX Pharma is set to become the largest independent Italian CDMO; equipped with state-of-the-art laboratories capable of supporting its customers in complex research and development (R&D) projects, starting from the investigational phase and product pre-formulation studies, up to the scale up of commercial production.

Vittorio Pignatti-Morano, Chairman and Co-Founder at Trilantic Europe, said: “This merger exemplifies our commitment to growing our portfolio companies into global players, and underscores our ability to identify strategic consolidation opportunities in ever-developing markets. By integrating both Doppel Farmaceutici’s and Mipharm’s unique strengths, scale-up capabilities, and advanced technologies, we're establishing a comprehensive platform to serve the intricate needs of global pharmaceutical clients, supporting with a broader range of activities and sophisticated drug development and manufacturing. We look forward to working with Alto Partners in this next chapter of the companies’ growth journeys.

Maurizio Silvestri, current Executive President of Mipharm and newly appointed Executive President of Domixtar Pharmaceuticals, said: "This strategic merger delivers powerful synergies both commercially and technologically, creating a real powerhouse in the pharmaceuticals market by combining decades of expertise with cutting-edge innovation.”
The terms of the transaction are not disclosed. Trilantic Europe was advised by LMCR / Studio Legale, EY, goetzpartners, ERM and Foglia & Partners.

Press Contact :

Trilantic Europe:

Agnes Riousse/Camilla Wyatt

Citigate Dewe Rogerson

E: agnes.riousse@citigatedewerogerson.com / camilla.wyatt@citigatedewerogerson.com 

T: +44 7770 762828

About Trilantic Europe

Trilantic Europe is a mid-market private equity firm focused on management buyouts, buy-ins and partnerships with founders, families and management teams across its themes and sectors of focus including energy transition, consumer and leisure, business services and healthcare. Trilantic Europe is managed by an experienced group of over 30 investment professionals and 15 operating partners and senior advisors, having invested over €2.7bn in 30 platform portfolio companies since 2004 and currently managing c. €2.6bn in assets from a wide base of investors.

More information: www.trilanticeurope.com 

About Alto Partners

Alto Partners SGR S.p.A. is an independent management company founded by Stefano Scarpis and Raffaele de Courten, focusing on private equity investments in the Italian mid-market. With close to 25 years market experience and 50 transactions completed, it is a choice partner to accompany medium to long-term growth programmes of portfolio companies. The team works alongside entrepreneurial families and managers to address the generation transition and bridge expansion capital gaps. 

Alto Capital V, vintage 2022 (Euro 273 million raised) has completed 5 investment transactions to date: Larioplast (cosmetic and food packaging), Dierre Group (industrial security solutions) e EF Group (general contractor for fairs and tri-dimensional spaces), Fragesa (pizza restaurant chain under the brand “Fra Diavolo”) and Eurosirel (manufacturer and distributor of woundcare and cosmetic products).

More information: www.altopartners.it 

Firms to take equal stakes in new entity Domixtar Pharmaceuticals

Trilantic Europe, a leading mid-market, pan-European private equity investor, is pleased to announce the successful merger of portfolio company Doppel Farmaceutici, and Alto Partners-owned Mipharm. Completion of the transaction is expected to occur in September 2024.

Headquartered in Italy and founded in 1994 and 1998 respectively, Doppel Farmaceutici and Mipharm are two leading contract development and manufacturing organisations (CDMOs), bringing fully integrated drug development and manufacturing solutions to the pharmaceuticals market.

Trilantic Europe and Alto Partners will each be taking a 50% stake in the new merged entity, named Domixtar Pharmaceuticals (“DMX Pharma”). The entity generated an aggregate turnover of approximately 180 million euros in 2023 and will be led by current Mipharm Executive President, Maurizio Silvestri.

Together, Doppel Farmaceutici and Mipharm service a 100-strong, global portfolio of blue-chip clients, offering a comprehensive suite of technologies and products including liquid, solid and semisolid dosage forms with myriad applications, including anti-tumour, anti-inflammatory, cardiovascular and metabolic.

With 900 employees spread across four production plants located between Milan, Piacenza and Ferrara, DMX Pharma is set to become the largest independent Italian CDMO; equipped with state-of-the-art laboratories capable of supporting its customers in complex research and development (R&D) projects, starting from the investigational phase and product pre-formulation studies, up to the scale up of commercial production.

Vittorio Pignatti-Morano, Chairman and Co-Founder at Trilantic Europe, said: “This merger exemplifies our commitment to growing our portfolio companies into global players, and underscores our ability to identify strategic consolidation opportunities in ever-developing markets. By integrating both Doppel Farmaceutici’s and Mipharm’s unique strengths, scale-up capabilities, and advanced technologies, we're establishing a comprehensive platform to serve the intricate needs of global pharmaceutical clients, supporting with a broader range of activities and sophisticated drug development and manufacturing. We look forward to working with Alto Partners in this next chapter of the companies’ growth journeys.

Maurizio Silvestri, current Executive President of Mipharm and newly appointed Executive President of Domixtar Pharmaceuticals, said: "This strategic merger delivers powerful synergies both commercially and technologically, creating a real powerhouse in the pharmaceuticals market by combining decades of expertise with cutting-edge innovation.”
The terms of the transaction are not disclosed. Trilantic Europe was advised by LMCR / Studio Legale, EY, goetzpartners, ERM and Foglia & Partners.

Press Contact :

Trilantic Europe:

Agnes Riousse/Camilla Wyatt

Citigate Dewe Rogerson

E: agnes.riousse@citigatedewerogerson.com / camilla.wyatt@citigatedewerogerson.com 

T: +44 7770 762828

About Trilantic Europe

Trilantic Europe is a mid-market private equity firm focused on management buyouts, buy-ins and partnerships with founders, families and management teams across its themes and sectors of focus including energy transition, consumer and leisure, business services and healthcare. Trilantic Europe is managed by an experienced group of over 30 investment professionals and 15 operating partners and senior advisors, having invested over €2.7bn in 30 platform portfolio companies since 2004 and currently managing c. €2.6bn in assets from a wide base of investors.

More information: www.trilanticeurope.com 

About Alto Partners

Alto Partners SGR S.p.A. is an independent management company founded by Stefano Scarpis and Raffaele de Courten, focusing on private equity investments in the Italian mid-market. With close to 25 years market experience and 50 transactions completed, it is a choice partner to accompany medium to long-term growth programmes of portfolio companies. The team works alongside entrepreneurial families and managers to address the generation transition and bridge expansion capital gaps. 

Alto Capital V, vintage 2022 (Euro 273 million raised) has completed 5 investment transactions to date: Larioplast (cosmetic and food packaging), Dierre Group (industrial security solutions) e EF Group (general contractor for fairs and tri-dimensional spaces), Fragesa (pizza restaurant chain under the brand “Fra Diavolo”) and Eurosirel (manufacturer and distributor of woundcare and cosmetic products).

More information: www.altopartners.it 

Firms to take equal stakes in new entity Domixtar Pharmaceuticals

Trilantic Europe, a leading mid-market, pan-European private equity investor, is pleased to announce the successful merger of portfolio company Doppel Farmaceutici, and Alto Partners-owned Mipharm. Completion of the transaction is expected to occur in September 2024.

Headquartered in Italy and founded in 1994 and 1998 respectively, Doppel Farmaceutici and Mipharm are two leading contract development and manufacturing organisations (CDMOs), bringing fully integrated drug development and manufacturing solutions to the pharmaceuticals market.

Trilantic Europe and Alto Partners will each be taking a 50% stake in the new merged entity, named Domixtar Pharmaceuticals (“DMX Pharma”). The entity generated an aggregate turnover of approximately 180 million euros in 2023 and will be led by current Mipharm Executive President, Maurizio Silvestri.

Together, Doppel Farmaceutici and Mipharm service a 100-strong, global portfolio of blue-chip clients, offering a comprehensive suite of technologies and products including liquid, solid and semisolid dosage forms with myriad applications, including anti-tumour, anti-inflammatory, cardiovascular and metabolic.

With 900 employees spread across four production plants located between Milan, Piacenza and Ferrara, DMX Pharma is set to become the largest independent Italian CDMO; equipped with state-of-the-art laboratories capable of supporting its customers in complex research and development (R&D) projects, starting from the investigational phase and product pre-formulation studies, up to the scale up of commercial production.

Vittorio Pignatti-Morano, Chairman and Co-Founder at Trilantic Europe, said: “This merger exemplifies our commitment to growing our portfolio companies into global players, and underscores our ability to identify strategic consolidation opportunities in ever-developing markets. By integrating both Doppel Farmaceutici’s and Mipharm’s unique strengths, scale-up capabilities, and advanced technologies, we're establishing a comprehensive platform to serve the intricate needs of global pharmaceutical clients, supporting with a broader range of activities and sophisticated drug development and manufacturing. We look forward to working with Alto Partners in this next chapter of the companies’ growth journeys.

Maurizio Silvestri, current Executive President of Mipharm and newly appointed Executive President of Domixtar Pharmaceuticals, said: "This strategic merger delivers powerful synergies both commercially and technologically, creating a real powerhouse in the pharmaceuticals market by combining decades of expertise with cutting-edge innovation.”
The terms of the transaction are not disclosed. Trilantic Europe was advised by LMCR / Studio Legale, EY, goetzpartners, ERM and Foglia & Partners.

Press Contact :

Trilantic Europe:

Agnes Riousse/Camilla Wyatt

Citigate Dewe Rogerson

E: agnes.riousse@citigatedewerogerson.com / camilla.wyatt@citigatedewerogerson.com 

T: +44 7770 762828

About Trilantic Europe

Trilantic Europe is a mid-market private equity firm focused on management buyouts, buy-ins and partnerships with founders, families and management teams across its themes and sectors of focus including energy transition, consumer and leisure, business services and healthcare. Trilantic Europe is managed by an experienced group of over 30 investment professionals and 15 operating partners and senior advisors, having invested over €2.7bn in 30 platform portfolio companies since 2004 and currently managing c. €2.6bn in assets from a wide base of investors.

More information: www.trilanticeurope.com 

About Alto Partners

Alto Partners SGR S.p.A. is an independent management company founded by Stefano Scarpis and Raffaele de Courten, focusing on private equity investments in the Italian mid-market. With close to 25 years market experience and 50 transactions completed, it is a choice partner to accompany medium to long-term growth programmes of portfolio companies. The team works alongside entrepreneurial families and managers to address the generation transition and bridge expansion capital gaps. 

Alto Capital V, vintage 2022 (Euro 273 million raised) has completed 5 investment transactions to date: Larioplast (cosmetic and food packaging), Dierre Group (industrial security solutions) e EF Group (general contractor for fairs and tri-dimensional spaces), Fragesa (pizza restaurant chain under the brand “Fra Diavolo”) and Eurosirel (manufacturer and distributor of woundcare and cosmetic products).

More information: www.altopartners.it 

Firms to take equal stakes in new entity Domixtar Pharmaceuticals

Trilantic Europe, a leading mid-market, pan-European private equity investor, is pleased to announce the successful merger of portfolio company Doppel Farmaceutici, and Alto Partners-owned Mipharm. Completion of the transaction is expected to occur in September 2024.

Headquartered in Italy and founded in 1994 and 1998 respectively, Doppel Farmaceutici and Mipharm are two leading contract development and manufacturing organisations (CDMOs), bringing fully integrated drug development and manufacturing solutions to the pharmaceuticals market.

Trilantic Europe and Alto Partners will each be taking a 50% stake in the new merged entity, named Domixtar Pharmaceuticals (“DMX Pharma”). The entity generated an aggregate turnover of approximately 180 million euros in 2023 and will be led by current Mipharm Executive President, Maurizio Silvestri.

Together, Doppel Farmaceutici and Mipharm service a 100-strong, global portfolio of blue-chip clients, offering a comprehensive suite of technologies and products including liquid, solid and semisolid dosage forms with myriad applications, including anti-tumour, anti-inflammatory, cardiovascular and metabolic.

With 900 employees spread across four production plants located between Milan, Piacenza and Ferrara, DMX Pharma is set to become the largest independent Italian CDMO; equipped with state-of-the-art laboratories capable of supporting its customers in complex research and development (R&D) projects, starting from the investigational phase and product pre-formulation studies, up to the scale up of commercial production.

Vittorio Pignatti-Morano, Chairman and Co-Founder at Trilantic Europe, said: “This merger exemplifies our commitment to growing our portfolio companies into global players, and underscores our ability to identify strategic consolidation opportunities in ever-developing markets. By integrating both Doppel Farmaceutici’s and Mipharm’s unique strengths, scale-up capabilities, and advanced technologies, we're establishing a comprehensive platform to serve the intricate needs of global pharmaceutical clients, supporting with a broader range of activities and sophisticated drug development and manufacturing. We look forward to working with Alto Partners in this next chapter of the companies’ growth journeys.

Maurizio Silvestri, current Executive President of Mipharm and newly appointed Executive President of Domixtar Pharmaceuticals, said: "This strategic merger delivers powerful synergies both commercially and technologically, creating a real powerhouse in the pharmaceuticals market by combining decades of expertise with cutting-edge innovation.”
The terms of the transaction are not disclosed. Trilantic Europe was advised by LMCR / Studio Legale, EY, goetzpartners, ERM and Foglia & Partners.

Press Contact :

Trilantic Europe:

Agnes Riousse/Camilla Wyatt

Citigate Dewe Rogerson

E: agnes.riousse@citigatedewerogerson.com / camilla.wyatt@citigatedewerogerson.com 

T: +44 7770 762828

About Trilantic Europe

Trilantic Europe is a mid-market private equity firm focused on management buyouts, buy-ins and partnerships with founders, families and management teams across its themes and sectors of focus including energy transition, consumer and leisure, business services and healthcare. Trilantic Europe is managed by an experienced group of over 30 investment professionals and 15 operating partners and senior advisors, having invested over €2.7bn in 30 platform portfolio companies since 2004 and currently managing c. €2.6bn in assets from a wide base of investors.

More information: www.trilanticeurope.com 

About Alto Partners

Alto Partners SGR S.p.A. is an independent management company founded by Stefano Scarpis and Raffaele de Courten, focusing on private equity investments in the Italian mid-market. With close to 25 years market experience and 50 transactions completed, it is a choice partner to accompany medium to long-term growth programmes of portfolio companies. The team works alongside entrepreneurial families and managers to address the generation transition and bridge expansion capital gaps. 

Alto Capital V, vintage 2022 (Euro 273 million raised) has completed 5 investment transactions to date: Larioplast (cosmetic and food packaging), Dierre Group (industrial security solutions) e EF Group (general contractor for fairs and tri-dimensional spaces), Fragesa (pizza restaurant chain under the brand “Fra Diavolo”) and Eurosirel (manufacturer and distributor of woundcare and cosmetic products).

More information: www.altopartners.it 

Firms to take equal stakes in new entity Domixtar Pharmaceuticals

Trilantic Europe, a leading mid-market, pan-European private equity investor, is pleased to announce the successful merger of portfolio company Doppel Farmaceutici, and Alto Partners-owned Mipharm. Completion of the transaction is expected to occur in September 2024.

Headquartered in Italy and founded in 1994 and 1998 respectively, Doppel Farmaceutici and Mipharm are two leading contract development and manufacturing organisations (CDMOs), bringing fully integrated drug development and manufacturing solutions to the pharmaceuticals market.

Trilantic Europe and Alto Partners will each be taking a 50% stake in the new merged entity, named Domixtar Pharmaceuticals (“DMX Pharma”). The entity generated an aggregate turnover of approximately 180 million euros in 2023 and will be led by current Mipharm Executive President, Maurizio Silvestri.

Together, Doppel Farmaceutici and Mipharm service a 100-strong, global portfolio of blue-chip clients, offering a comprehensive suite of technologies and products including liquid, solid and semisolid dosage forms with myriad applications, including anti-tumour, anti-inflammatory, cardiovascular and metabolic.

With 900 employees spread across four production plants located between Milan, Piacenza and Ferrara, DMX Pharma is set to become the largest independent Italian CDMO; equipped with state-of-the-art laboratories capable of supporting its customers in complex research and development (R&D) projects, starting from the investigational phase and product pre-formulation studies, up to the scale up of commercial production.

Vittorio Pignatti-Morano, Chairman and Co-Founder at Trilantic Europe, said: “This merger exemplifies our commitment to growing our portfolio companies into global players, and underscores our ability to identify strategic consolidation opportunities in ever-developing markets. By integrating both Doppel Farmaceutici’s and Mipharm’s unique strengths, scale-up capabilities, and advanced technologies, we're establishing a comprehensive platform to serve the intricate needs of global pharmaceutical clients, supporting with a broader range of activities and sophisticated drug development and manufacturing. We look forward to working with Alto Partners in this next chapter of the companies’ growth journeys.

Maurizio Silvestri, current Executive President of Mipharm and newly appointed Executive President of Domixtar Pharmaceuticals, said: "This strategic merger delivers powerful synergies both commercially and technologically, creating a real powerhouse in the pharmaceuticals market by combining decades of expertise with cutting-edge innovation.”
The terms of the transaction are not disclosed. Trilantic Europe was advised by LMCR / Studio Legale, EY, goetzpartners, ERM and Foglia & Partners.

Press Contact :

Trilantic Europe:

Agnes Riousse/Camilla Wyatt

Citigate Dewe Rogerson

E: agnes.riousse@citigatedewerogerson.com / camilla.wyatt@citigatedewerogerson.com 

T: +44 7770 762828

About Trilantic Europe

Trilantic Europe is a mid-market private equity firm focused on management buyouts, buy-ins and partnerships with founders, families and management teams across its themes and sectors of focus including energy transition, consumer and leisure, business services and healthcare. Trilantic Europe is managed by an experienced group of over 30 investment professionals and 15 operating partners and senior advisors, having invested over €2.7bn in 30 platform portfolio companies since 2004 and currently managing c. €2.6bn in assets from a wide base of investors.

More information: www.trilanticeurope.com 

About Alto Partners

Alto Partners SGR S.p.A. is an independent management company founded by Stefano Scarpis and Raffaele de Courten, focusing on private equity investments in the Italian mid-market. With close to 25 years market experience and 50 transactions completed, it is a choice partner to accompany medium to long-term growth programmes of portfolio companies. The team works alongside entrepreneurial families and managers to address the generation transition and bridge expansion capital gaps. 

Alto Capital V, vintage 2022 (Euro 273 million raised) has completed 5 investment transactions to date: Larioplast (cosmetic and food packaging), Dierre Group (industrial security solutions) e EF Group (general contractor for fairs and tri-dimensional spaces), Fragesa (pizza restaurant chain under the brand “Fra Diavolo”) and Eurosirel (manufacturer and distributor of woundcare and cosmetic products).

More information: www.altopartners.it 

Firms to take equal stakes in new entity Domixtar Pharmaceuticals

Trilantic Europe, a leading mid-market, pan-European private equity investor, is pleased to announce the successful merger of portfolio company Doppel Farmaceutici, and Alto Partners-owned Mipharm. Completion of the transaction is expected to occur in September 2024.

Headquartered in Italy and founded in 1994 and 1998 respectively, Doppel Farmaceutici and Mipharm are two leading contract development and manufacturing organisations (CDMOs), bringing fully integrated drug development and manufacturing solutions to the pharmaceuticals market.

Trilantic Europe and Alto Partners will each be taking a 50% stake in the new merged entity, named Domixtar Pharmaceuticals (“DMX Pharma”). The entity generated an aggregate turnover of approximately 180 million euros in 2023 and will be led by current Mipharm Executive President, Maurizio Silvestri.

Together, Doppel Farmaceutici and Mipharm service a 100-strong, global portfolio of blue-chip clients, offering a comprehensive suite of technologies and products including liquid, solid and semisolid dosage forms with myriad applications, including anti-tumour, anti-inflammatory, cardiovascular and metabolic.

With 900 employees spread across four production plants located between Milan, Piacenza and Ferrara, DMX Pharma is set to become the largest independent Italian CDMO; equipped with state-of-the-art laboratories capable of supporting its customers in complex research and development (R&D) projects, starting from the investigational phase and product pre-formulation studies, up to the scale up of commercial production.

Vittorio Pignatti-Morano, Chairman and Co-Founder at Trilantic Europe, said: “This merger exemplifies our commitment to growing our portfolio companies into global players, and underscores our ability to identify strategic consolidation opportunities in ever-developing markets. By integrating both Doppel Farmaceutici’s and Mipharm’s unique strengths, scale-up capabilities, and advanced technologies, we're establishing a comprehensive platform to serve the intricate needs of global pharmaceutical clients, supporting with a broader range of activities and sophisticated drug development and manufacturing. We look forward to working with Alto Partners in this next chapter of the companies’ growth journeys.

Maurizio Silvestri, current Executive President of Mipharm and newly appointed Executive President of Domixtar Pharmaceuticals, said: "This strategic merger delivers powerful synergies both commercially and technologically, creating a real powerhouse in the pharmaceuticals market by combining decades of expertise with cutting-edge innovation.”
The terms of the transaction are not disclosed. Trilantic Europe was advised by LMCR / Studio Legale, EY, goetzpartners, ERM and Foglia & Partners.

Press Contact :

Trilantic Europe:

Agnes Riousse/Camilla Wyatt

Citigate Dewe Rogerson

E: agnes.riousse@citigatedewerogerson.com / camilla.wyatt@citigatedewerogerson.com 

T: +44 7770 762828

About Trilantic Europe

Trilantic Europe is a mid-market private equity firm focused on management buyouts, buy-ins and partnerships with founders, families and management teams across its themes and sectors of focus including energy transition, consumer and leisure, business services and healthcare. Trilantic Europe is managed by an experienced group of over 30 investment professionals and 15 operating partners and senior advisors, having invested over €2.7bn in 30 platform portfolio companies since 2004 and currently managing c. €2.6bn in assets from a wide base of investors.

More information: www.trilanticeurope.com 

About Alto Partners

Alto Partners SGR S.p.A. is an independent management company founded by Stefano Scarpis and Raffaele de Courten, focusing on private equity investments in the Italian mid-market. With close to 25 years market experience and 50 transactions completed, it is a choice partner to accompany medium to long-term growth programmes of portfolio companies. The team works alongside entrepreneurial families and managers to address the generation transition and bridge expansion capital gaps. 

Alto Capital V, vintage 2022 (Euro 273 million raised) has completed 5 investment transactions to date: Larioplast (cosmetic and food packaging), Dierre Group (industrial security solutions) e EF Group (general contractor for fairs and tri-dimensional spaces), Fragesa (pizza restaurant chain under the brand “Fra Diavolo”) and Eurosirel (manufacturer and distributor of woundcare and cosmetic products).

More information: www.altopartners.it 

Firms to take equal stakes in new entity Domixtar Pharmaceuticals

Trilantic Europe, a leading mid-market, pan-European private equity investor, is pleased to announce the successful merger of portfolio company Doppel Farmaceutici, and Alto Partners-owned Mipharm. Completion of the transaction is expected to occur in September 2024.

Headquartered in Italy and founded in 1994 and 1998 respectively, Doppel Farmaceutici and Mipharm are two leading contract development and manufacturing organisations (CDMOs), bringing fully integrated drug development and manufacturing solutions to the pharmaceuticals market.

Trilantic Europe and Alto Partners will each be taking a 50% stake in the new merged entity, named Domixtar Pharmaceuticals (“DMX Pharma”). The entity generated an aggregate turnover of approximately 180 million euros in 2023 and will be led by current Mipharm Executive President, Maurizio Silvestri.

Together, Doppel Farmaceutici and Mipharm service a 100-strong, global portfolio of blue-chip clients, offering a comprehensive suite of technologies and products including liquid, solid and semisolid dosage forms with myriad applications, including anti-tumour, anti-inflammatory, cardiovascular and metabolic.

With 900 employees spread across four production plants located between Milan, Piacenza and Ferrara, DMX Pharma is set to become the largest independent Italian CDMO; equipped with state-of-the-art laboratories capable of supporting its customers in complex research and development (R&D) projects, starting from the investigational phase and product pre-formulation studies, up to the scale up of commercial production.

Vittorio Pignatti-Morano, Chairman and Co-Founder at Trilantic Europe, said: “This merger exemplifies our commitment to growing our portfolio companies into global players, and underscores our ability to identify strategic consolidation opportunities in ever-developing markets. By integrating both Doppel Farmaceutici’s and Mipharm’s unique strengths, scale-up capabilities, and advanced technologies, we're establishing a comprehensive platform to serve the intricate needs of global pharmaceutical clients, supporting with a broader range of activities and sophisticated drug development and manufacturing. We look forward to working with Alto Partners in this next chapter of the companies’ growth journeys.

Maurizio Silvestri, current Executive President of Mipharm and newly appointed Executive President of Domixtar Pharmaceuticals, said: "This strategic merger delivers powerful synergies both commercially and technologically, creating a real powerhouse in the pharmaceuticals market by combining decades of expertise with cutting-edge innovation.”
The terms of the transaction are not disclosed. Trilantic Europe was advised by LMCR / Studio Legale, EY, goetzpartners, ERM and Foglia & Partners.

Press Contact :

Trilantic Europe:

Agnes Riousse/Camilla Wyatt

Citigate Dewe Rogerson

E: agnes.riousse@citigatedewerogerson.com / camilla.wyatt@citigatedewerogerson.com 

T: +44 7770 762828

About Trilantic Europe

Trilantic Europe is a mid-market private equity firm focused on management buyouts, buy-ins and partnerships with founders, families and management teams across its themes and sectors of focus including energy transition, consumer and leisure, business services and healthcare. Trilantic Europe is managed by an experienced group of over 30 investment professionals and 15 operating partners and senior advisors, having invested over €2.7bn in 30 platform portfolio companies since 2004 and currently managing c. €2.6bn in assets from a wide base of investors.

More information: www.trilanticeurope.com 

About Alto Partners

Alto Partners SGR S.p.A. is an independent management company founded by Stefano Scarpis and Raffaele de Courten, focusing on private equity investments in the Italian mid-market. With close to 25 years market experience and 50 transactions completed, it is a choice partner to accompany medium to long-term growth programmes of portfolio companies. The team works alongside entrepreneurial families and managers to address the generation transition and bridge expansion capital gaps. 

Alto Capital V, vintage 2022 (Euro 273 million raised) has completed 5 investment transactions to date: Larioplast (cosmetic and food packaging), Dierre Group (industrial security solutions) e EF Group (general contractor for fairs and tri-dimensional spaces), Fragesa (pizza restaurant chain under the brand “Fra Diavolo”) and Eurosirel (manufacturer and distributor of woundcare and cosmetic products).

More information: www.altopartners.it 

Firms to take equal stakes in new entity Domixtar Pharmaceuticals

Trilantic Europe, a leading mid-market, pan-European private equity investor, is pleased to announce the successful merger of portfolio company Doppel Farmaceutici, and Alto Partners-owned Mipharm. Completion of the transaction is expected to occur in September 2024.

Headquartered in Italy and founded in 1994 and 1998 respectively, Doppel Farmaceutici and Mipharm are two leading contract development and manufacturing organisations (CDMOs), bringing fully integrated drug development and manufacturing solutions to the pharmaceuticals market.

Trilantic Europe and Alto Partners will each be taking a 50% stake in the new merged entity, named Domixtar Pharmaceuticals (“DMX Pharma”). The entity generated an aggregate turnover of approximately 180 million euros in 2023 and will be led by current Mipharm Executive President, Maurizio Silvestri.

Together, Doppel Farmaceutici and Mipharm service a 100-strong, global portfolio of blue-chip clients, offering a comprehensive suite of technologies and products including liquid, solid and semisolid dosage forms with myriad applications, including anti-tumour, anti-inflammatory, cardiovascular and metabolic.

With 900 employees spread across four production plants located between Milan, Piacenza and Ferrara, DMX Pharma is set to become the largest independent Italian CDMO; equipped with state-of-the-art laboratories capable of supporting its customers in complex research and development (R&D) projects, starting from the investigational phase and product pre-formulation studies, up to the scale up of commercial production.

Vittorio Pignatti-Morano, Chairman and Co-Founder at Trilantic Europe, said: “This merger exemplifies our commitment to growing our portfolio companies into global players, and underscores our ability to identify strategic consolidation opportunities in ever-developing markets. By integrating both Doppel Farmaceutici’s and Mipharm’s unique strengths, scale-up capabilities, and advanced technologies, we're establishing a comprehensive platform to serve the intricate needs of global pharmaceutical clients, supporting with a broader range of activities and sophisticated drug development and manufacturing. We look forward to working with Alto Partners in this next chapter of the companies’ growth journeys.

Maurizio Silvestri, current Executive President of Mipharm and newly appointed Executive President of Domixtar Pharmaceuticals, said: "This strategic merger delivers powerful synergies both commercially and technologically, creating a real powerhouse in the pharmaceuticals market by combining decades of expertise with cutting-edge innovation.”
The terms of the transaction are not disclosed. Trilantic Europe was advised by LMCR / Studio Legale, EY, goetzpartners, ERM and Foglia & Partners.

Press Contact :

Trilantic Europe:

Agnes Riousse/Camilla Wyatt

Citigate Dewe Rogerson

E: agnes.riousse@citigatedewerogerson.com / camilla.wyatt@citigatedewerogerson.com 

T: +44 7770 762828

About Trilantic Europe

Trilantic Europe is a mid-market private equity firm focused on management buyouts, buy-ins and partnerships with founders, families and management teams across its themes and sectors of focus including energy transition, consumer and leisure, business services and healthcare. Trilantic Europe is managed by an experienced group of over 30 investment professionals and 15 operating partners and senior advisors, having invested over €2.7bn in 30 platform portfolio companies since 2004 and currently managing c. €2.6bn in assets from a wide base of investors.

More information: www.trilanticeurope.com 

About Alto Partners

Alto Partners SGR S.p.A. is an independent management company founded by Stefano Scarpis and Raffaele de Courten, focusing on private equity investments in the Italian mid-market. With close to 25 years market experience and 50 transactions completed, it is a choice partner to accompany medium to long-term growth programmes of portfolio companies. The team works alongside entrepreneurial families and managers to address the generation transition and bridge expansion capital gaps. 

Alto Capital V, vintage 2022 (Euro 273 million raised) has completed 5 investment transactions to date: Larioplast (cosmetic and food packaging), Dierre Group (industrial security solutions) e EF Group (general contractor for fairs and tri-dimensional spaces), Fragesa (pizza restaurant chain under the brand “Fra Diavolo”) and Eurosirel (manufacturer and distributor of woundcare and cosmetic products).

More information: www.altopartners.it 

Firms to take equal stakes in new entity Domixtar Pharmaceuticals

Trilantic Europe, a leading mid-market, pan-European private equity investor, is pleased to announce the successful merger of portfolio company Doppel Farmaceutici, and Alto Partners-owned Mipharm. Completion of the transaction is expected to occur in September 2024.

Headquartered in Italy and founded in 1994 and 1998 respectively, Doppel Farmaceutici and Mipharm are two leading contract development and manufacturing organisations (CDMOs), bringing fully integrated drug development and manufacturing solutions to the pharmaceuticals market.

Trilantic Europe and Alto Partners will each be taking a 50% stake in the new merged entity, named Domixtar Pharmaceuticals (“DMX Pharma”). The entity generated an aggregate turnover of approximately 180 million euros in 2023 and will be led by current Mipharm Executive President, Maurizio Silvestri.

Together, Doppel Farmaceutici and Mipharm service a 100-strong, global portfolio of blue-chip clients, offering a comprehensive suite of technologies and products including liquid, solid and semisolid dosage forms with myriad applications, including anti-tumour, anti-inflammatory, cardiovascular and metabolic.

With 900 employees spread across four production plants located between Milan, Piacenza and Ferrara, DMX Pharma is set to become the largest independent Italian CDMO; equipped with state-of-the-art laboratories capable of supporting its customers in complex research and development (R&D) projects, starting from the investigational phase and product pre-formulation studies, up to the scale up of commercial production.

Vittorio Pignatti-Morano, Chairman and Co-Founder at Trilantic Europe, said: “This merger exemplifies our commitment to growing our portfolio companies into global players, and underscores our ability to identify strategic consolidation opportunities in ever-developing markets. By integrating both Doppel Farmaceutici’s and Mipharm’s unique strengths, scale-up capabilities, and advanced technologies, we're establishing a comprehensive platform to serve the intricate needs of global pharmaceutical clients, supporting with a broader range of activities and sophisticated drug development and manufacturing. We look forward to working with Alto Partners in this next chapter of the companies’ growth journeys.

Maurizio Silvestri, current Executive President of Mipharm and newly appointed Executive President of Domixtar Pharmaceuticals, said: "This strategic merger delivers powerful synergies both commercially and technologically, creating a real powerhouse in the pharmaceuticals market by combining decades of expertise with cutting-edge innovation.”
The terms of the transaction are not disclosed. Trilantic Europe was advised by LMCR / Studio Legale, EY, goetzpartners, ERM and Foglia & Partners.

Press Contact :

Trilantic Europe:

Agnes Riousse/Camilla Wyatt

Citigate Dewe Rogerson

E: agnes.riousse@citigatedewerogerson.com / camilla.wyatt@citigatedewerogerson.com 

T: +44 7770 762828

About Trilantic Europe

Trilantic Europe is a mid-market private equity firm focused on management buyouts, buy-ins and partnerships with founders, families and management teams across its themes and sectors of focus including energy transition, consumer and leisure, business services and healthcare. Trilantic Europe is managed by an experienced group of over 30 investment professionals and 15 operating partners and senior advisors, having invested over €2.7bn in 30 platform portfolio companies since 2004 and currently managing c. €2.6bn in assets from a wide base of investors.

More information: www.trilanticeurope.com 

About Alto Partners

Alto Partners SGR S.p.A. is an independent management company founded by Stefano Scarpis and Raffaele de Courten, focusing on private equity investments in the Italian mid-market. With close to 25 years market experience and 50 transactions completed, it is a choice partner to accompany medium to long-term growth programmes of portfolio companies. The team works alongside entrepreneurial families and managers to address the generation transition and bridge expansion capital gaps. 

Alto Capital V, vintage 2022 (Euro 273 million raised) has completed 5 investment transactions to date: Larioplast (cosmetic and food packaging), Dierre Group (industrial security solutions) e EF Group (general contractor for fairs and tri-dimensional spaces), Fragesa (pizza restaurant chain under the brand “Fra Diavolo”) and Eurosirel (manufacturer and distributor of woundcare and cosmetic products).

More information: www.altopartners.it 

Firms to take equal stakes in new entity Domixtar Pharmaceuticals

Trilantic Europe, a leading mid-market, pan-European private equity investor, is pleased to announce the successful merger of portfolio company Doppel Farmaceutici, and Alto Partners-owned Mipharm. Completion of the transaction is expected to occur in September 2024.

Headquartered in Italy and founded in 1994 and 1998 respectively, Doppel Farmaceutici and Mipharm are two leading contract development and manufacturing organisations (CDMOs), bringing fully integrated drug development and manufacturing solutions to the pharmaceuticals market.

Trilantic Europe and Alto Partners will each be taking a 50% stake in the new merged entity, named Domixtar Pharmaceuticals (“DMX Pharma”). The entity generated an aggregate turnover of approximately 180 million euros in 2023 and will be led by current Mipharm Executive President, Maurizio Silvestri.

Together, Doppel Farmaceutici and Mipharm service a 100-strong, global portfolio of blue-chip clients, offering a comprehensive suite of technologies and products including liquid, solid and semisolid dosage forms with myriad applications, including anti-tumour, anti-inflammatory, cardiovascular and metabolic.

With 900 employees spread across four production plants located between Milan, Piacenza and Ferrara, DMX Pharma is set to become the largest independent Italian CDMO; equipped with state-of-the-art laboratories capable of supporting its customers in complex research and development (R&D) projects, starting from the investigational phase and product pre-formulation studies, up to the scale up of commercial production.

Vittorio Pignatti-Morano, Chairman and Co-Founder at Trilantic Europe, said: “This merger exemplifies our commitment to growing our portfolio companies into global players, and underscores our ability to identify strategic consolidation opportunities in ever-developing markets. By integrating both Doppel Farmaceutici’s and Mipharm’s unique strengths, scale-up capabilities, and advanced technologies, we're establishing a comprehensive platform to serve the intricate needs of global pharmaceutical clients, supporting with a broader range of activities and sophisticated drug development and manufacturing. We look forward to working with Alto Partners in this next chapter of the companies’ growth journeys.

Maurizio Silvestri, current Executive President of Mipharm and newly appointed Executive President of Domixtar Pharmaceuticals, said: "This strategic merger delivers powerful synergies both commercially and technologically, creating a real powerhouse in the pharmaceuticals market by combining decades of expertise with cutting-edge innovation.”
The terms of the transaction are not disclosed. Trilantic Europe was advised by LMCR / Studio Legale, EY, goetzpartners, ERM and Foglia & Partners.

Press Contact :

Trilantic Europe:

Agnes Riousse/Camilla Wyatt

Citigate Dewe Rogerson

E: agnes.riousse@citigatedewerogerson.com / camilla.wyatt@citigatedewerogerson.com 

T: +44 7770 762828

About Trilantic Europe

Trilantic Europe is a mid-market private equity firm focused on management buyouts, buy-ins and partnerships with founders, families and management teams across its themes and sectors of focus including energy transition, consumer and leisure, business services and healthcare. Trilantic Europe is managed by an experienced group of over 30 investment professionals and 15 operating partners and senior advisors, having invested over €2.7bn in 30 platform portfolio companies since 2004 and currently managing c. €2.6bn in assets from a wide base of investors.

More information: www.trilanticeurope.com 

About Alto Partners

Alto Partners SGR S.p.A. is an independent management company founded by Stefano Scarpis and Raffaele de Courten, focusing on private equity investments in the Italian mid-market. With close to 25 years market experience and 50 transactions completed, it is a choice partner to accompany medium to long-term growth programmes of portfolio companies. The team works alongside entrepreneurial families and managers to address the generation transition and bridge expansion capital gaps. 

Alto Capital V, vintage 2022 (Euro 273 million raised) has completed 5 investment transactions to date: Larioplast (cosmetic and food packaging), Dierre Group (industrial security solutions) e EF Group (general contractor for fairs and tri-dimensional spaces), Fragesa (pizza restaurant chain under the brand “Fra Diavolo”) and Eurosirel (manufacturer and distributor of woundcare and cosmetic products).

More information: www.altopartners.it 

Firms to take equal stakes in new entity Domixtar Pharmaceuticals

Trilantic Europe, a leading mid-market, pan-European private equity investor, is pleased to announce the successful merger of portfolio company Doppel Farmaceutici, and Alto Partners-owned Mipharm. Completion of the transaction is expected to occur in September 2024.

Headquartered in Italy and founded in 1994 and 1998 respectively, Doppel Farmaceutici and Mipharm are two leading contract development and manufacturing organisations (CDMOs), bringing fully integrated drug development and manufacturing solutions to the pharmaceuticals market.

Trilantic Europe and Alto Partners will each be taking a 50% stake in the new merged entity, named Domixtar Pharmaceuticals (“DMX Pharma”). The entity generated an aggregate turnover of approximately 180 million euros in 2023 and will be led by current Mipharm Executive President, Maurizio Silvestri.

Together, Doppel Farmaceutici and Mipharm service a 100-strong, global portfolio of blue-chip clients, offering a comprehensive suite of technologies and products including liquid, solid and semisolid dosage forms with myriad applications, including anti-tumour, anti-inflammatory, cardiovascular and metabolic.

With 900 employees spread across four production plants located between Milan, Piacenza and Ferrara, DMX Pharma is set to become the largest independent Italian CDMO; equipped with state-of-the-art laboratories capable of supporting its customers in complex research and development (R&D) projects, starting from the investigational phase and product pre-formulation studies, up to the scale up of commercial production.

Vittorio Pignatti-Morano, Chairman and Co-Founder at Trilantic Europe, said: “This merger exemplifies our commitment to growing our portfolio companies into global players, and underscores our ability to identify strategic consolidation opportunities in ever-developing markets. By integrating both Doppel Farmaceutici’s and Mipharm’s unique strengths, scale-up capabilities, and advanced technologies, we're establishing a comprehensive platform to serve the intricate needs of global pharmaceutical clients, supporting with a broader range of activities and sophisticated drug development and manufacturing. We look forward to working with Alto Partners in this next chapter of the companies’ growth journeys.

Maurizio Silvestri, current Executive President of Mipharm and newly appointed Executive President of Domixtar Pharmaceuticals, said: "This strategic merger delivers powerful synergies both commercially and technologically, creating a real powerhouse in the pharmaceuticals market by combining decades of expertise with cutting-edge innovation.”
The terms of the transaction are not disclosed. Trilantic Europe was advised by LMCR / Studio Legale, EY, goetzpartners, ERM and Foglia & Partners.

Press Contact :

Trilantic Europe:

Agnes Riousse/Camilla Wyatt

Citigate Dewe Rogerson

E: agnes.riousse@citigatedewerogerson.com / camilla.wyatt@citigatedewerogerson.com 

T: +44 7770 762828

About Trilantic Europe

Trilantic Europe is a mid-market private equity firm focused on management buyouts, buy-ins and partnerships with founders, families and management teams across its themes and sectors of focus including energy transition, consumer and leisure, business services and healthcare. Trilantic Europe is managed by an experienced group of over 30 investment professionals and 15 operating partners and senior advisors, having invested over €2.7bn in 30 platform portfolio companies since 2004 and currently managing c. €2.6bn in assets from a wide base of investors.

More information: www.trilanticeurope.com 

About Alto Partners

Alto Partners SGR S.p.A. is an independent management company founded by Stefano Scarpis and Raffaele de Courten, focusing on private equity investments in the Italian mid-market. With close to 25 years market experience and 50 transactions completed, it is a choice partner to accompany medium to long-term growth programmes of portfolio companies. The team works alongside entrepreneurial families and managers to address the generation transition and bridge expansion capital gaps. 

Alto Capital V, vintage 2022 (Euro 273 million raised) has completed 5 investment transactions to date: Larioplast (cosmetic and food packaging), Dierre Group (industrial security solutions) e EF Group (general contractor for fairs and tri-dimensional spaces), Fragesa (pizza restaurant chain under the brand “Fra Diavolo”) and Eurosirel (manufacturer and distributor of woundcare and cosmetic products).

More information: www.altopartners.it 

Firms to take equal stakes in new entity Domixtar Pharmaceuticals

Trilantic Europe, a leading mid-market, pan-European private equity investor, is pleased to announce the successful merger of portfolio company Doppel Farmaceutici, and Alto Partners-owned Mipharm. Completion of the transaction is expected to occur in September 2024.

Headquartered in Italy and founded in 1994 and 1998 respectively, Doppel Farmaceutici and Mipharm are two leading contract development and manufacturing organisations (CDMOs), bringing fully integrated drug development and manufacturing solutions to the pharmaceuticals market.

Trilantic Europe and Alto Partners will each be taking a 50% stake in the new merged entity, named Domixtar Pharmaceuticals (“DMX Pharma”). The entity generated an aggregate turnover of approximately 180 million euros in 2023 and will be led by current Mipharm Executive President, Maurizio Silvestri.

Together, Doppel Farmaceutici and Mipharm service a 100-strong, global portfolio of blue-chip clients, offering a comprehensive suite of technologies and products including liquid, solid and semisolid dosage forms with myriad applications, including anti-tumour, anti-inflammatory, cardiovascular and metabolic.

With 900 employees spread across four production plants located between Milan, Piacenza and Ferrara, DMX Pharma is set to become the largest independent Italian CDMO; equipped with state-of-the-art laboratories capable of supporting its customers in complex research and development (R&D) projects, starting from the investigational phase and product pre-formulation studies, up to the scale up of commercial production.

Vittorio Pignatti-Morano, Chairman and Co-Founder at Trilantic Europe, said: “This merger exemplifies our commitment to growing our portfolio companies into global players, and underscores our ability to identify strategic consolidation opportunities in ever-developing markets. By integrating both Doppel Farmaceutici’s and Mipharm’s unique strengths, scale-up capabilities, and advanced technologies, we're establishing a comprehensive platform to serve the intricate needs of global pharmaceutical clients, supporting with a broader range of activities and sophisticated drug development and manufacturing. We look forward to working with Alto Partners in this next chapter of the companies’ growth journeys.

Maurizio Silvestri, current Executive President of Mipharm and newly appointed Executive President of Domixtar Pharmaceuticals, said: "This strategic merger delivers powerful synergies both commercially and technologically, creating a real powerhouse in the pharmaceuticals market by combining decades of expertise with cutting-edge innovation.”
The terms of the transaction are not disclosed. Trilantic Europe was advised by LMCR / Studio Legale, EY, goetzpartners, ERM and Foglia & Partners.

Press Contact :

Trilantic Europe:

Agnes Riousse/Camilla Wyatt

Citigate Dewe Rogerson

E: agnes.riousse@citigatedewerogerson.com / camilla.wyatt@citigatedewerogerson.com 

T: +44 7770 762828

About Trilantic Europe

Trilantic Europe is a mid-market private equity firm focused on management buyouts, buy-ins and partnerships with founders, families and management teams across its themes and sectors of focus including energy transition, consumer and leisure, business services and healthcare. Trilantic Europe is managed by an experienced group of over 30 investment professionals and 15 operating partners and senior advisors, having invested over €2.7bn in 30 platform portfolio companies since 2004 and currently managing c. €2.6bn in assets from a wide base of investors.

More information: www.trilanticeurope.com 

About Alto Partners

Alto Partners SGR S.p.A. is an independent management company founded by Stefano Scarpis and Raffaele de Courten, focusing on private equity investments in the Italian mid-market. With close to 25 years market experience and 50 transactions completed, it is a choice partner to accompany medium to long-term growth programmes of portfolio companies. The team works alongside entrepreneurial families and managers to address the generation transition and bridge expansion capital gaps. 

Alto Capital V, vintage 2022 (Euro 273 million raised) has completed 5 investment transactions to date: Larioplast (cosmetic and food packaging), Dierre Group (industrial security solutions) e EF Group (general contractor for fairs and tri-dimensional spaces), Fragesa (pizza restaurant chain under the brand “Fra Diavolo”) and Eurosirel (manufacturer and distributor of woundcare and cosmetic products).

More information: www.altopartners.it 

Firms to take equal stakes in new entity Domixtar Pharmaceuticals

Trilantic Europe, a leading mid-market, pan-European private equity investor, is pleased to announce the successful merger of portfolio company Doppel Farmaceutici, and Alto Partners-owned Mipharm. Completion of the transaction is expected to occur in September 2024.

Headquartered in Italy and founded in 1994 and 1998 respectively, Doppel Farmaceutici and Mipharm are two leading contract development and manufacturing organisations (CDMOs), bringing fully integrated drug development and manufacturing solutions to the pharmaceuticals market.

Trilantic Europe and Alto Partners will each be taking a 50% stake in the new merged entity, named Domixtar Pharmaceuticals (“DMX Pharma”). The entity generated an aggregate turnover of approximately 180 million euros in 2023 and will be led by current Mipharm Executive President, Maurizio Silvestri.

Together, Doppel Farmaceutici and Mipharm service a 100-strong, global portfolio of blue-chip clients, offering a comprehensive suite of technologies and products including liquid, solid and semisolid dosage forms with myriad applications, including anti-tumour, anti-inflammatory, cardiovascular and metabolic.

With 900 employees spread across four production plants located between Milan, Piacenza and Ferrara, DMX Pharma is set to become the largest independent Italian CDMO; equipped with state-of-the-art laboratories capable of supporting its customers in complex research and development (R&D) projects, starting from the investigational phase and product pre-formulation studies, up to the scale up of commercial production.

Vittorio Pignatti-Morano, Chairman and Co-Founder at Trilantic Europe, said: “This merger exemplifies our commitment to growing our portfolio companies into global players, and underscores our ability to identify strategic consolidation opportunities in ever-developing markets. By integrating both Doppel Farmaceutici’s and Mipharm’s unique strengths, scale-up capabilities, and advanced technologies, we're establishing a comprehensive platform to serve the intricate needs of global pharmaceutical clients, supporting with a broader range of activities and sophisticated drug development and manufacturing. We look forward to working with Alto Partners in this next chapter of the companies’ growth journeys.

Maurizio Silvestri, current Executive President of Mipharm and newly appointed Executive President of Domixtar Pharmaceuticals, said: "This strategic merger delivers powerful synergies both commercially and technologically, creating a real powerhouse in the pharmaceuticals market by combining decades of expertise with cutting-edge innovation.”
The terms of the transaction are not disclosed. Trilantic Europe was advised by LMCR / Studio Legale, EY, goetzpartners, ERM and Foglia & Partners.

Press Contact :

Trilantic Europe:

Agnes Riousse/Camilla Wyatt

Citigate Dewe Rogerson

E: agnes.riousse@citigatedewerogerson.com / camilla.wyatt@citigatedewerogerson.com 

T: +44 7770 762828

About Trilantic Europe

Trilantic Europe is a mid-market private equity firm focused on management buyouts, buy-ins and partnerships with founders, families and management teams across its themes and sectors of focus including energy transition, consumer and leisure, business services and healthcare. Trilantic Europe is managed by an experienced group of over 30 investment professionals and 15 operating partners and senior advisors, having invested over €2.7bn in 30 platform portfolio companies since 2004 and currently managing c. €2.6bn in assets from a wide base of investors.

More information: www.trilanticeurope.com 

About Alto Partners

Alto Partners SGR S.p.A. is an independent management company founded by Stefano Scarpis and Raffaele de Courten, focusing on private equity investments in the Italian mid-market. With close to 25 years market experience and 50 transactions completed, it is a choice partner to accompany medium to long-term growth programmes of portfolio companies. The team works alongside entrepreneurial families and managers to address the generation transition and bridge expansion capital gaps. 

Alto Capital V, vintage 2022 (Euro 273 million raised) has completed 5 investment transactions to date: Larioplast (cosmetic and food packaging), Dierre Group (industrial security solutions) e EF Group (general contractor for fairs and tri-dimensional spaces), Fragesa (pizza restaurant chain under the brand “Fra Diavolo”) and Eurosirel (manufacturer and distributor of woundcare and cosmetic products).

More information: www.altopartners.it